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ABSTRACT 
Mitral valve disease is a multifactorial process. The valve is a complex structure that contains 
an amalgam of extracellular proteins, cellular components, nerves and blood vessels. It is 
predicted that some of the central portions of the valve leaflets could exist under hypoxic 
conditions. Hypoxia could play a role in initiating the structural changes in the valve that lead 
to dysfunction of the valve. It is known to cause the up-regulation of hypoxia-induced factor 
(HIF) that can regulate the differentiation of cells, the production of extracellular matrix 
(ECM) and expression of matrix remodelling enzymes, all of which are characteristic 
changes seen in one or more forms of the disease. 
This study aimed to investigate the effect of hypoxia on the basic behaviour and phenotypic 
profile of mitral valve interstitial cells (MVICs), and their functional response to produce and 
control the ECM components. The expression of HIF-1α and its role in mediating the effects 
induced by hypoxia were also investigated, and also the characteristics of blood vessels in the 
mitral valve leaflet in porcine as well as normal and diseased human valves.  
MVICs incubated under hypoxia remained viable and continued to grow, while retaining 
their morphology and phenotype. On the other hand, severe hypoxia resulted in reduced 
production of the ECM components sulphated glycosaminoglycan (sGAG) and collagen, 
while it induced matrix metabolism through up-regulating the gene expression of matrix 
metalloproteases and their tissue inhibitors. Human rheumatic valves had more evident 
expression of HIF-1α compared with normal or myxomatous degeneration valves. Porcine 
MVICs (pMVICs) expressed HIF-1α under hypoxia. Stimulating HIF-1α chemically causes a 
reduction in the amount of GAG produced, similar to the effect observed under severe 
hypoxia. The study also confirmed the presence of vascular supply to the normal mitral valve 
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leaflets and showed that there was increased vascularisation in rheumatic valves, while there 
was a loss of vessels in myxomatous degenerative ones.  
In conclusion, normal mitral valve leaflets are vascular structures of variable pattern. 
Diseased valves are associated with changes in leaflet vascularity either by 
neovascularisation in rheumatic disease, or by loss of vascularisation in myxomatous 
degeneration. Hypoxia affects the production of certain ECM proteins and remodelling 
enzymes by MVICs. These effects appear to be mediated by the induction of HIF-1α. This 
study highlights an important process and mechanism in heart valve in health and disease and 
helps improve the understanding of its complex biology. This could have future implications 
on the treatment of valve disease and the future applications in heart valve tissue engineering.  
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1.1 THE MITRAL VALVE  
The mitral valve (MV), along with the three other heart valves: the aortic, the pulmonary and 
the tricuspid valves, regulates the unidirectional and synchronised blood flow through the 
heart during the cardiac cycle. The competence of the heart valves is essential in allowing 
unobstructed blood flow through the heart, preventing its backflow and generating adequate 
cardiac output and, subsequently, overall cardiac function, supplying de-oxygenated blood to 
the lungs and oxygenated blood to the rest of the body.  
 
The MV is especially important in cardiac function; it is the left atrioventricular valve that 
controls the inflow of oxygenated blood coming from the lung through the left atrium, filling 
of the left ventricle (LV) in diastole and timely competent closure in systole, allowing blood 
to go through the outflow tract, through the aortic valve to the aorta and to the rest of the 
body.  
 
It is a complex structure that is also part of the LV architecture. It is subjected to high-
pressure haemodynamic changes through the cardiac cycle, is closely related to the aortic 
valve and contributes to the stability and function of the LV itself. MV disease (MVD) 
adversely affects both left and right sides of the heart, and is equally affected by diseases in 
other parts of the heart, in particular the LV (Hinton et al. 2011). Contrary to the long-
standing belief that heart valves are passive flaps of tissue that open and close in response to 
passage of blood (Williams et al. 2004), they are now considered living structures with highly 
sophisticated biological mechanisms that contribute to their function and durability. These 
include cellular responses to physical, chemical and biological stimuli via various 
proliferative, secretory and contractile mechanisms that work through various pathways and 
communications including cell-cell and cell-matrix (Latif et al. 2005b; Salhiyyah et al. 2011). 
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Investigating the contribution of cellular components of the MV to valve function in health 
and disease will aid the understanding of how the durability and function of the valve is 
regulated, and possibly highlight molecular and pharmacological targets for the development 
of novel treatments for MVD.  
1.2 MITRAL VALVE ANATOMY 
The MV is a complex and dynamic structure. It is located at the left atrioventricular orifice 
(Figure 1.1). The junction between the left atrium and LV is reinforced with a thick fibrous 
ring or annulus. From this annulus, two leaflets arise; anterior and posterior. The valve 
apparatus also involves complex connections between valve leaflets with the papillary 
muscles and the rest of the LV through fibrous tendon-like structures called chordae 
tendineae (ChT). The integrity of each of these structures and their interactions together are 
crucial to the optimal function of the valve (Anderson et al. 2013; Quill et al. 2009).  
 
Figure ‎1.1 - Mitral valve anatomy. 
A schematic drawing of the heart with both atria removed and showing all four heart valves 
and their relation to each other and to the skeleton of the heart. 
From: http://www.netterimages.com/image/9905.htm 
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1.2.1 Mitral valve leaflet 
Unlike the other heart valves, the MV has only two valve leaflets: the anterior (aortic) and the 
posterior (mural). The two leaflets are attached to the annulus at their bases, while their 
apices project into the ventricular cavity. They are both comparable in their area, but differ in 
shape. The anterior leaflet covers nearly a third of the valve circumference, but projects more 
into the orifice, whereas the posterior is longer, covering the other two thirds of the 
circumference, but is narrower in width. Leaflets are defined by two commissures, and have 
variable indentations or clefts dividing the leaflets into “scallops”. These clefts are more 
prominent in the posterior leaflet, and usually divide the leaflet into three scallops (Figure 
1.2). The most common nomenclature describes then as P1, P2 and P3, with the 
corresponding anterior A1, A2 and A3 (Cohn 2008). The anterior leaflet that is placed in 
front and to the right, between the atrioventricular and aortic orifices, and is directly related 
to the fibrous skeleton of the heart, the aortic valve cusps and the sub-aortic curtain. The 
atrial side of the mitral leaflets has a smooth surface directed toward the blood flow from the 
left atrium. The ventricular surface of the leaflets gives attachments to the ChT. This pattern 
of attachments gives another morphological classification, by which the leaflets are divided 
into two areas: the rough zone, which is the free edge of the leaflet where the majority of the 
ChT attach, and is the area of coaptation, where both leaflets meet when the valve closes. The 
other area is the clear zone, with little chordal attachments. The posterior leaflet has another 
area, referred to the basal zone, near the annulus where it receives attachments from the basal 
(tertiary) chordae (Ho 2002; Misfeld et al. 2007; Muresian 2009; Quill et al. 2009; Silbiger et 
al. 2009). 
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Figure ‎1.2 - Mitral valve leaflets.  
Schematic figures showing the anatomy of the mitral valve leaflets.  
From Wikipedia: http://en.wikipedia.org/wiki/File:Mitral_Valve.png. 
 
 
The microstructure of the leaflets is made of fibroskeleton organised into three distinct layers, 
often referred to as the ECM, which is populated by a group of heterogeneous cells 
collectively called valve interstitial cells (VIC) and covered from both surfaces by a 
monolayer of valve endothelial cells (VEC) which are continuous with the endocardium.  
The three layers composing the leaflet ECM are the atrialis (equivalent to the ventricularis in 
the aortic valve), the spongiosa, which is the middle layer, and the fibrosa on the ventricular 
side of the valve (Figure 1.3). The atrialis is formed as a dense sheet of elastic fibres that give 
the leaflet it elasticity. The spongiosa is rich in glycosaminoglycans (GAGs) and 
proteoglycans (PGs) within a fine, interweaving, spongy elastin network. It functions to resist 
compression between the outer layers, give flexibility to the valve leaflet and dampen 
vibrations from closing. The fibrosa, which is the thickest part of the leaflet, is made 
primarily of organised collagen fibres which give the valve its tensile strength (Schoen 2005; 
Schoen 2008). The VICs are distributed throughout the leaflet ECM and consist of different 
phenotypes of cells including fibroblasts, myofibroblasts (MFB), myocytes, smooth muscle 
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cells (SMC) and autonomic nervous fibres. The cells can be grouped under two major 
phenotypes; a contractile subtype characterised by prominent stress fibres and expression of 
smooth muscle α-actin, and a secretory phenotype, which is characterised by the presence of 
the synthetic and secretory organelles, and is involved in secreting and maintaining the ECM 
components (Brand et al. 2006; Chester et al. 2007). 
 
In addition, the MV leaflets were shown to be innervated with a network of nerves that 
provide sensory, sympathetic and parasympathetic activity (Marron et al. 1996). The anterior 
leaflet has twice the number of nerves relative to the posterior leaflet. Nerve fibres run mainly 
on the proximal atrial side of the leaflets and in close proximity with VECs, SMCs and 
fibroblasts. Valve leaflets are responsive to both chemical and electrical neurostimulation, 
and are capable of both contraction and relaxation (Chester et al. 2008). Atrial depolarisation 
stimulates the anterior MV leaflet, resulting in contraction and increased stiffness, aiding 
valve closure, an effect potentially mediated by neuronal mechanisms (Swanson et al. 
2011b). The other component of the leaflet microstructure is the leaflet microvessels. These 
are a network of small vessels that run within valve leaflet and provide a blood supply to the 
VICs within the leaflet. Although they have been described long ago in humans and animal 
valves, their function remains controversial and disputed among valve researchers (Hakuno et 
al. 2011; Saini et al. 2013).  
 
Valve leaflets also house many other biologically active substances and mediators that play a 
vital role in maintaining its structure and function. Some of these components include ECM 
enzymes called matrix metalloproteinases (MMPs), and tissue inhibitors of 
metalloproteinases (TIMPs) that are essential for leaflet remodelling (Hinton et al. 2011). 
MMPs function to degrade various ECM components like collagens and PGs through 
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proteolysis, while TIMPs act to control this action by inhibiting MMPs. The balanced action 
of these two groups helps maintain leaflet structure. 
 
 
Figure ‎1.3 - Microscopic structure of the mitral valve leaflet. 
Section through the mitral valve anterior leaflet stained with alcian blue and sirius red, 
showing the three layers of the valve leaflet. Picture is courtesy of Dr Padmini Sarathchandra. 
 
1.2.2 The mitral valve annulus 
The MV annulus refers to the circumference of the MV orifice located at the left 
atrioventricular opening. It is an incomplete fibro-elastic ring from which the free MV 
leaflets arise. Anteriorly, the annulus is deficient towards the aorta, where the anterior mitral 
leaflet is continuous with aortic valve forming the sub-aortic or mitro-aortic curtain. The 
annulus is the transitional or hinge zone, where the leaflets are anchored to the myocardium. 
It is covered by endocardium. Elastic and colagen fibres form a three-dimensional network 
that radiates and connects both the left atrium myocardium and the valve leaflet (Ho 2002). 
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Figure ‎1.4 - Mitral valve annulus.  
Figure showing the saddle shaped mitral annulus.  From (Levine et al. 1989). 
 
The MV annulus is a dynamic three-dimensional structure. It has an ovoid shape with a 
longer inter-commissural diameter, taking a saddle shape in its horizontal dimension (Figure 
1.4). The annulus is very dynamic throughout the cardiac cycle, and it changes both in shape 
and dimensions. It becomes more elliptical in systole, with reduction in the diameter (Carlhall 
et al. 2004; Levine et al. 1989; Timek et al. 2001a). It was also found that the saddle-shaped 
annulus redistributes the forces on the chords by altering the coapting geometry, which is 
therefore essential for the function of the MV and its configuration (Jimenez et al. 2003). 
 
1.2.3 Chordae Tendineae 
 The ChT are rope-like structures that connect the mitral leaflets to the papillary muscles and 
the left ventricular wall (Figure 1.5). They are composed of multiple layers of strong 
connective tissue. The inner-most core is made of tightly bound collagen, surrounded with 
another loose layer of elastin and collagen fibres and covered on the outside by layer of 
endothelial cells, and populated by fibroblasts evenly distributed throughout (Liao et al. 
2009; Ritchie et al. 2005). These components play an essential role in preventing MV 
prolapse, and transmitting the contraction of the papillary muscles to the MV leaflet. The 
ChT can be divided into three types according to their insertion sites on the mitral leaflets: the 
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primary (marginal), which insert on the leaflets’ free edges (rough zone) and are essential for 
leaflet coaptation, secondary (rough zone cords) which insert on rough zone beyond the free 
margin on the ventricle surface of the leaflets and are essential for leaflet geometry, and 
tertiary (strut/basal), which arises directly from the LV wall and connects only to the 
posterior leaflet. They are essential for ventricular geometry and annular re-enforcement 
(Rodriguez et al. 2004). The ChT divide into multiple branches after coming off the papillary 
muscle and attach to the leaflet in a parachute-like manner (Muresian 2009; Ritchie et al. 
2005; Timek et al. 2001b). 
 
 
 
 
 
Figure ‎1.5 - Mitral valve leaflet relation to ChT and papillary muscles. 
The mitral valvular complex is exposed by cutting a porcine heart specimen through the left 
ventricle. In this specimen, the anterior leaflet is on the left side, and the posterior leaflet is on 
the right. Both leaflets are connected to the annulus (top). Multiple ChT attachments to both 
leaflets connect them to the papillary muscles, which project from the left ventricular cavity.  
 
1.2.4 Papillary muscles 
These are longitudinal muscular columns, which project from the inner surface of the 
ventricle and are continuous by their bases with the wall of the ventricle, while their apices 
give origin to the ChT (Figure 1.5), and together they are called the subvalvular apparatus. 
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They originate at the junction of the middle and apical thirds of the LV (Ho 2002). There are 
two main papillary muscles in the left ventricle; anterolateral (anterior) and posteromedial 
(posterior). ChT arising from each muscle usually give attachments to the corresponding 
leaflet, and also cross to the other leaflet especially at the free margin (Muresian 2009). These 
muscles usually divide into a few heads or bellies with large variability in number, shapes 
and connections, but they are still distributed to provide circumferentially constant support 
and even distribution of stress over the leaflets (Victor et al. 1995). 
1.2.5 The left ventricle 
The LV is the largest and strongest chamber of the heart. It is capable of producing a rapid 
and forceful contraction to generate high pressure to overcome the aortic pressure, and pump 
blood to the whole body, followed by a rapid relaxation and drop in pressure to allow 
adequate filling. The ventricular walls are made of thick myocardium. Its inner side is 
covered by irregular muscle ridges called trabeculations. The left ventricle, through the 
papillary muscles and their connections to the leaflets, and through direct attachment through 
the strut cords contribute to the geometry and stability of the MV complex and vice versa 
(Rodriguez et al. 2004). Their function is well coordinated, and abnormalities affecting either 
one will directly affect the other, and therefore it is now considered as part of the MV 
complex (Yacoub et al. 2004).  
 
1.3 MITRAL VALVE PHYSIOLOGY 
The sophisticated function of the heart depends on a highly coordinated electromechanical 
system. The timely contraction and relaxation of the heart chambers is synchronised with 
changes in the mechanical loading and changes in pressure and volume (Fukuta et al. 2008; 
Swanson et al. 2011b; Swanson et al. 2011a).  
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Looking at a snapshot across the MV, we can appreciate the high complexity of this system; 
the end of the LV contraction (systole) and pumping blood through the aortic valve, the 
ventricle starts to relax, and its pressure will drop below the aortic pressure. This will close 
the aortic valve. The ventricle will continue this isovolumetric relaxation, and the pressure 
will continue to drop rapidly, with both the aortic and the MV closed, until the pressure drops 
below the left atrial pressure. As the ventricle relaxes, it gently pulls on the ChT and assists 
the rapid and smooth opening of the valve. The coordinated movements of the constituent 
parts of the valve reduce the resistance for the passing blood and facilitate opening of the MV 
and blood passage from the left atrium to fill up the left ventricle. Initially, this filling is 
passive across pressure gradient, but at the end of diastole, the left atrium contracts pushing 
some more blood into the ventricle to ensure adequate filling. Contraction of the filled 
ventricle will increase its pressure significantly over the aortic pressure, and will open the 
aortic valve, pumping blood to the aorta. At the same time, while the ventricle contracts, its 
diameter is reduced and the ChT initially lengthen, allowing the MV to start to close in 
response to increased ventricular pressure. Further contraction of the papillary muscles will 
pull the ChT to the correct length and parachute the free edges of the leaflets, to allow them 
to tolerate the high pressure and prevent their prolapse back to the atrium (Fukuta et al. 2008; 
Hall 2010; Richards et al. 2012; Yoganathan et al. 2004).  
 
Therefore, MV leaflets are not just passive curtains that just open and shut. They are dynamic 
living structures that actively contribute to their function and are coordinated with the rest of 
the heart. Their precise structure, the relative distribution and orientation of the fibroskeleton 
and the contractile capacity of the leaflet all contribute to the ability of the leaflet to open and 
close in a timely, competent manner, while tolerating the pressure and volume load from both 
sides of the valve.  
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1.4 SIGNIFICANCE OF MITRAL VALVE DISEASE 
MVD is a significant health issue worldwide. Whereas degenerative valve disease is on the 
rise in developed countries, rheumatic valve disease (RVD) continues to be a major issue in 
many developed countries. There are an 332,000 cases worldwide, with an average of 5.5 per 
100,000 people (Anonymous 2004) being affected, mostly children and young adults, with a 
mean age of presentation 15.1 years (Padmavati 2001). Although new presentations are now 
very rare in Western countries, it still counts for 14% of all cases of MR, and 85% of all cases 
of mitral stenosis in Europe (Iung et al. 2003). 
 
Degenerative MVD is most prevalent in developed countries. It is usually related to MV 
prolapse (Chandrashekhar et al. 2009; Nkomo et al. 2006), which has been found to be 
present in 2–15% of the population (Freed et al. 1999). In the European Heart Survey on 
valvular heart disease, the prevalence of mitral regurgitation (MR) was 31.5% of all patients 
with primary heart valve disease, second only to aortic stenosis, whereas mitral stenosis was 
still present in 12.1% of all VHD (Iung et al. 2003). In an American population-based study, 
moderate to severe MVD was found to be the commonest valve pathology, especially in older 
people, reaching up to 9.3% of all the population above 75 years old, and if adjusted to the 
whole population, it counts for 1.7% of all Americans (Nkomo et al. 2006).  
The incidence of MVD (and other degenerative valve disease) is predicted to increase 
significantly with the increase in the elderly population in the developed world. In the UK, by 
2018 it is estimated that there will be 4 million people aged 75–84 years. This will have 
important health implications for society (d'Arcy et al. 2011). In the UK, over 2,825 surgical 
procedures for MV were performed in 2011 (http://www.bluebook.scts.org/), and in the USA 
nearly 60,000 isolated primary MV operations were performed in the eight years between 
2000 and 2007 (Gammie et al. 2009). There are no clear data on the cost of MVD on the 
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economy, but as part of the whole burden of cardiovascular disease (CVD), it is a major 
health issue and a significant economic concern. The CVD economic cost was, for the UK in 
2009, nearly £9 billion (http://www.bhf.org.uk/research/statistics/economic-costs.aspx), and 
in the European Union it was about €190 billion (Nichols et al. 2012). In the USA, the direct 
costs of CVD in 2010 were estimated to be $156 billion, rising to $503 billion when the 
indirect costs were taken into account (Lloyd-Jones et al. 2010).  
 
1.5 MITRAL VALVE DISEASE 
The competent function of the MV depends on the proper interaction of the MV leaflets and 
the whole valve apparatus including the valve annulus, the ChT, papillary muscles, and the 
LV itself. MVD is associated with abnormalities affecting one or more of the structures of the 
valve apparatus. Usually, abnormality in one of the component structures will induce further 
changes in other parts. Disturbances in the function of the valve can affect cardiac function, 
either through the valve being too narrow to allow good flow of blood (stenosis) or by failure 
to close tightly permitting blood to leak back to the left atrium (regurgitation) (Carabello 
2008). MVD is related to various etiological factors like rheumatic disease, myxomatous 
degeneration, functional or ischaemic MR, calcific degeneration, congenital anomalies and 
collagen-vascular disorders (Carabello 2008; Donnelly 2008). Many of these conditions share 
common features of changes to the structure, distribution, interaction and function of the 
ECM proteins and enzymes, including collagens (Hadian et al. 2010), elastin, GAGs, PGs 
(Grande-Allen et al. 2003), MMPs and TIMP (Soini et al. 2001). Changes to the structure of 
all valve components are evident in MVD; these include valve leaflet changes such as 
prolapse, retraction or calcification, chordal abnormalities like rupture, elongation, 
shortening, annular dilatation or calcification, papillary muscle dysfunction or displacement, 
and finally left ventricular abnormalities due to dilatation or altered motion of the ventricular 
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wall. However, many of the different manifestations of MVD share these common features 
that sometimes make it difficult to differentiate between them.  
 
1.5.1 Recognised Types of MVD 
1.5.1.1 Rheumatic Valve Disease 
RVD is the commonest cause of MVD in the developing world. It is an inflammatory disease 
and it develops as a consequence of infection with group A, β-hemolytic streptococcus 
bacteria. Mainly it is associated with stenosis, but can also cause regurgitation or a 
combination of both (mixed disease) and usually affects more than one heart valve (Donnelly 
2008; Rajamannan et al. 2009). Macroscopically, it is characterised by thickened, fibrotic 
leaflets with fusion at the commissures. There is associated thickening and shortening of the 
ChT (Figure 1.6). 
 
 
Figure ‎1.6 - Rheumatic mitral valve disease.  
Viewed from the atrial side and showing thickened, rigid, nodular appearance with calcium 
deposition in the leaflet and commissural fusion.   
From:  http://library.med.utah.edu/WebPath/CVHTML/CV061.html.  
 
 
Microscopically, there are features of diffuse chronic inflammation including non-specific 
oedema and a large number of inflammatory cellular infiltrates. This reaction is a 
consequence of humoral and cellular immune responses against bacterial proteins that cross-
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react with cardiac proteins such as myosin and laminin (Veinot 2006). The ECM is also 
remodelled with areas of degradation and other areas of localised thickening due to increased 
collagen synthesis. There are also areas of calcification across the leaflet. Valve leaflets are 
also characterised by significant neovascularisation (Donnelly 2008; Rajamannan et al. 
2005). 
1.5.1.2 Myxomatous degeneration  
 
Myxomatous degenerative valves are characterised by excessive expansion and distortion of 
the valve leaflets with areas of irregularity and nodular fibrosis, resulting in systolic billowing 
of the leaflet and subsequent regurgitation (Figure 1.7).  
 
Figure ‎1.7 - Myxomatous mitral valve disease in small breed dog. 
Viewed from the atrial side and showing bellowing prolapsed of the anterior leaflet, with 
ruptured chordae tendineae (arrow). From (Fox 2012) 
 
The hallmark of myxomatous degeneration is weakness of the ECM (Donnelly 2008; 
Prunotto et al. 2010; Schoen 2005). There is generalised fibroelastic deficiency, with elastin 
and collagen fragmentation and disorganisation in all layers of the ECM resulting in loss of 
the zonal pattern (Hadian et al. 2010). There is nodular and diffuse accumulation of poorly 
organised PGs and acid mucopolysaccharide resulting in local thickening. This is most 
pronounced in the spongiosa layer. PGs play a role in the assembly of collagen fibrils and 
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over-production and deposition of the PGs contribute further to the loosening of the valve 
(Dainese et al. 2007; Tamura et al. 1995). The majority of the affected patients have sporadic 
acquired disease. A small minority of affected patients are linked to familial associations, or 
related to other connective tissue diseases like Marfan’s syndrome and Ehlers-Danlos 
syndrome, with genetic links like mutations in fibrillin-1, collagen III or filamin A (Grau et 
al. 2007; Levine et al. 2007; Prunotto et al. 2010).  The exact mechanism of the disease is not 
clear. Some theories relate to the ability of repeated mechanical stress on the valve, triggering 
the VICs to mediate changes in ECM metabolism. These changes include synthesis of 
collagen and elastin and expression of matrix remodelling enzymes (Mahimkar et al. 2009; 
Rabkin et al. 2001). 
1.5.1.3 Functional and ischaemic regurgitation  
Traditionally, MVD was classified as either primary or secondary valve disease. In secondary 
or “functional” disease, it is thought that the mitral leaflets are structurally intact and the 
regurgitation is secondary to changes in the LV (Figure 1.8), unlike in the primary disease, 
where the main pathology is in the valve leaflet itself, as in myxomatous degeneration. 
Secondary MVD applies to two distinct but similar conditions; functional regurgitation, 
which is the consequence of the dilated or ischaemic regurgitation when the main cause of 
cardiomyopathy is ischaemic damage to the left ventricle. In dilated cardiomyopathy, the 
whole of the ventricle including the annulus is dilated. MV leaflets are then unable to close 
over the whole orifice of the valve, resulting in regurgitation. In ischaemic cardiomyopathy 
similar mechanisms occur, but in addition there is usually wall motion abnormality, papillary 
muscle ischemia and displacement, deformity and rupture of the ChT. The dilatation of the 
annulus and the change of the geometry of the valve contribute to the regurgitation (Donnelly 
2008). 
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Figure ‎1.8 - Mechanism of functional mitral regurgitation. 
Schematic diagram showing that changes in left ventricular geometry causes papillary muscle 
displacement. Subsequently, this will result in pulling the chordate tendineae, tethering of the 
valve leaflet and mitral regurgitation. From http://www.mardil.com/overview/. 
 
Recent studies have shown that functional MVD is not purely secondary to change in 
function or geometry of the left ventricle. It is associated with biochemical and mechanical 
changes of the leaflets themselves that contribute further to the disease process. Human 
valves from patients with congestive heart failure secondary to either dilated or ischaemic 
cardiomyopathy, appeared grossly normal, but on further analysis they were found to have 
dysfunctional remodelling. There was increased DNA content, possibly secondary to cell 
proliferation and an increase in collagen and GAG content, making the valve thicker and 
larger (Grande-Allen et al. 2005). Experimental studies of animal models with dilated 
cardiomyopathy or pure MR have similarly shown that the MR was associated with leaflet 
remodelling (Dal-Bianco et al. 2009; Stephens et al. 2008b; Stephens et al. 2009; Timek et 
al. 2006). In addition, Chaput et al. have shown that there is a significant increase in MV 
leaflet area in patients with MR compared to normal patients on echocardiography (Chaput et 
al. 2008). 
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This remodelling appears to be a compensatory mechanism that attempts to increase the 
leaflet size and tensile strength, but in reality it contributes further into the pathophysiology 
of functional MVD. It involves segmental lengthening, change in the orientation of ECM 
fibres, subsequent changes in stiffness and viscosity of the affected leaflets and eventually 
altered valve mechanics. 
1.5.1.4 Serotonin (5-HT) induced disease  
Increased levels of circulating Serotonin or 5-hydroxytryptamine (5-HT) were found to be 
linked to distinct subtypes of valvular heart disease. Although not very common, it may 
represent an important pathway in the pathogenesis of MVD. Serotonin-induced disease was 
first reported secondary to carcinoid tumours. These are small bowel tumours with malignant 
metastasis to the liver that are characterised by increased levels of circulating 5-HT. A similar 
type of valvular disease was seen with the use of 5-HT agonists like the migraine drugs 
ergotamine and methysergide, the anti-Parkinson’s drugs pergolide, cabergoline and 
bromocriptine, and the appetite suppressants fenfluramine and phentermine (Alizzi et al. 
2006; Baumann et al. 2009; Hopkins et al. 2003; Zanettini et al. 2007). 
 
5-HT induced disease is associated with thickening and retraction of the valve leaflets, 
resulting in regurgitation. Microscopically there is characteristic plaque formation on the 
surface of the valve. It contains proliferating (sub-endothelial) MFBs in a fibromyxoid matrix 
that contains some vascular channels and inflammatory infiltrate (Rothman 2002). The exact 
mechanism of the disease is not well known, but it is well documented that increased 5-HT 
levels induce valvulopathy through its action on various receptors, mostly through 5-HT1B 
and 5-HT2B receptors, the activation of which was shown to induce mitogenic pathways 
(Rothman et al. 2000; Rothman et al. 2009).  
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1.5.1.5 Calcification  
Valve calcification is not a common pathology in MVD compared with aortic calcific 
stenosis. Primary calcification in the MV is seen mainly in the annulus, and to a lesser extent 
it involves the leaflets (Figure 1.9). On the other hand, significant calcification is associated 
with the other types of MVD and is present as areas or foci of calcification in the leaflets 
associated with other characteristic changes of a particular pathology. It is more common in 
rheumatic, but is also seen in myxomatous degeneration and even functional MR. It is also 
reported that premature calcification can sometimes occur in Marfan’s syndrome (De et al. 
1996). Valve calcification results in loss of the annular geometry and flexibility, stiffness of 
the leaflets and can cause either stenosis or regurgitation. 
 
 
Figure ‎1.9 - Mitral valve calcification.  
Extensive calcification is seen in the mitral valve annulus (arrow) extending to both leaflets.  
From http://www.heart-valve-surgery.com/heart-surgery-blog/2008/10/02/the-patients-
lifespan-after-heart-valve-surgery-for-valerie/. 
 
MV calcification is not well studied compared with aortic calcification. Recent studies have 
given more attention to calcification to try and identify some of the important pathways 
involved and its relation to other types of MVD.  
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1.6 VALVE COMPONENTS AND THEIR RELATION TO VALVE DISEASE 
1.6.1 Valve endothelial cells  
VECs function as a regulatory interface between the blood and the underlying tissue by being 
able to respond to their mechanical and humoral environment. VECs have been shown to be 
different from other endothelial cells in the vascular system (Butcher et al. 2004; Simmons et 
al. 2005). Their function is regulated by an as yet undefined series of mechanosensitive signal 
transduction pathways that regulate their response to various mechanical or inflammatory 
stimuli (Butcher et al. 2008). Studies on valve calcification show that the endothelium plays 
an important role in the disease process. While many of these studies have focused on 
calcification on the aortic valve, little is currently know about how they may influence the 
process that is seen in some types of MVD.  
The endothelium is a “factory” for the production of biologically active molecules, some of 
which have opposing effects on blood components or underlying cells. These mediators can 
be released by a wide range of vasoactive agents and, more importantly, by mechanical 
stimuli. The flow of blood over the surface of the valve is perhaps the principal physiological 
stimulus for the release of agents such as nitric oxide, which act as a vasodilator on SMCs. 
Other vasodilators manufactured by endothelial cells include prostacyclin (Chiu et al. 2011). 
Endothelial cells also release vasoconstrictors like endothelin and angiotensin II.  
 A wide variety of mediators have been shown to stimulate the endothelium to stimulate the 
release of nitric oxide. One such mediator, with relevance to heart valves is 5-HT, which has 
also been shown to stimulate the release of nitric oxide from VICs (El-Hamamsy et al. 2009). 
It is known that high levels of 5-HT are associated with the pathological changes seen in 
carcinoid MVD and the disease induced by certain appetite suppressants (Rothman 2002). 
The role of VECs in the changes induced by 5-HT is unclear. The raised levels of the amine 
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or mimetic substances that can act as 5-HT agonists may target receptors only found on VICs 
and overpower any modulating effects that might be produced by the endothelium.  
It has recently been shown that the endothelium can modulate the stiffness of valve tissue via 
the action of nitric oxide and endothelin (El-Hamamsy et al. 2009). Changes to the humoral 
and mechanical milieu of the endothelium could therefore have an effect of the distensibility 
of the leaflets. Changes in leaflet stiffness will affect the coaptation of the valve and possibly 
account for initiation of regurgitation of blood across the valve. In comparison to the aortic 
valve, the precise regulatory capacity of the VECs on the MV is understudied. 
VECs and VICs share a common embryonic origin. During embryonic development, some 
VECs undergo a process called EMT, where valve VECs cells lose the expression of surface 
markers, migrate and transform into VICs (Armstrong et al. 2004). Later in life it appears that 
this process continues and may contribute to the replenishment of VICs within the valve. It 
may be considered that while VICs are responsible for maintaining the ECM, VECs are 
responsible for maintaining levels of VICs. This strong relation between these two cell 
phenotypes suggests that they are both involved in common pathways to maintain the 
structure and function of the valve and similarly affected in various disease processes. For 
example, in a model of ischaemic MR in sheep, Dal-Bianco and colleagues have shown a 
four-fold increase in MV VECs undergoing EMT, which is suggested to be an adaptive 
response to leaflet tethering in an attempt to compensate by increasing leaflet area and 
thickness (Dal-Bianco et al. 2009). There is now strong evidence to suggest that secondary 
“functional” MVD is not purely a disease that occurs secondary to other events, and that there 
are associated changes within the MV leaflet itself. Recently, Wylie-Sears et al. have shown 
the importance of mitral VECs in modulating some of the changes seen in functional 
regurgitation (Wylie-Sears et al. 2011). There is a four-fold increase in EMT and expression 
of osteoblastic markers in functional MVD. It is believed that this is a response to changes in 
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the mechanical load (stretch) experienced by the leaflets, as well as possibly other stimuli, 
and the contribution of VECs to the disease process by inducing resident multipotent cells to 
differentiate into osteoblastic VICs 
 
It is not clear whether VECs are involved in the inflammatory process of rheumatic disease, 
but they play a major role in the calcification pathway of rheumatic MVD. Rheumatic valves 
have areas of extensive new vessel formation, inflammatory infiltrate and express makers of 
osteoblastic activity (osteocalcin and osteopontin) in the proliferating MFBs, and on the 
endothelial lining of the newly formed vessels (Rajamannan et al. 2005). Vascular 
Endothelial Growth Factor (VEGF) is also present in inflammatory areas across the entire 
valve, with expression on macrophages and MFBs, while in normal and degenerative valves 
VEGF was only present in the endothelial lining along the atrial surface of the MV 
(Mariscalco et al. 2011). As well as stimulating neo-angiogenesis, VEGF is also believed to 
be involved in regulating bone remodelling by attracting endothelial cells and stimulating 
differentiation of stem cells into osteoblast-like phenotypes (Behr et al. 2011; Street et al. 
2009).  
 
The role of VECs in myxomatous disease is less clear, but the presence of some calcification 
and the change in the mechanical properties of the leaflet suggest that VECs may have some 
involvement in the disease pathway (Wylie-Sears et al. 2011). This could be due an initial 
change to VEC function precipitating changes in valve mechanics, and change in the profile 
of mechanical stimulation seen by VICs, which will subsequently mediate changes in valve 
structure.  
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1.6.2 Valve interstitial cells 
Cells that reside within the valve and are collectively known as VICs; they include 
fibroblasts, MFBs, SMCs and progenitor cells (Durbin et al. 2002). In addition, a population 
of atrial myocytes has also been reported to be present within the annular region of the MV 
leaflets, which appear to contribute to “valvular tone”, which is regulated by a number of 
different contractile systems within the valve (Swanson et al. 2011a). VICs can differentiate 
into MFB-like cells that synthesize ECM and matrix enzymes (Dreger et al. 2002). Enzymes 
secreted include MMPs like collagenase (MMP-1) and gelatinases (MMP-2 and MMP-9), as 
well as the inhibitors of MMPs, TIMPs. VICs are considered the principal initiators of 
collagen synthesis and degradation in the valve leaflets. To maintain leaflet strength and 
function, a tight balance is required between degradation and synthesis of matrix proteins. 
Changes that upset this balance can, therefore, initiate either over-production or excessive 
breakdown. Overproduction of collagens or PGs can result in leaflet thickening, as seen in 
myxomatous valves, while increased expression and activity of MMPs (or a reduction in 
TIMPs) contribute to the accumulation of breakdown products and associated weakness of 
the fibroskeleton of the leaflet.  
 
VICs also synthesise and secrete various mediators, including cytokines, chemokines and 
growth factors (Chester et al. 2007). Although the products released by VICs are well 
understood, the stimuli that initiate VICs to change their production of various biologically 
active substances and enzymes is poorly understood. Inflammatory mediators, mechanical 
loading and stress, genetic factors, all are potential stimuli that affect the behaviour of the 
VICs. Communication between VICs and VECs is important to the homeostasis of the valve. 
VECs appear to contribute to the VIC levels and provide multipotent cells that could 
differentiate into VICs compatible with zonal function (Armstrong et al. 2004) as well as 
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modulating tension that the VICs experience (El-Hamamsy et al. 2009). On the other hand, 
the signalling pathway that mediates the effect of VICs on ECs is not well understood.  
 
In the RVD, and possibly secondary to injury to ECM proteins, VICs are able to produce 
more collagen which will cause the valve leaflet to thicken and fibrose. The VIC population 
is enriched in cells capable of osteogenic differentiation, which include both VICs and VECs 
(Wylie-Sears et al. 2011). These cells may contribute to the calcification seen in rheumatic 
and other subtypes of MVD. It has been shown that there is an inverse relationship between 
levels of Fetuin-A, an acute-phase glycoprotein that inhibits ectopic calcification and the 
extent of MV calcification in patients with RVD (Cagli et al. 2010).  
 
VICs also contribute to disease process by an increase in proliferation in response to 
increased stress and a higher demand to synthesise various ECM components and growth 
factors. In secondary mitral disease, the initial change in geometry of the LV and the annulus 
will cause alterations to the mechanical loading of the leaflet, which has been shown to be a 
stimulus for a change in cell function and most likely the stimulus for leaflet remodelling. It 
has been shown that changes to the mechanical environment of the valve leaflet can stimulate 
the production of matrix proteins (GAGs by 57% and collagen by 15%) that results in 
remodelling of the leaflet (Dal-Bianco et al. 2009; Gupta et al. 2008b; Gupta et al. 2008a; 
Gupta et al. 2009b; Stephens et al. 2009). The remodelling responses appear to be initiated as 
a compensatory response to increase leaflet area and strength.  
 
In myxomatous valves, leaflet remodelling is also the prominent feature of the disease, but 
unlike other types, where there is an increase in the thickness of the leaflet, the most 
prominent feature is that the leaflet becomes “floppy” with excessive redundant tissue. It 
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appears that more MMPs are produced resulting in degradation of matrix proteins exceeding 
the rate of production by the VICs (Mahimkar et al. 2009; Rabkin-Aikawa et al. 2004).  
1.6.3 Valve nerves 
The exact role of the valve nerves in the disease process is not well understood. There is 
evidence to support the involvement of a neural network of both sensory and autonomic 
components within the valve leaflet (Marron et al. 1996), that affect the contractile tissue 
within valve leaflet, and alter valve stiffness in response to change in mechanical demand 
(Swanson et al. 2012).  Nerve fibers within valves release different neurotransmitters like 
nitric oxide and prostaglandins, which can affect the contractility of heart valves leaflets in 
different way, and subsequently could affect VICs function (Chester et al. 2008). Valve nerve 
fibres could play an important role in explaining the remodelling changes associated with 
functional or secondary regurgitation. The changes in the pressure load and fluid dynamics 
could be sensed by the nerve fibres, which will induce a cascade of responses to affect 
endothelial and possibly interstitial cells. 
 
1.6.4 Valve vascular supply 
The cellular components of the valve, which perform a wide range of function to support 
valve durability and function, require an oxygen (O2) supply to support their metabolic 
activity. The MV complex covers a large area in the heart and therefore derives its blood 
supply through different routes. While the left ventricular blood may contribute directly to 
these needs, the MV also has its own network of blood vessels that penetrate the body of the 
valve. Most of the blood supply of the MV complex comes through the left circumflex (LCx) 
artery and its branches. Some variable blood supply comes through the RCA. Blood supply to 
the LV and subsequently to the papillary muscles is crucial to the structure and function of 
the LV and the MV complex. But blood supply to the valve leaflets themselves is more 
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controversial. In 1852, Luschka first described blood vessels in human heart valves, and he 
believed that all atrioventricular and semilunar valves were vascularised normally. Later on, 
this concept changed and it was widely accepted that MV leaflets are avascular structures, 
and that cells in the body of the valve derive their O2 requirement through diffusion from the 
highly oxygenated left ventricular blood (Yoshioka et al. 2006). The presence of vessels in 
the valve leaflets is considered to be a pathological feature by many researchers (Soini et al. 
2003; Yoshioka et al. 2008).  
 
Advances in valve cellular and molecular biology have illustrated the concept of the living 
valve leaflet with cellular components of the valve playing an important role in maintenance 
and function of the valve complex altogether, and modulate many pathophysiological 
pathways. This suggests that valve cells have metabolic activity and therefore require a 
supply of O2 above a level that can be supplied by simple diffusion. This is supported by 
studies that have modelled the diffusion of O2 across heart valves and shown that the thickest 
regions of the valve would be hypoxic without an additional supply of O2 delivered via a 
vascular network (Filion et al. 2003; Wang et al. 2008; Weind et al. 2001; Weind et al. 
2002). Indeed, the vascular supply appears to be directed to these thicker regions (Weind et 
al. 2002). The requirement for O2 may be important for cell function that maintains the 
normal structure and function of the valve.  
 
The role of the vascular blood supply to parts of the MV apparatus is well documented at the 
macroscopic level, where ischaemic events affect the different components of the valve. 
Changes to the blood supply to the left ventricular or septal myocardium, papillary muscles, 
annulus, and the chordae result in changes to the LV geometry and possibly rupture of the 
papillary muscles and the ChT, causing mitral incompetence and regurgitation (Donnelly 
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2008). In contrast, the involvement of the microvascular leaflet supply and their effect on 
VICs is poorly understood; it is not very clear whether the presence of vessels with the valve 
leaflet is a physiological or a pathological process, O2 requirements for valvular cells are not 
known, the effect of changes in blood and O2 supply on the mitral VICs has not been 
examined before, and whether these cells are induced to activate or trigger different pathways 
or functional changes that will contribute further to the disease process.  
 
1.7 OXYGEN HOMEOSTASIS 
1.7.1 Biological function of oxygen 
O2 is the third most abundant element in the universe and constitutes about 50% of the earth. 
It comprises most of the mass in water (H2O) and living organisms. It is an essential 
component in the structure of living cells’ structural molecules including proteins, 
carbohydrates, fats and nucleic acid. It is a key element in the structure and function of the 
cellular enzymes, and an essential part of most of the functional pathways and living 
activities, like synthesis of various cellular products and cellular metabolism (Bartz et al. 
2010; Heffner 2013).  
In addition to its structural significance, the main function of O2 is to support respiration in 
all aerobic cells (Rolfe et al. 1997). O2 is used by the cellular mitochondria to convert energy 
from glucose and fatty acid to the most usable form of Adenosine Triphosphate (ATP), using 
oxidative phosphorylation (Pittman 2013). This process involves the transport of hydrogen 
ions across the inner mitochondrial membrane by means of the electron transport chain. In 
the electron transport chain, electrons are passed through a series of proteins via oxidation-
reduction reactions, with each acceptor protein along the chain having a greater reduction 
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potential than the previous one. The last destination for an electron along this chain is O2, 
which is the ultimate electron receptor in the cell (Babcock 1999; Bartz et al. 2010). 
1.7.2 Oxygen balance  
It is crucial for the cells and organisms to maintain a tight balance of O2 to meet the 
requirements of the cellular survival, growth and function without having serious side effects 
from over- or under-exposure to O2. The rate of O2 consumption varies between different 
types of cells and tissues. Complex physiological structural and functional mechanisms are 
used by mammals to ensure appropriate O2 delivery and homeostasis is achieved. Both over- 
and under-exposure to O2 can have undesired effects (Heffner 2013; Pittman 2011; Semenza 
2011).  
Breathing high O2 concentration or higher partial pressures result in a harmful effect. This 
occurs in conditions of prolonged exposure to O2 therapy such as premature babies and 
ventilated patients, increased partial pressure of O2 such as hyperbaric O2 therapy or diving. 
Potential injury or harmful effects include pulmonary (such as acute lung injury, acute 
respiratory distress syndrome (ARDS) and bronchopulmonary dysplasia) neurological (such 
as dizziness, anxiety and seizures), visual (such as retinopathy of prematurity).  
Hypoxia is deficiency of adequate O2 supply to cells and tissues. Complete deprivation of O2 
is referred to as anoxia. Hypoxia is a relative phenomenon, and depends on what is 
considered normal (normoxic) or physiological O2 level. The complexity of the metazoan 
structures creates a differential O2 environment, where cells are exposed to different levels of 
O2 under normal conditions. Cellular demand, metabolism and requirement of O2 are very 
variable within the same organism, and what is regarding a normoxic for some tissues can be 
hypoxic for others. For example, the level of O2 in the arterial blood is about 10%, compared 
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with bone and cartilage, which have an O2 level of about 1% under physiological conditions 
(Ratcliffe 2013; Simon et al. 2008).  
 
1.7.3 Physiological and pathophysiological role of hypoxia 
Cellular hypoxia is not an uncommon phenomenon both in sickness and health. 
Physiologically, embryonic development occurs under the uterine hypoxic conditions 
(Dunwoodie 2009) and stem cells are maintained in hypoxic niches to protect them from 
oxidative damage. Humans are exposed to hypoxia when living on high altitudes or while 
swimming, diving and exercising (Formenti et al. 2010; Simon et al. 2008).  
 
Pathologically, hypoxia is associated with a few conditions such as ischaemia, wound 
healing, cancer and many others. In vascular ischaemia, there is reduced or loss of O2 supply 
secondary to narrowing or blockage in the blood vessels (Semenza 2010). In cancer, fast-
growing cancer cells have a high proliferation rate and metabolic activity and they will 
usually grow in a spherical fashion, making cells at the centre of the sphere hypoxic. Hypoxic 
cancer cells will then activate various pathways that will support its growth and survival, as 
we will see later (Luan et al. 2013). The wound centre gets relatively hypoxic due to cutting 
off of the blood supply and this subsequently triggers hypoxic pathways that will help in 
recruiting the necessary cells for healing and new vessel formation (Xing et al. 2011).  
 
Lack of adequate O2 supply to the cells will result in making the cells unable to produce 
enough energy to maintain its biological structure and function, and could eventually result in 
cell death, depending on the level and duration of hypoxia and the type of cell involved. 
Since hypoxia is not an unusual event in the cellular life cycle, cells have intrinsic pathways 
to tolerate, cope, adapt and reverse hypoxia (Lee et al. 1996). 
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Generally speaking, cellular responses to hypoxia usually start by altering the metabolism. O2 
consumption and metabolic rate are first reduced (Formenti et al. 2010), then glucose intake 
is increased with increased glycolysis; increased glycolytic pathway and glucose transporters 
(Maxwell et al. 1999). Then it activates various cell survival pathways that will help cells to 
tolerate the hypoxic insult like insulin-like growth Factor-2 (IGF2) (Feldser et al. 1999) and 
Transforming growth factor-α (TGF-α) (Krishnamachary et al. 2003).  
 
Hypoxic response also increases erythropoiesis and iron metabolism in order to increase the 
O2 carrying capacity to the tissue through increasing haemoglobin and erythrocytes. 
Similarly, hypoxia induces angiogenesis to increase blood supply to the affected area and 
provide a long-term solution for hypoxia (Hirota et al. 2006).  
 
1.7.4  Biological pathways involved in the response to hypoxia 
Changes to O2 concentration triggers many changes at cellular and organic levels, and 
subsequently activate various biochemical mechanisms pathways to tolerate, adapt and 
reverse undesired O2 levels and especially hypoxia (Rey et al. 2010). It is now believed that 
the majority of the O2 homeostasis is mediated through the hypoxia-inducible factor-1α (HIF-
1α). It is considered the master O2 regulator, and the most important key player in O2 
homeostasis (Semenza 2013). 
 
HIF-1α is a constitutively expressed transcription factor that, under normoxic conditions, gets 
hydroxylated by prolyl hydroxylase domain protein (PHD) using O2 as a substrate, and then 
gets rapidly degraded. It is very sensitive to reductions in O2 concentration, and once O2 
levels drop it becomes stabilised, translocates to the nucleus, and forms a heterodimer with a 
another subunit called HIF-1β, and induces the expression of large number of genes through 
Introduction 
 
55 
 
binding to hypoxic response elements (HRE) (Masson et al. 2003). Over 1000 genes were 
shown to be modulated by the HIF-1α pathway (Semenza 2013). Some of the well-known 
genes include VEGF (Levy et al. 1995), platelet derived growth factor (PDGF) (Laughner et 
al. 2001), glucose transporter-1 (Glut-1) (Chen et al. 2001), erythropoietin (EPO) (Semenza 
et al. 1992) and caspase-3 and many others (Ke et al. 2006).  
 
Despite the important physiological role of HIF-1α and its importance in regulating O2 levels 
and responses in cells and tissue, this pathway can have maladaptive outcomes and be 
associated with various disease processes (Czibik 2010; Semenza 2011). Even in conditions 
where HIF-1α expression is favourable, like in lung disease associated with reduction in the 
level of O2 in the whole body, where tissues express HIF-1α to counteract the hypoxic insult 
of the disease, over-expression, or uncontrolled expression can result in maladaptive 
responses that can worsen the pathology, like in this case the induction of pulmonary 
hypertension and lung fibrosis (Harrington et al. 2010; Semenza 2005; Tzouvelekis et al. 
2007) 
 
The O2 requirement of the MVICs is not known. Recent studies and models have shown that 
diffusion alone is not enough to meet the O2 requirements of the aortic VICs (Weind et al. 
2001), which is much thinner than the MV. This and the presence of small blood vessels 
supplying parts of the MV suggest that MVICs require a significant amount of O2 to survive 
and maintain the functional integrity of the valve. There have been no studies that have 
examined how VICs respond to hypoxic conditions and how this may impact on their role in 
maintaining valve durability and function. Similarly, it is unknown if VICs express HIF-1α in 
response to hypoxia or what functional responses this transcription factor in turn stimulates.  
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1.8 HYPOTHESIS 
Normal MV leaflets possess a vascular network that is altered in diseased valves. These 
changes will affect the O2 supply to VICs, resulting in tissue hypoxia. Hypoxia will induce 
changes in the functionality of the valve by stimulating the cells to synthesize and secrete 
proteins and enzymes that induce changes in the ECM and vascularisation of the MV. This 
process is mediated by the induction of the transcription factor HIF-1α. 
 
1.9 AIMS AND OBJECTIVES 
The specific aims of this thesis are as follows. 
 
1. To identify the presence and distribution of MV leaflet vessels in porcine valves, as 
well as normal and diseased human valves. 
2. To design and validate a reliable and affordable hypoxic incubation chamber for in 
vitro cell culture, and have the capacity to adapt to various applications of valve 
biology and tissue engineering  
3. To study the effect of hypoxia on MVICs cellular proliferation, death, morphology 
and phenotype.  
4. To determine the effect of hypoxia on MVICs functional response and capacity to 
produced ECM components. 
5. To examine the expression of HIF-1α in normal and diseased human valves, and 
analyse the expression of HIF-1α by MVICs and the role of HIF-1α in mediating the 
hypoxic effects on MVICs.  
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Chapter 2: Mitral valve vascular characteristics 
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2.1 BACKGROUND 
Metazoan cells require energy to survive and function. This energy is generated through the 
metabolism of nutrients, such as glucose and fatty acids, in the presence of O2 as the terminal 
electron acceptor. The cardiovascular system is one of the first systems to develop in utero, to 
ensure enough O2 and nutrients are delivered and distributed to growing cells in adequate 
amounts (Dunwoodie 2009). The cardiovascular system develops into a complex system 
maintaining this vital function. It provides different organs and structures with blood carrying 
O2 and nutrients at different flow rates, concentration and pressure that correspond to the 
needs and demands of the various tissues, with differential perfusion between organs and 
tissues depending on importance and variability in their physiology.  
 
The difference in the needs of various tissues and organs is reflected in the characteristics of 
the vascular supply to them. For example, some organs, e.g. lungs and liver, have dual 
circulation systems; some have extensive vascular distribution, e.g. the kidneys; dual blood 
supply, e.g. the limbs; and bilateral communication, e.g. the brain. 
 
Learning about vascular patterns and characteristics proved to be crucially important; it 
identified various pathological processes affecting different organs, and with increased 
knowledge, more preventive intervention and better treatment options are being designed and 
used. For example, antiplatelet and statins therapy are now widely used to reduce 
atherosclerosis complications; revascularisation treatment is used to restore vascular supply 
beyond diseased vessels.  
 
Very little is known about the vascular characteristics of heart valve leaflets, and for decades 
it was widely believed that heart valves are passive flaps of tissue that open and shut due to 
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changes in flow and pressure. It is now well known that valve leaflets are active structures 
that contribute to the function of the valve. There is also increased understanding of the role 
of valve cells in maintaining the function and durability of the valve, suggesting that those 
cells are metabolically active. Nevertheless, their metabolic rate, O2 requirements and effect 
of changes to O2 supply are unknown.  
 
The vascular characteristics of the MVs are not well understood, and there is significant 
controversy on the presence of leaflet microvessels and relationship to valve disease. In 
addition, the role of valve vascular supply and O2 requirements of MVICs are unknown.  
  
2.1.1 Aims and objectives  
The aim of this study was to identify the vascular characteristics of the MV in normal porcine 
valves as well as normal and diseased human MVs. The study used up-to-date imaging 
techniques that will aim to map the distribution of blood vessels across the MV to understand 
the reliance of MV cells on a continual O2 supply.  
 
This was achieved by assessing porcine MV leaflet vascular characteristics using different 
techniques, including macroscopic assessment using ink perfusion, microscopic assessment 
using 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI dye perfusion 
and immunohistochemistry. The vascular characteristics of normal and diseased (rheumatic 
and myxomatous) human MV leaflet will be assessed using immunohistochemistry. 
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2.2 METHODS 
2.2.1 Porcine mitral valve collection 
Porcine hearts (18–30 months old) were obtained from a commercial abattoir (Cheale Meats, 
UK). After sacrifice, the hearts were immediately placed in an ice-cold Hanks solution 
(Sigma, UK), and transported to the lab. They were kept in sterile conditions and used for 
various experiments within 4 hours of animal sacrifice.  
 
2.2.2 Macroscopic assessment of porcine mitral valve leaflet vessels 
In order to examine the macroscopic characteristics of vascular supply to the MV, dye 
perfusion experiments were designed and adapted from previously reported similar 
experiments (Muti et al. 1972; Smith et al. 1971a; Smith et al. 1971b; Weind et al. 2002). 
The aortic root was dissected and both the right and left coronary directly cannulated using 
Tibbs arterial cannula (DTR Medical, Swansea, UK). Sometimes the left main stem was 
noticed to be very short, in which case the left anterior descending artery (LAD) and LCx 
arteries were cannulated separately. The arteries were flushed with heparin/saline 1,000 
IU/ml. About 30–50 ml of undiluted water-soluble commercial ink was infused into each 
ostium using a 50 ml syringe connected through a three-way tap to a pressure manometer. 
Perfusion pressure was maintained at 140–160 mmHg. The heart was then opened and the 
MV was dissected en bloc. The valve was viewed using a dissecting microscope, and pictures 
were taken using a digital camera (iphone 4, Apple, California, USA).  
 
2.2.3 Microscopic assessment of porcine mitral valve leaflet vessels 
In order to examine the characteristics of the MV vessels at higher magnification, DiI 
perfusion was used. Lipophilic carbocyanine dye DiI directly binds to endothelial cell 
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membranes and has high fluorescent signal intensities unlike other dyes like Indian ink, 
which are mainly space-occupying contrast solutions.  
 
The method used is the same as previously described for smaller animals by (Li et al. 2008). 
Briefly, DiI stock solution was prepared by dissolving 100 mg of DiI crystals in 16.7 ml of 
100% ETOH on a rocker overnight covered with aluminium foil, and stored at RT. DiI 
working solution was prepared before use by adding 200 µl of the DiI stock solution into 
10 ml of diluents (phosphate buffered saline (PBS) and 5% glucose at 1:4 ratio). Hearts were 
prepared as described above, direct cannulation of the coronary ostia, and washed out with 
1,000 IU/ml heparin/saline solution initially, then washed with PBS. Then DiI dye was 
injected; 10 ml were injected to each of the LAD, LCx and RCA through three separate 
cannulae over 15–20 minutes. At the end of the perfusion, the hearts were opened and the 
MV leaflets excised, washed with PBS, mounted on slides and viewed on laser confocal 
microscope.  
 
2.2.4 Immunohistochemical staining for vessels in porcine mitral valve leaflets 
The microvascular characteristics of porcine MV leaflets were examined using 
Immunohistochemistry. Porcine valves were collected, fixed in 10% formal saline and 
processed into paraffin, sectioned and stained for isolectin B4 (IsLB4), which specifically 
binds endothelial cells (Li 2008). 
 
Paraffin fixed valves were cut into 5 µm thick sections and dewaxed in xylene and rehydrated 
to water with descending concentrations of alcohol. Sections were microwaved in 0.1 M 
citrate buffer (PH 6) for 10 minutes and left in the same buffer for further 20 minutes; washed 
in water before blocking for 60 minutes. The blocking buffer contained 5 µl of 1 mm MgCl2, 
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13.3 µl of 1 mm MnCl2, 4 µl of CaCl2 in10 ml tris(hydroxymethyl)aminomethane (Tris) 
buffer. Sections were incubated with biotinylated IsLB4 at 1:100 dilution for 60 minutes, 
washed in Tris buffer several times and streptavidin peroxidise (Dako, Ely, UK) for 20 
minutes followed by 3,3'-diaminobenzidine (DAB) and chromogen for 5 minutes. Sections 
were washed in tap water, stained with haematoxylin for 2 minutes and mounted using 
Aquatex (VWR, Lutterworth, UK). 
 
2.2.5 Human valves collection  
Normal human valves were collected from the Royal Brompton and Harefield NHS trust 
Valve Bank. These valves were judged to be unsuitable for clinical use and were then given 
over to research if the appropriate consent had been obtained. Reason for rejection by the 
Valve Bank ranged from early sign of calcification in the aortic valve or root, tears or 
fenestrations on the aortic valve cusp, prior recent travel to certain countries or recent body 
tattoos.  
 
Typically, aortic valves are harvested by the Valve Bank. However, the anterior leaflet of the 
MV is always left attached to the aortic root. However, on some occasions we also received 
the posterior leaflet as well. Six normal MVs were collected from four females, and two 
males with age range of 41 to 58 years. The normal MV leaflets were initially fixed in 10% 
formal saline for 24 hours, and then valve leaflets were cut into strips in the radial or 
circumferential direction (when there was enough tissue present strips were prepared in both 
direction from the same specimen) and fixed in paraffin. The rheumatic valves were obtained 
from Aswan Heart Centre, Egypt, courtesy of Prof Sir Magdi Yacoub. There were no clinical 
data available for the rheumatic valves as part of the agreement with Aswan Heart Centre. All 
samples were kept completely anonymous.  
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Because the majority of the leaflets of the normal and rheumatic valves were anterior leaflets, 
only anterior leaflets of myxomatous degenerative valves were collected. These valves were 
collected from patients with MVD who underwent valve replacement. Segments from 
repaired valves were not collected because of their small size, which would not have been 
very representative, and also lacks the control from normal or rheumatic valves. Myxomatous 
MVs were collected from two males and two females with age range of 61 to 83 years. 
 
2.2.6 Immunohistochemical staining for vessels in human mitral valve leaflets 
The microvascular characteristics of human anterior MVs leaflets were examined using 
immunohistochemistry. Paraffin fixed valves were sectioned and stained by CD31. Paraffin 
sections were incubated at 60°C overnight, dewaxed in xylene and rehydrated in industrial 
methylated spirit. The slides were put in a Tris-ethylenediaminetetraacetic acid (Tris-EDTA) 
buffer, microwaved for 10 minutes, cooled at RT, then washed with TBS. Peroxidase-
blocking solution (3% H2O2 in Tris-EDTA) was added for 10 minutes, and then washed with 
TBS twice. Slides were incubated with 3% bovine serum albumin (BSA) (Sigma, UK) in 
TBS with 0.1% Tween-20 (TBS-T) for 30 minutes before incubating with CD31 primary 
antibody (Dako, UK) diluted in TBS with 1.5% BSA at 1:40 for 1 hour. Slides were washed 
three times with TBS for 5 minutes each time, and incubated with link biotinylated secondary 
antibody for 30 minutes, washed again with TBS, incubated with streptavidin peroxidase for 
20 minutes, and finally incubated with 2% of DAB for 3 to 4 minutes, washed with cold 
water and put in haematoxylin for 1 minute and mounted with Aquatex (VWR).  
Two independent assessors assessed the presence, distribution and characteristics of the 
vessels qualitatively. A semi-quantitative analysis was also performed to compare the 
dimensions of the vessels. Leaflet vessels were chosen randomly from three normal, three 
rheumatic and three myxomatous valves. Ten vessels were chosen from each valve (total 30 
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for each condition), and were analysed using NIS elements software v3.0 (Nikon, UK). A line 
was drawn around each vessel’s outer diameter and another one around the lumen of the 
vessels. The software then calculated the outer diameter and the lumen area of each vessel. 
Data was pooled and t-student test was calculated using GraphPad prism software. Data were 
represented as mean ± standard error of the mean (SEM). 
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2.3 RESULTS 
2.3.1 Macroscopic examination of porcine mitral valve leaflet vessel 
2.3.1.1 Ink perfusion 
The ink perfusion of porcine coronary circulation resulted in discolouration of the whole 
heart, and demarcated the MV leaflets rich network of vessels. These vessels penetrate the 
leaflet through two routes: mostly through the annulus; some through the ChT. The vessels 
are more prominent on the atrial side of the leaflet. Most of the bigger branches appeared to 
cross the leaflet from the annulus in a radial fashion. There was no specific distribution 
pattern between different hearts, and they appeared to branch in all directions. The density of 
the vessels was also variable (Figure 2.1 A–D). The vessels arising from the ChT appear to 
result in general discolouration at the junction between the chord and the leaflet (Figure 2.1 
E), which indicates that there are central vessels as well as small superficial vessels on the 
outer side of the chordae (Figure 2.1 F) that run from the papillary muscles all the way up to 
the leaflet. The anterior MV leaflets appeared to have more vessels compared with the 
posterior leaflet.  
 
Selective perfusion for separate coronary arteries was also performed. RCA perfusion alone 
produced little perfusion to the MV leaflets compared with the left side. Performing selective 
perfusion to the LAD and the LCx separately showed variability in the distribution pattern 
with selective perfusion to one artery or the other resulted in anywhere between extensive 
perfusion to very little.  
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Figure ‎2.1 - Ink perfusion of the porcine mitral valves  
Macroscopic assessment of the vascular network of a porcine mitral valve leaflets excised 
after perfusing the whole heart with water-soluble black ink. The view is of the atrial side of 
the leaflet, and shows vessels running down from the annulus (top) throughout the leaflets 
and travelling in both directions. Anterior leaflets (A, B) are more vascular compared with 
posterior leaflets (C, D). The figure also shows vessels originating from the papillary muscles 
and travelling up the ChT towards the mitral valve anterior leaflet both deep within ChT (E) 
as well as superficially (F). 
 
 
A B 
C D 
F E 
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2.3.1.2 DiI perfusion 
MV leaflets from DiI dye-perfused porcine hearts were removed and viewed under confocal 
microscope. Leaflet blood vessels were coloured with strong red fluorescent colour and 
showed the extent of the vascular tree within the MV (n=2). In addition to the superficial 
vessels viewed by ink perfusion, this technique showed that leaflet vessels branch into an 
extensive vascular tree, and penetrate the leaflet in al directions and cover most of it in a 
three-dimensional fashion (Figure 2.2). This data confirms the extensive vascularisation of 
the MV leaflets. 
 
Figure ‎2.2 - DiI perfusion of the anterior mitral valve leaflet 
Microscopic assessment of the vascular network of a porcine mitral valve leaflets excised 
after perfusing the whole heart with DiI dye and visualised under the confocal microscope at 
10x (A) and 40x (B). The figures show the extensive three-dimensional vascular tree 
penetrating valve leaflet in al direction and branching into different sizes covering most of 
the leaflet structure. 
 
2.3.2 Mitral valve leaflet vessel assessment using immunohistochemistry 
2.3.2.1 Porcine valves 
Histological examination of porcine MV leaflets using IsLB4 immunostaining has shown 
clearly wel-defined vessels in anterior and posterior leaflets as wel as vessels in the ChT 
(Figure 2.3). The vessels crossed in diferent directions. Vessels were identified by clear 
endothelial staining in a rounded form. The identified vessels had also clear wals with 
prominent media. Some capilaries with only endothelial lining were also occasionaly seen. 
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Figure ‎2.3 - Immunohistochemical assessment of porcine mitral valve vessels 
Porcine mitral valve leaflets and ChT were paraffin fixed, sectioned and stained for IsLB4 at 
10x (Panel A) and 40x (Panel B). The figures show leaflet vessels in both anterior (1A, B) 
and posterior (2A, B) leaflets as well as ChT (3A, B).  
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2.3.2.2 Human valves 
2.3.2.2.1 Normal human valves 
Vascular structures within normal human anterior (n=6) and posterior (n=3) MV leaflets as 
well as ChT (n=3) were characterised by the presence of CD31 staining. Vessels were present 
in all valves examined. They were present in all three layers of the leaflets of anterior (Figure 
2.4) and posterior (Figure 2.5) leaflets. There was no specific pattern of distribution of blood 
vessels in the valves examined. The vessels crossed the leaflet in both vertical and horizontal 
dimensions. The vessels appeared to have only a single endothelial layer. There was a high 
degree of variability in the pattern of distribution of the vessels where some areas had clusters 
of vessels together, while others had scattered vessels throughout. There were many areas and 
sections where no vessels could be identified. Vessels were also present in ChT (Figure 2.6), 
usually in the outer layer. Sections proximal to the papillary muscles showed extensive 
vascularisation at the transitional area between the muscle and the ChT, mainly in the core, 
and is related to myocardial fibres (Figure 2.6 -1A, B). 
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Figure ‎2.4 - Immunohistochemical assessment of normal human anterior mitral valve 
leaflet vessels 
Human anterior mitral valve leaflets were paraffin fixed, sectioned and stained for CD31 at 
10x (Panel A) and 40x (Panel B). Figures show a different vascularisation pattern for three 
leaflets. (Panel 1) shows vessels distributed in the middle of the leaflet, while in (Panel 2) 
leaflet was void of any vessels. (Panel 3) shows a cluster of microvessels near the surface of 
the leaflet.  
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Figure ‎2.5 - Immunohistochemical assessment of normal human posterior mitral valve 
leaflet vessels 
Human posterior mitral valve leaflets were paraffin fixed, sectioned and stained for CD31 at 
10x (Panel A) and 40x (Panel B). Figures show a different vascularisation pattern for three 
leaflets where (Panel 1) shows leaflet void from any vessels, (Panel 2) shows vessels 
distributed in the middle of the leaflet and (Panel 3) shows a cluster of vessels near the 
surface of the leaflet.  
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Figure ‎2.6 - Immunohistochemical assessment of normal human mitral valve ChT 
vessels 
Human posterior mitral valve ChT were paraffin fixed, sectioned and stained for CD31 at 10x 
(Panel A) and 40x (Panel B). In (Panel 1) a section was taken at the junction of the papillary 
muscle and the chordate and shows vessels are seen in the fibrous part of chordate (solid 
arrow). The other vessels seen in middle (dotted arrows) are vessels within the papillary 
muscle, which are more extensively vascularised. (Panel 2) also shows vessels within the 
ChT, and (Panel 3) shows a chordate that does not have vessels running within.  
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2.3.2.2.2 Rheumatic human valves 
The rheumatic leaflets examined clearly showed a high degree of vascularisation (Figure 2.7). 
There was an increase in number, size and morphology of the vessels. The observed vessels 
were larger in size, and had a very thick wall compared with normal leaflet vessels. Vessels 
had different shapes, and some were irregular. There was also some variability between 
valves examined and within the same valve sections. In some valves, extensive 
vascularisation was limited to some areas only, while the rest of the valve did not have any 
vessels. In some other valves, vessels were distributed across the whole valve area.  
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Figure ‎2.7 - Immunohistochemical assessment of rheumatic human valve anterior 
mitral valve leaflet vessels 
Rheumatic human anterior mitral valve leaflets were paraffin fixed, sectioned and stained for 
CD31 at 10x (Panel A) and 40x (Panel B). Figures show vascularisation of three different 
leaflets (Panels 1, 2, 3) where there is increased in vascular density, size and thickness of 
leaflet vessels.  
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2.3.2.2.3 Myxomatous human valves 
In the myxomatous degenerative valves examined, no vessel could be identified (Figure 2.8). 
There were very few CD31 positive cells seen scattered in the valve, and more in the 
subendothelial layers, but were unable to relate to vascular structures.  
 
 
Figure ‎2.8 - Immunohistochemical assessment of myxomatous human valve anterior 
mitral valve leaflet vessels 
Myxomatous human anterior mitral valve leaflets were paraffin fixed, sectioned and stained 
for CD31 at 10x (Panel A) and 40x (Panel B). Figures show three different leaflets (Panels 1, 
2, 3), which completely lack any vessels.  
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2.3.2.2.4 Leaflet vessel semi-quantification 
Analysis of individual valve leaflet vessel dimensions showed that vessels from normal MV 
leaflets have an average lumen area of 197±28 µm2 (Figure 2.9A) and an outer diameter is 
15±1 µm (Figure 2.9B). In rheumatic valves there is a significant increase in the vessel’s 
dimensions; the average lumen area was 2144±815 µm2 (P<0.001) and outer diameter of 
120±29 µm (P<0.001). No vessels from myxomatous valves were identified.    
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Figure ‎2.9 - Mitral valve leaflet vessels semi-quantification 
Leaflet vessels from normal, rheumatic and myxomatous human mitral valves were randomly 
selected and measured using NIS elements software. Both lumen area (A) and outer diameter 
(B) were statistically larger in rheumatic valve vessels compared with normal valve vessels. 
No myxomatous vessels were identified. *P<0.001 (n=3) 
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2.4 DISCUSSION 
 
This study clearly shows the vascularisation of porcine and human MVs. Porcine MV leaflets 
are supplied by an extensive three-dimensional network of vessels that travel both through 
the annulus and up the ChT. Histologically, the vessels are well defined with clear three 
layers within the wall, prominent media and clear lumen. Normal human MV leaflets were 
shown to have vascular structures. Vessels were present in all three layers of the leaflets. 
There was no specific pattern of distribution of blood vessels in the valve. The vessels 
appeared to have only a single endothelial layer. 
The use of a porcine model was very useful since it allowed some experiments to be 
performed that would have been be extremely difficult to perform in human specimens, such 
as the ink perfusion tests. Porcine valves are commonly used as a study model because of the 
similarities between human and pig, and pig valves are commonly used for providing a 
bioprosthetic valve implants.  
The presence of vessels within heart valves was first described (Bayne-Jones 2014; Kerr et 
al. 1925; Muti et al. 1972) by Lushcka in 1852. He first described the constant presence of 
vessels in the atrioventricular valvular cusps in humans and other species using stained liquid 
perfusion of the coronary arteries, and in 1858 the same author reported the presence of valve 
vessels in the semi-lunar valves. These finding were confirmed by subsequent studies like 
Henle in 1868 and others (Bayne-Jones 2014; Gross 1937; Wearn et al. 1937).  There have 
also been more recent observation using modern techniques (Saini et al. 2013).  
Despite these observations, other researchers disagreed with these findings and showed that 
normal human valves are avascular structures. They believed that all human valves do not 
have any vessels under normal conditions (Joseph and Virshow both in 1858), and the 
presence of valvular vessels could be related to myocardial extensions within the leaflet 
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(Langer 1881) and (Muti et al. 1972) or secondary to a disease process like inflammation as 
in RVD (Cadiat 1877), or atherosclerosis (Soini et al. 2003). Another interesting theory was 
introduced first by Langer 1880, and followed up by Gross and Kugel (Gross 1937) and 
Duran and Gunning (Duran et al. 1968), that blood vessels may exist in normal human valves 
as vestiges of the embryonic state. This has originated from the fact that human foetuses 
possess an extremely dense, very prominent vascular network of capillaries in all valves 
reaching the free edge and anastomosing with vessels from papillary muscles travelling up 
the ChT, whereas adult valves are hardly vascularised. They believe this is due to a degree of 
regression from the normal foetal circulation that occurs at an early age.  
 
The normal human valves used in this study were obtained from donors without any evidence 
of cardiac or inflammatory disease taken from patients with age range of 41–58 years. There 
was no evidence of macroscopic or microscopic disease upon examining the specimens. Any 
myocardial extensions noticed grossly were carefully removed before fixing the valve.  
 
The method used to define valve vessels was immunohistochemical staining using CD31, 
which is a specific endothelial marker that positively identifies the endothelium of the 
vessels. This technique is much more specific and reliable than ink or dye perfusion initially 
used in this and many of the previous studies. Although hearts were washed with a solution 
containing heparin, maintained in a physiological solution and coronary arteries perfused 
with ink under physiological pressure, there is still a significant chance that some clots, 
spasms and poor perfusion prevented the visualisation of all the vessels. 
 
The study showed that 100% of the normal valves contained valve vessels. This is much 
higher than what was reported in previous studies. There has been large variability in viewing 
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the vessels within valve leaflets, and that ranged from about 2 to 74% (Gross 1937). Wearn et 
al. (Wearn et al. 1937) reported that 66% of all non-inflamed hearts have one or more 
vascular valve, but only 24% of all MVs contained vessels extending beyond the proximal 
third and not related to myocardial extensions. Most recently Saini and co-workers (Saini et 
al. 2013), looked at normal human atrioventricular vascularisation using microscopic 
assessment with Masson’s trichrome and van Gieson staining, and found blood vessels 
present in 23% of the MVs examined, yet with large variability, and no specific pattern of 
distribution. The fact that all the normal valves examined in this study contained vessels 
could be explained with the unique technique of using CD31 as a marker for vascular 
endothelial cells, which would present in any vascular structure, and is very sensitive 
compared with the perfusion methods used before. Nevertheless, within the examined valves, 
there was a very high degree of variability, similar to previous studies where there was no 
specific distribution pattern. Some sections of the valves were completely avascular; some 
others contained scattered vessels; while other parts had clusters of vessels. It is very difficult 
to explain this variability in vascularisation, but possible theories could include age-related 
changes, valvular or individual variations or unknown pathological process. 
 
The study has shown a clear and remarkable level of vascularisation of the porcine MV 
leaflet that was easily demonstrable even at macroscopic level. The presence of valvular 
vasculature in pigs and other species is well documented and was more consistent. Other 
species studied include cattle, sheep, dog, rabbit and guinea-pig (Duran et al. 1968; Ellison et 
al. 1973; Kerr et al. 1925; Smith et al. 1971a; Smith et al. 1971b). 
 
Weind and colleagues (Weind et al. 2000) more recently re-examined the vascular blood 
supply of the thinner normal aortic valve in pigs using the same old principle of ink perfusion 
but using a more advance setup, including microscope, digital camera and software. They 
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clearly show the microcirculation of the leaflets. Subsequently, the group mapped the 
relationship between vessel density and thickness of the leaflet in porcine aortic valve 
leaflets, and found the presence of leaflet vessels correlated with the thickness of the valve 
leaflet and generally vessels were present when the cusp leaflet exceeded 0.5 mm (Weind et 
al. 2002). Swanson and colleagues (Swanson et al. 2009) described the MV anterior leaflet 
perfusion patterns in sheep using fluorescein angiograms. They showed the presence of a 
complex web of blood vessels within the leaflet tissue with vessels forming loops and 
extending to the insertion of the secondary ChT and created anastomotic loops. Selective 
perfusion showed that most of the vessels originate from mid and distal LCx via both annular 
and papillary muscle branches.  
 
Despite these observations on the presence of a vascular supply to the valve, it became 
widely accepted that valve leaflets are avascular structures (Hakuno et al. 2011; Yoshioka et 
al. 2008) and they derive their O2 requirement through diffusion from the highly oxygenated 
left ventricular blood (Weind et al. 2000), such as cartilage and cornea (Kalluri et al. 2006). 
Thus the precise role and function and in physiology or pathophysiology of these blood 
vessels remain unclear.  
 
Weind and colleagues (Weind et al. 2001) started the work on measuring O2 diffusion and 
consumption in valve leaflets. They used porcine aortic valve leaflets, and then they modelled 
the O2 diffusion and requirement across the leaflet in one-dimensional model. They predicted 
that based on diffusion alone many areas within the valve leaflet will be hypoxic. They 
calculated the diffusion capacity of maximum distance that O2 can be supplied from cusp 
surface in the tissue of about 0.2 mm, i.e. leaflet must be less than 0.4 mm thick to avoid zero 
O2 levels at the centre of the leaflet (Weind et al. 2002). Further similar studies in two-
Mitral valve vascular characteristics 
 
81 
 
dimensional (Filion et al. 2003) and three-dimensional (Wang et al. 2008) models showed 
similar results and predicted large hypoxic areas inside the “relatively” thin aortic valve and 
that a microcirculation is needed to satisfy the O2 demands of the thicker regions of the native 
aortic valve cusps. The predicted data correlated well with the measured O2 consumption data 
and with the actual distribution of the microvessels shown before (Weind et al. 2002).  
 
These models still have limitations and it remains difficult to discern the real in vivo 
metabolic demand, O2 consumption and diffusion capacity of the valve, because it is a 
complex process that contains multiple factors, many of which are difficult to measure. These 
models used valve cusps that were static, while in real-life the cusps are mobile and very 
active. Also there is variability in the leaflet relative composition of compounds like 
collagens and GAGs. Cusps are variable in the thickness and surface geometry. Some areas 
are under more stress and pressure than others, and more likely to sustain tissue injury and 
repair, therefore have higher metabolic activity. Also valve thickness itself is dynamic and 
changes in systole and diastole, where is it about 40% thinner. In vitro studies showed that 
VICs O2 consumption also varies with cell density, passage number and the level of O2 
(Wang et al. 2009). This indicates that valve tissue has significantly high metabolic activity 
(Weind et al. 2001) and that diffusion of O2 to the centre of the valve from the surrounding 
blood will be not able to meet the metabolic demand of the valve cells alone like previously 
assumed. 
The present study was initially planned to quantify the density of the valve vessels in 
different regions of valve leaflet in healthy and diseased valves, as vascular density can be an 
important biological marker in many conditions, such as cancer and lymph node metastasis, 
and can have an important diagnostic value and a prognostic indicator. A standard method 
that is used for this quantification is the Weidner technique (Weidner et al. 1991), which 
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involves immunohistochemical staining with various endothelial markers like CD31, CD34 
and von Willebrand Factor (vWF) (Hamid et al. 2003) and then identifying areas of highest 
vascular density called “hot spots”, and counting high-power fields (HPFs) using a counting 
grid (Moreira et al. 2011; Winter et al. 2011). This technique is subjective and observer-
dependent, especially when identifying which hot spots to evaluate. New alternative 
techniques thought to be more precise and able to reproduce the same results include whole 
slide quantification using motorised stage scanning optical microscope or autofocus device 
slide scanner (Balsat et al. 2011). This is along with using more complex computerised 
software (van Niekerk et al. 2009). Unfortunately, this new technology was not available for 
this study to perform a reliable vessel density analysis. Performing manual quantification 
would have been very unreliable in view of the large variability of the presence and 
distribution of vessels within valve leaflets, and therefore was abandoned. Sections were 
reviewed by two independent assessors to reduce bias. The study was able to clearly 
demonstrate the presence of vessels in the normal anterior human MV leaflets from middle-
aged donors that are disease free, and not related to myocardial extensions.  
Further study of diseased MV leaflets has shown two significant patterns of leaflet 
vascularisation seen in two different conditions. In rheumatic MV anterior leaflets, there was 
an obvious increase in vascularisation, in terms of number of vessels, size, morphology and 
frequency. On the other hand, there was complete abscence of vascularisation in myxomatous 
degeneration.  
The vascular changes seen in the rheumatic valves were very striking. The affected areas 
were full of vessels of variable shapes and sizes. Semi-quantification of the vessels, has 
confirmed the big significant difference between rheumatic and normal vessels. Rheumatic 
vessels have much larger outer diameter and lumen area. Vessels were very muscular with 
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clear three layers as well. These findings support the idea that there is a neovascularisation 
process happening at the site of the disease. The increased vascularity of rheumatic valves 
has been well documented before (Donnelly 2008; Rajamannan et al. 2005), and due to the 
high prevalence of RVD at the time, many researchers were led to believe that the presence 
of vessels in valve leaflet labelled as “normal” could be due that fact that that these leaflet 
must have been affected by some form or another of RVD already. But none of these studies 
have described the characteristics of these vessels.  
The neovascularisation phenomenon was also seen in other types of valve disease including 
endocarditis (which is also considered inflammatory) and more recently in aortic valve 
stenosis, sometimes referred to as “atherosclerotic” valve disease (Soini et al. 2003). 
Different theories have been proposed to explain this observation. First was the theory that 
normal valve have microvessels within them, and bacteria reaches the valves through the 
bloodstream and cause infection and inflammation (Kerr et al. 1925). Another theory on the 
neovascularisation seen in atherosclerotic valve disease is that process is initiated by an 
endothelial injury causing thickening of the valve as a consequence of abnormal deposition of 
ECM and thus preventing O2 supply by diffusion. Hypoxia will then induce the production of 
angiogenic factors that will cause angiogenesis like VEGF and NOS. Also the associated 
inflammatory response contributes to this process where inflammatory cells like macrophages 
and monocytes are induced by hypoxia to release large quantities of angiogenic factors (Soini 
et al. 2003). More recently a new theory was proposed. That is, in adults, angiogenesis is 
considered constitutively quiescent due to the balance between angiogenic and angiostatic 
factors, and, in disease, this balance is deregulated, and angiogenesis is increased as in 
cancer, inflammatory and atherosclerotic diseases (Carmeliet et al. 2000).  
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The Japanese group of Yoshioka and colleagues adopted this idea. They believe that cardiac 
valves are avascular and O2 supply is via diffusion from bloodstream. They believe that 
vascularisation is present in pathological process like rheumatic heart disease and 
atherosclerosis (aortic stenosis) due to reductions in anti-angiogenic factors. Firstly they 
looked at chondromodulin-I (Chm-I), which is a glycoprotein located primarily in avascular 
tissue of eye and cartilage. It has anti-angiogenic activity, and a capacity to inhibit endothelial 
cell proliferation and tube morphogenesis. Chm-I was present in all normal human heart 
valves, which were found to be completely avascular too. In comparison, valves with 
atherosclerosis and rheumatic heart disease showed increased vasculature. Chm-I was 
markedly down-regulated in regions of new vessel formation that strongly expressed VEGF-
A (Yoshioka et al. 2006). In their subsequent work, they looked at the ChT (Kimura et al. 
2008b). ChT did not have any Chm-I, but expressed tendomodulin, although this 
glycoprotein was not expressed in heart valve tissue. It is another glycoprotein that is present 
in hypovascular tissues, such as tendons and ligaments, and is related to Chm-I and has anti-
angiogenic effect too. They also found ChT to be avascular structures similar to skeletal 
tendons. When they examined ruptured human ChT, they found that ruptured area was 
associated with decreased tendomodulin, an increase in VEGF, neovascularisation and 
activation of MMPs. They believe this is the mechanism involved in ruptured ChT.  
Another pro-angiogenic factor examined was periostin (Hakuno et al. 2010). It is a TGF-β1-
inducible protein that is expressed in different cells like cancer cells, fibroblasts and vascular 
SMCs and contributes to angiogenesis, metastasis and cell migration. Periostin was present in 
all four normal human valves mainly in the subendothelial superficial layer. It was up-
regulated in atherosclerotic and rheumatic heart valve disease especially in areas with 
increased neo-angiogenesis, and the expression pattern has changed to involve all layers. 
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Similar findings were also reported by Rajamannan et al. (Rajamannan et al. 2005) where 
rheumatic mitral and aortic valves showed significant neoangiogenesis associated with 
increase in VEGF expression, an intense inflammatory response and expression of osteogenic 
markers in areas of calcification. Mariscalco and colleagues (Mariscalco et al. 2011) also 
found reduced expression of Chm-1 and increased expression of VEGF and its receptors in 
rheumatic valves. 
 
Unlike rheumatic valves, the difference in vascularisation between normal and myxomatous 
MVs is less remarkable. All previous work in this area reported that both normal and 
myxomatous valves were avascular structures and, therefore, there was no difference between 
them with regard to vascularisation (Mariscalco et al. 2011; Rajamannan et al. 2005; 
Yoshioka et al. 2006). This can be justified by the large variability of the distribution of 
vessels in normal leaflets noticed in this study and previous studies as discussed earlier. Loss 
of valve vessels is also likely to occur in other similar pathologies like dilated aortic root as 
evident from Soini and colleagues (Soini et al. 2003); the valves they referred to as normal 
were obtained from patients with dilated aortic root/valve and showed no vessels compared 
with stenotic valves.  
 
This study has defined a different pattern of vascularisation between normal and myxomatous 
valves, where there was abscence of vascularisation of the later compared with the former 
and, therefore, it is important to appreciate that there are two different disease processes that 
affect human MVs that have opposite vascular characteristics. This concept can be 
challenged by few criticisms. First is that the sample size of the study was small and, second, 
is that the myxomatous valves were taken from an older population compared with the 
normal valves which could have more regression of vessels anyway. 
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The small sample size is one of the limitations of this work. But, even if we assumed that 
there is a loss of vascularity of the leaflets as a consequence of ageing (Saini et al. 2013) 
rather than disease per se, this cannot be considered a natural change, and does not rule out 
the association of myxomatous disease with loss of vascularisation. Rather, it supports the 
argument that loss of vascularisation can be an initial step, a contributing factor, or a 
consequence of the myxomatous disease process. This is supported by the finding from the 
same studies that showed no difference between normal and myxomatous disease. 
Rajamannan and colleagues (Rajamannan et al. 2005) showed no expression of VEGF in 
myxomatous valves. Hakuno and colleagues (Hakuno et al. 2010) showed no difference in 
the expression of the pro-angiogenic periostin, while Mariscalco and colleagues (Mariscalco 
et al. 2011) showed a significant increase in the anti-angiogenic Chm-1 in myxomatous 
valves. Even if we assume that loss of vascularisation is just a coincidental finding and an 
unrelated event to myxomatous disease, it by itself is an important finding. It indicates that 
whatever pathological process is activated in conditions, like inflammatory or atherosclerotic 
heart disease and associated with neovascularisation, is different from what happens in 
degenerative myxomatous MVD. 
In conclusion, this study clearly demonstrates the consistent yet variable presence of MV 
vessels in both normal human valves as well as porcine ones. It also identifies two distinct 
vascular patterns associated with two different diseases, and introduces the new concept that 
vascular characteristics of MV leaflets change in opposite directions between inflammatory 
and degenerative valve diseases. Therefore, MV leaflet vessels must have an important 
function in the maintenance and homeostasis of those leaflets, and point to the importance of 
O2 and other vascular mediators in this process, and the potential involvement of different 
mechanisms and pathways in valve leaflet biology. The effect of changes in O2 concentration 
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on MV cells has never been examined before. Therefore, it will be pertinent to determine the 
dependence of VICs on different O2 concentrations to survive, and maintain their function, in 
order to elucidate the importance and role of the vascular supply in valve leaflets.  
  
The hypoxic chamber 
 
88 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3: The hypoxic chamber 
 
 
 
 
 
 
 
 
  
The hypoxic chamber 
 
89 
 
3.1 BACKGROUND 
The use of cells isolated from tissue and grown in culture is a valuable and widely used tool 
in biological research. Many different types of cells can be grown in the laboratory under a 
controlled environment that provides the required nutrients and growth factors, as well as 
optimal levels of temperature control, humidity and gas concentration.  
Standard laboratory conditions are designed to culture cells under atmospheric levels of O2, 
i.e. a concentration of nearly 21%. However, there are a number of different cell types that 
reside in vivo at much lower O2 concentrations. Also a number of pathophysiological 
conditions are associated with cells being exposed to hypoxic conditions. In order to 
accurately recapitulate these conditions and thereby determine the likely behaviour of cells in 
their in vivo environment, an accurate and reliable method is needed to control O2 
concentration. The ideal criteria for such apparatus should include: 
1. Achievement of stable O2 concentrations down to as low as 0.5%. 
2. Ability to achieve variable O2 concentrations. 
3. Concomitant control of CO2 concentration, temperature and pressure within the 
chamber. 
4. Ability to expose cells to multiple treatments without disruption of incubation 
conditions.  
In terms of approach and price, there are a wide variety of types of equipment that can be 
used to expose cultured cells to hypoxic conditions. In choosing which method to adopt, or 
how to combine the best parts of existing methods to develop a new approach, it is important 
to appreciate the strengths and weaknesses of existing technologies.  
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3.1.1 Commercially available hypoxic incubation systems 
3.1.1.1 GasPak™ Systems 
The GasPak™ system (BD, UK) http://www.bd.com/ds/productCenter/ES-Gaspak.asp is 
made of rigid plastic jar container with an air-tight seal (Figure 3.1). It is designed to mainly 
house stacks of standard size Petri dishes. This system creates an anaerobic or 
microaerophilic environment by opening a sachet of chemicals before closing the jar. The 
chemical reaction, which may require the addition of water to the sachet, is a hydrogen and 
carbon dioxide generator, and in the presence of a catalyst will cause O2 and hydrogen to 
form water, and therefore will result in consumption of O2 in the jar. Different types of 
sachets or pouches can be used for different conditions namely anoxia, or low residual O2 of 
5–12%. This system is designed for culturing anaerobic bacteria. The level of O2 inside the 
jar is very variable and uncontrollable. There is high level of CO2 levels of about 10%. Some 
models are described to have vents in the lids, which can be used for flushing the jar with an 
external gas. While the GasPak system is a relatively primitive apparatus for hypoxic control, 
the cost starts from nearly $500 (£325) 
 
Figure ‎3.1 - GasPak hypoxic system 
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3.1.1.2 Flush boxes  
Flush or glove boxes are small, sealable, airtight containers usually made of plastic or similar 
material. They have multiple trays to hold various tissue culture plates. Boxes have integral 
gas flushing inlet and outlet ports with hose clamps on them. The box typically has two parts: 
a base and a lid (with steel clamp for opening and closing). The lid has a rubber seal that fits 
over the base.  
Once the box is sealed with the cultures inside, it is flushed with the desired gas mixture 
through an inlet, flushing all the gas out, then both ports are clamped and the chamber is 
placed in a conventional incubator.  
The most “famous” example is Modular Incubator Chamber by Billups-Rothenberg Inc. (Del 
Mar, CA, USA) http://www.brincubator.com, which has been in the market for over 30 years 
and is indeed widely used (Figure 3.2). The cost for one unit starts at $479 (£310).  
The advantages of this equipment are that it is simple to use. It requires premixed gas, and 
any mixture can be used. Once it is closed it can be moved without interrupting the gas 
content of the box, which is useful if the incubator door is opened frequently. It is relatively 
economical, and a number of boxes can be used simultaneously in the same incubator.  
The disadvantages of these boxes are that they are blinded to the concentration of O2 or other 
gases and, once the box is sealed, there is no way of knowing how the concentration of the 
gases within the box may vary over time. Although there are flow meters available with this 
box, to determine when 100% gas exchange has been achieved, the lack of subsequent 
monitoring remains a major limitation. In addition, as the box relies completely on a 
competent seal, it is difficult to know when the seal becomes defective especially considering 
that the company offers only a 1-year warranty on leaks. 
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Figure ‎3.2 - Modular hypoxic flush chamber  
3.1.1.3 Automated hypoxia chambers 
The controlled hypoxia chambers are similar in principle to the flush boxes above as they do 
not require a large space, and they can be put inside the standard incubator, where they 
maintain the gas composition irrespective of the incubator condition. However, they cannot 
function stand-alone as they still depend on the incubator for temperature regulation. The 
main advantage of these chambers is the availability of gas monitoring, mixing and top-up 
facilities, to maintain a controlled gas concentration, and account for any leak that could 
“inevitably” occur, and will not leave experimental control to chance.  
One recognised brand is the hypoxia chamber from Biospherix (www.biospherix.com NY, 
USA). The chamber is supplied with an O2 controller unit, which measures O2 and/or other 
gas concentrations, and automatically flushes small amounts of gas into the chamber until the 
programmed concentration is reached (Figure 3.3A). This unit will continue to provide a 
feedback circuit to maintain the O2 concentration where it gets measurements of the O2 
concentration and flushes gas accordingly. This will also save gas because it will be supplied 
as needed. The chamber supports a full range of O2 control (0.1–99.9%), and can be 
programmed for dynamic control of O2/CO2. The company also offers more advanced O2 
control through dissolved pericellular O2. This is achieved by having a highly sensitive O2 
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probe immersed in tissue culture media measuring the concentration of the dissolved O2 and 
feeding back to the O2 controller (Figure 3.3B).  
This chamber is a well-designed, sophisticated device, but comes at a substantial cost, 
starting at nearly $5,000 (£3,250) for the entry-level small chamber. Also the chamber cannot 
house any other instruments inside, although the company can build a custom design at an 
additional cost. The dissolved pericellular O2 sensor alone is in the region of $10,000 
(£6,500). 
 
           
Figure ‎3.3 - Automated C-hypoxic chamber 
The device is connected to an automatic O2 controller unit (A). An additional pericellular 
sensor can be added and measures dissolved O2 in culture media (B).  
 
3.1.1.4 Hypoxia workstations  
The hypoxia workstations are modified from the anaerobic bacteria glove box, used 
traditionally to grow anaerobic bacteria under strict anoxic condition. They are stand-alone 
units with intrinsic heating and humidification. They do not require to be placed in another 
incubator like the above boxes/chambers. These workstations or glove boxes were modified 
for mammalian cell or even animal use with the addition of O2 and CO2 control. These 
workstations allow handling cells under continuous, uninterrupted hypoxic conditions; 
therefore, it serves as a hood, incubator and hypoxic chamber. 
A B 
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There are a variety of models available on the market, for example, the Invivo2 range from 
Ruskinn Technology (Bridgend, UK http://www.ruskinn.com), with the entry model Invivo2-
300 starts at £18,500 (Figure 3.4). 
 
Figure ‎3.4 - Invivo2-300 hypoxic workstation  
 
Another model is by Coylab (Grass Lake, Michigan, USA http://www.coylab.com) is 
available in the UK retailing at £8,000 to £16,000 (http://www.wolflabs.co.uk). This model 
can also be used for animal use too. It comes with an O2 sensor and controller and an internal 
fan to provide uniform gas distribution. It is of a large size that allows housing different 
instruments inside. Excess gas is relieved by bleed valves (Figure 3.5).  
 
 
 
Figure ‎3.5 - Coylab hypoxic workstation 
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The downside of these incubators is potential contamination. As they serve as a hood for 
processing the cells as well as an incubator, they require a dedicated laboratory space and are 
very costly.  
3.1.1.5 Conventional incubators with triple gas control 
Some of the conventional/standard lab incubators come with a triple gas control and allow 
controlling O2 (as well as CO2 and N2). They are usually medium size similar to a small 
fridge. They are convenient to use, since they can still be used as standard lab incubator. 
Although they can accommodate large amounts of culture plates, they can only be 
programmed to one level of hypoxia at a time. They do not allow housing some 
“instruments” if they require an external power supply. One of the major limitations for these 
incubators is that when the door is opened, the external air will mix with the gas within the 
incubator and disrupt desired level of hypoxia. Nevertheless, many incubators cannot reach 
low O2 concentrations (<2%). Models such as the Nuaire AutoFlow Water Jacket CO2 
Incubator (NU-4950E) are available from Triple Red Ltd (Aylesbury, UK) for £5385 (Figure 
3.6). 
 
Figure ‎3.6 - Nuaire AutoFlow triple gas hypoxic incubator  
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3.1.1.6 Large integrated systems 
These are large sophisticated systems that combine a closed hood, incubator and work area 
into one large system. It allows a very controlled environment of hypoxia and allow cells to 
be processed, treated and incubated without disruption. They are designed to accommodate 
most of the required instruments for cell culture. Biospherix is one of the leading 
manufacturers of these systems. The cost of these units starts from $100,000 (£65,000) for 
the basic unit. In addition to the high cost of these units, there are additional costs relating to 
the installation of the unit into a dedicated room (Figure 3.7).  
 
Figure ‎3.7 - Integrated hypoxia system  
 
All of the above units have advantages and disadvantages. The simpler, and therefore cheaper 
versions, will likely not meet the requirements that are needed to have confidence that 
reliable, low levels of O2 were being delivered. Those that are capable of fulfilling our 
requirements are associated with a financial outlay and space requirements that are beyond 
the resources available to this project. Thus, we have chosen to develop a custom-made, 
affordable and adaptable system that is capable of meeting the requirements needed for this 
study.  
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3.1.2 The Salhiyyah hypoxic chamber 
3.1.2.1 Aims 
The proposed design should be able to provide an environment to culture cells in different 
cell culture plates under tightly controlled O2 concentration as low as 0.1%. This environment 
should be friendly to the cells providing buffered CO2 concentration, appropriate 
temperature, pressure and humidity. The design should be able to provide validated 
confirmation and monitoring of the chamber O2 concentration. It should be flexible and easily 
modifiable to accommodate for experimental design including housing different instruments 
like bioreactors, tissue stretch devices and mechanical stimulation. The fabricating of the 
proposed design is required to be reasonably affordable in light of the financial constraints.  
3.1.2.2 Technical considerations 
This design will be in the form of a small chamber or glove box that can be put inside a 
standard incubator and should be airtight. It will need one or more gas inlets to allow flushing 
the box and potentially mixing different gases. The gas should escape through a one-way 
valve thus maintaining atmospheric pressure. A pressure valve that can control internal 
chamber pressure can also be useful for future experimental design. The chamber will be 
connected to a gas (O2) sensor to control or at least monitor gas concentration. It should be 
adaptable in different sizes and can allow different ports for various devices to be introduced. 
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3.2 METHODS 
3.2.1 Material and size of the chamber 
Two types of chambers were considered for use. First, a custom-built box made from a gas 
impermeable material such as Perspex. However, the design of the joints and door that would 
have a gas-tight seals made the potential cost of the production of multiple units of such a 
box prohibitively expensive. The second option was to locate a commercially available box 
that would fulfil all the requirements for use as a hypoxic chamber: i.e. easy-to-access lid, 
gas-tightness, readily modifiable to allow introduction of ports into the box, suitable size to 
allow house multiple tissue culture plates and inexpensive. These requirements were met by 
the Lock & Lock food containers (Lock & Lock Co. Ltd, Seoul, South Korea). These 
containers are made of silicon and have a patented hinge-locking system that forms an air-
tight seal. The boxes come in a wide range of sizes (1 L to 10 L) and different shapes. The 
2.3 L rectangular box was identified to suit our requirements the best since it could house up 
to six standard-size culture plates and up to six individual boxes could be fitted into the 
incubator easily (Figure 3.8).  
      
Figure ‎3.8 - The Salhiyyah hypoxic chamber primary design 
Primary design included the use of a 2.3 L food container with two gas inlets and an outlet 
PEEP valve connected to a Vandagraph (Keighley, UK) O2 sensor.  
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3.2.2 Connectors 
A number of modifications were made to each box to allow the inlet and outlet of gas, 
inclusion of monitoring probes to measure O2 concentration and pressure. A 33 mm hole was 
drilled into the one end of the box and a plastic inlet connection was inserted into the hole 
and tightened between rubber O-rings on either side of the box. Inside these ports, a one-way 
air valve was snugly fit (valve usually used in fish tanks). A second hole was drilled at the 
opposite end of the box to house a 17 mm pluming tank connector (Wicks, UK) secured in 
the same way as the inlet valve. To the other end of this connection, an adjustable one-way 
outlet valve was used. This was a one-way medical positive end expiratory pressure (PEEP) 
valve used in medical ventilators and continuous positive airway pressure (CPAP) circuits 
(Ambu® Disposable PEEP Valve 20, Ballerup, Denmark [Figure 3.9]). It permits adjusting 
the pressure at which the valve will open between 0–20mmHg.  
 
Figure ‎3.9 - Respiratory PEEP valve  
 
3.2.3 Oxygen sensors 
An O2 sensor was used to measure the O2 concentration inside the chamber. Initially a sensor 
with an electro-galvanic fuel cell was used (VN202, Vandagraph, Keighley, UK), which 
measures the amount of O2 through an O2-dependent chemical reaction when potassium 
hydroxide in the cell comes into contact with O2, which generates an electric current. The 
current produced is proportional to the O2 concentration. This O2 cell was connected to the 
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sidewall of the box through a tight hole tightened between rubber O-rings on either side of 
the box. The cell was connected to the VN202 device. However, it was discovered that the O2 
cell loses its accuracy when exposed to CO2 as high as 5% for a long time. The sensor was 
replaced with different model (Rapidox 1100Z, Cambridge Sensotec, UK [Figure 3.10]). It 
uses a Zirconia ceramic that gets heated to 650°C, and measures O2 by conduction. This 
sensor is not affected by CO2 or other experimental conditions like temperature or humidity. 
It allowed fast, reliable and real-time measurements through computer software. It is highly 
sensitive with accuracy of ± 1% of the actual measured O2 with precision of ± 0.5%. It has a 
very fast measurement response, which is typically 4 seconds for 90% response (Sensor 
manual). The Zirconia sensor is located inside a unit. The unit has an internal gas pump and 
two ports. It measures O2 by sampling the gas from the chamber through pumping it inside 
the unit to the sensor and pumping it back again to the chamber. The reading is displayed on 
small screen. The unit is connected to computer software, which plots the measurements over 
time. The unit is able to measure pressure and compensate for changes in pressure in the O2 
reading. The design of the chamber was modified to two ports for the sampling of the gas 
fixed to the side of the box in the same way mentioned above, creating a closed loop with the 
O2 sensor unit.  
3.2.4 Gases used 
During the development of the chamber, hypoxia was achieved through manually mixing two 
gases of 100% O2 and a mixture of 95% nitrogen and 5% CO2 guided by the O2 sensor. It was 
noticed that this technique was not very accurate and had a degree of variability, as well the 
need for frequent adjustments of gas concentration. Therefore premixed gases were used 
which contain the desired O2 level with 5% CO2 and balanced with nitrogen (BOC, UK).  
The chamber was flushed with the desired gas until it reached the desired concentration. It 
was noticed that the O2 level drifted back up (described below) and there is a need for 
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continuous O2 perfusion to maintain stable levels. Different types of gas regulators were 
tested, including two stage pressure regulators: (C202/2-BS3-6mm HE, BOC, UK), adult 
medical O2 flow regulator (Select Flow-1068790), and a paediatric medical O2 flow regulator 
(Select Flow-1068792) (GCE SABRE Medical, Warrington, UK). The third was found to be 
the most suitable as it provided a stable flow rate with the lowest rate of 0.1 L/minute and a 
low range 0.1–5 L/minute. It was then used in the final design (Figure 3.10).  
 
 
                        
  
Figure ‎3.10 - The Salhiyyah hypoxic chamber modified design 
The chamber design was improved by using one gas inlet for premixed gases. The O2 sensor 
was changed to the Rapidox sensor (Cambridge Sensotec, St Ives, UK), which provided 
continuous real-time accurate measurements.  
 
3.2.5 Number of chambers and their connections 
The above chamber design allowed having multiple chambers within one incubator. This 
enabled running different experiments with different conditions at the same time without 
being affected by each other (Figure 3.11).  
Each gas cylinder was connected to two chambers using a 6 mm non-conductive bubble tube 
(Universal Hospital Supplies, Enfield, UK) in a Y fashion with a (tubing clip) on one of the 
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arms to allow flushing one chamber selectively. If the clip is opened, then two chambers will 
be flushed with the same gas, and will allow either having a larger number of plates or 
running one experiment for two time points, when one experiment can be terminated earlier, 
clamping the feeding gas tube and keep it on the second chamber for later.  
As the Rapidox O2 sensor will allow sampling or testing one source, it was not possible to 
measure O2 from all chambers at the same time. Alternatively a method of parallel sampling 
was used where three chambers out of six had connections to the O2 sensor using 
polyurethane 6x4 mm tubing (RS, UK). These connections were attached to a three-way tap 
(BD, UK) that allowed alternating between different chambers. 
            
Figure ‎3.11 - Hypoxic chambers setup 
The picture shows the setup of the hypoxic chambers. Six chambers are housed within a 
conventional lab incubator and connected to different cylinders of premixed gas containing 
the required O2 concentration. Chambers are also connected to an O2 sensor connected to 
computer software for real-time monitoring. 
 
3.2.6 Testing the chamber and optimising the protocol  
3.2.6.1 Testing the chamber for leaks 
It was difficult to directly test the Lock & Lock box for any air leaks through the box lid or 
the connections inserted onto it. Therefore, it was tested indirectly for any water leaks into 
the chamber when it is immersed in water. First, an empty box was tested for water leaks. 
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Four kilogrammes of weight were put inside the box, which was then immersed into a 50 L 
bucket of water. Strips of cobalt chloride (CoCl2) paper were used inside the chamber. 
Anhydrous CoCl2 paper is blue. In the presence of water or any sort of moisture it starts to 
turns pink. The box was placed under water for 24 hours. Then it was visually examined for 
any change in the colour of the CoCl2 paper. On manufacturing the chamber, each time a port 
or a connection was added, it was tested individually in same way, and once the whole 
chamber was finished it was also examined.  
3.2.6.2 Testing chamber material for permeability  
The description above of testing the chambers for leaks does not account for testing the 
permeability of the box plastic material to O2 or other gases. Therefore, the chamber was 
tested for the permeability of the plastic by comparing the stability of the O2 concentration 
over time, and comparing that with the stability of the O2 if the chamber is immersed under 
water.  
Gases have limited solubility in water under set temperature and pressure, for example, O2 
solubility in water at room temperature (RT) and atmospheric pressure is 9–10 mg/L, 
therefore, gas permeating from the box outwards will encounter another barrier, the water to 
dissolve in, and there is a limited amount of gas to diffuse to the inside of the box.  
In the first part of the experiment, the chamber was placed inside the conventional lab 
incubator and flushed with a 5% O2 gas for 1 hour until the level of O2 in the chamber is 
stable. Then the gas was switched off, and O2 level was continuously monitored for 24 hours. 
In the second part, the chamber was immersed in a 50 L water bucket using 4 kg of weights 
inside the box, it was then flushed with 5% O2 gas in the same manner. The difference in the 
level of O2 represents the diffusion of O2 and/or nitrogen across the plastic of the chamber.  
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3.2.6.3 Testing and optimising gas flow  
The chamber was tested for the flow rate and time required to achieve the desired stable O2 
concentration using a relatively small (or minimum) amount of gas. Upon closure of the 
chamber to commence an experiment, the O2 concentration will be near atmospheric, which 
is 20.9%. The chamber was flushed with the premixed gas (e.g. 5% O2). The time and flow 
rates of the gas needed to replace all the atmospheric gas were tested. This was achieved by 
testing various combinations of gas flow rates for variable durations, while continuously 
measuring the intra-chamber O2 concentration as displayed on the O2 sensor in real time. This 
“optimisation” included testing a single chamber perfusion and a dual chamber perfusion 
(two chambers perfused with the same gas cylinder at the same time)  
Using single chamber and single gas, the flow rates were varied with time. The second stage 
paediatric flow regulator used has the following flow rates: 5, 4, 3, 2.5, 2, 1.5, 1, 0.75, 0.5, 
0.25 and 0.1 L/minute. We started by flushing the chamber with highest flow rate (5 
L/minute) until the O2 sensor measures the same O2 concentration or very close. Time to this 
point was recorded (Time-1), and the flow rate was then dropped to the lowest flow (0.1 
L/minute). If the O2 level started to drift back up again, the flow rate was increased gradually 
again until it reached the lowest level that achieves gas stability for example (3 L/minute) and 
was allowed to stay there for (Time-1) minute, and the process was repeated few times until 
flow was stable at 0.1 L/minute. The same process was then repeated thus allowing flow at 
each level for twice the time (2x Time-1) i.e. twice the time needed to reach a stable level, 
and were recorded. Using this, a flushing protocol was optimised and tested at different 
chambers and different gases. Once, the protocol was optimised for one chamber, the same 
method was applied to flushing two chambers together.  
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The protocol was then tested by flushing the chambers blindly (i.e. without O2 monitoring), 
and then sampling O2 at different time points to confirm if they reach the required O2 level 
and remained stable.  
3.2.6.4 Testing chamber pressure 
The Rapidox O2 sensor is also capable of measuring pressure in real time as well as O2 level. 
The O2 level is adjusted to the pressure measurements. The sensor measures pressure relative 
to the atmospheric pressure. i.e. at room air, the sensor will measure O2 as 20.9%, and 
pressure at 0 bar. Pressure measurements of the chamber were taken every time the chamber 
was tested for any other condition. The aim was to confirm that cells in the chamber are not 
exposed to higher levels of pressure than normal room levels.  
3.2.6.5 Testing chamber temperature 
Temperature was measured by a small electronic thermometer placed inside the chamber and 
temperature was recorded manually at different time points over 24 hours. The temperature of 
the chamber was then compared with the temperature of the incubator.  
3.2.6.6 Testing chamber humidity 
The effect of gas flushing and humidity inside the chamber were tested using a small 
commercial “home use” (hygrometer) which was placed inside the chamber and the reading 
was recorded manually. Humidity was tested also with the presence of an open plate of sterile 
water inside the chamber.  
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3.3 RESULTS 
3.3.1 Testing chamber for leaks 
The hypoxic chamber was tested under water for 24 hours. It remained watertight and the 
strips of CoCl2 paper inside retained their blue colour indicating no exposure to water. Each 
chamber used was tested individually. If any leak was detected during manufacturing and 
installation of the ports and connection, further adjustments were made to ensure the final 
product was watertight for at least 24 hours.  
3.3.2 Testing chamber material for permeability  
In the first part of the experiment, the chamber was placed inside the incubator, closed and 
flushed with 5% O2 until levels were stable for 1 hour. The gas was switched off, and the O2 
concentration was monitored for 24 hours. O2 levels remained stable for 2 hours after the gas 
flow was switched off and then started to fluctuate, gradually increasing and eventually 
reached 6.9% by 24 hours (Figure 3.12).  
On the second part, the chamber was closed with weights inside it and flushed in the same 
manner under water. O2 levels remained stable at 5% for 24 hours (Figure 3.12). 
   
Figure ‎3.12 - Hypoxic chamber permeability testing 
Figures show real-time O2 monitoring while testing the chambers’ permeability. The hypoxic 
chamber was flushed with 5% O2 and left inside the incubator (left) and shows that O2 levels 
started to increase again. When the chamber was kept under water (right), O2 levels remained 
stable.  
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3.3.3 Testing and optimising gas flow  
The characteristics of gas flow to the chamber were tested firstly to assess the flow and time 
requirement to achieve the desired O2 level inside the chamber after closure to replace all the 
atmospheric gas present at the start, and secondly as it became evident that the chamber 
material is permeable to gas to assess the minimum flow requirement to maintain stable gas 
concentration.  
For the first part the “best” gas-flushing protocol when using one chamber was to start with 
the maximum flow of 5 L/minute for 5–6 minutes (2x Time-1), the flow was then dropped to 
2 L/minute for a similar time, and then to 1 L/minute before it was dropped to 0.1 L/minute, 
When using two chambers simultaneously the method of flushing was with 5 L/minute for 
10–12 minutes, the flow was then dropped to 2 L/minute for similar time, and then to 1 
L/minute, then 0.25 L/minute before it is dropped to 0.1 L/minute (Figure 3.13). 
    
Figure ‎3.13 - Optimisation of hypoxic chambers gas-flushing protocol 
Figures show real-time monitoring of O2 levels while flushing one (left) or two (right) 
hypoxic chambers with premixed 5% O2. The desired level of O2 was achieved according to 
the optimised protocol and maintained using continuous low flow of gas (0.1 L/minute).  
 
The protocol was then tested by flushing the chambers blindly (i.e. without O2 monitoring), 
and then sampling O2 at different time points to confirm if they reach the required O2 level 
and remained stable. This has shown excellent prediction of the values.  
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3.3.4 Gas stability over time 
For the second part, we tested O2 stability in different gas conditions using the lowest 
possible flow, which is 0.1L/minute using the paediatric flow regulator. So after the desired 
level of O2 was achieved, the chambers were flushed with continuous flow at 0.1L/minute 
and the stability of the O2 was measured for 3 days (Figure 3.14).  
      
     
Figure ‎3.14 - Oxygen stability over time 
Figures showing continuous real-time monitoring of the O2 level in baseline conditions inside 
a conventional tissue culture incubator of 19.5% (A), and inside hypoxic chambers flushed 
with different gases at 5% (B), 2% (C) and 0.5% (D) for 3 days.  
 
3.3.5 Testing chamber pressure 
The Rapidox O2 sensor is also capable of measuring pressure in real time as well as the O2 
level. The sensor unit measures the pressure relative to the atmospheric pressure, i.e. it reads 
C 
A B 
D 
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0 bars at sea level. Harefield is 75 m only above sea level. The baseline reading was 0 ± 
0.002 bar. The baseline recording of the control incubator conditions showed a pressure of (-
0.002 to -0.001 bar), which is equivalent to (-.075 to -1.5 mmHg) as shown in (Figure 
3.15A). Pressure measurements of the chambers showed pressure of (0.003–0.004 bar equals 
2.25–3.0 mmHg). Pressure remained stable thought the flushing of the chamber for 3 days. 
Flushing either one or two chambers did have an effect on pressure, and closing one chamber 
after 24 hours did not affect the pressure in the second chamber too (Figure 3.15).  
 
     
     
Figure ‎3.15 - Pressure control inside hypoxic chambers 
Figures show continuous real-time monitoring of pressure (red trace) inside different hypoxic 
chambers with an O2 concentration of 5% (B), 2% (C) and 0.5% (D) compared with the 
pressure inside a conventional tissue culture incubator with O2 of 19.5% (A).  
 
A 
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B 
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3.3.6 Testing chamber temperature 
Temperature inside the chamber was measured through an electric thermometer placed inside 
the chamber, and the readings were recorded manually (Figure 3.16). The baseline 
temperature of the chamber thermometer was 0.1–0.2 lower than the housing incubator. After 
flushing the chamber with gas the temperature dropped over 60–90 minutes reaching a lower 
of 35.8 at 50 minutes. Then it started to climb back up again, reaching baseline levels at 180 
minutes, and remained stable for 24 hours despite continuous gas flushing at 0.1 L/minute.  
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Figure ‎3.16 - Temperature control inside the chamber  
Figure shows changes in temperature inside the hypoxic chamber (dotted line) compared with 
the incubator temperature (solid line). 
 
3.3.7 Testing chamber humidity 
Control incubator humidity was measured at 95–100%. Chamber humidity was measured 
with an empty chamber and was 10%. When a Petri dish was placed open in the chamber 
filled with distilled water, the humidity of chamber dropped to 10–20% when the gas was 
first flushed and then it went up to 50–75%, and when two boxes were flushed 
simultaneously, the humidity was slightly higher at 65–87%.  
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3.4 DISCUSSION 
The available methods and devices on the market to study the effects of hypoxia in biological 
studies have limitations. Limitations include the variable gas control, the blinded flushing of 
gas and the risk of contamination and, equally important, the exceptionally high cost of the 
more appropriate ones. When we hypothesised that MVICs could be exposed to hypoxic 
levels of O2, and there is a need to study this, and we needed to introduce the best appropriate 
hypoxic incubator to our lab at an affordable cost. The alternative was to develop our own 
hypoxia incubating chamber, and validate it for future use.  
Our chamber is 2.3 L in size, which will accommodate six 96-well plates. We put six 
chambers inside a standard lab incubator. The size of the chamber can be easily modified, as 
the lock and lock containers have volumes up to 10 L, and even if a larger or different shape 
chamber is needed, it can be fabricated from similar plastic material and same validation 
methods can be safely copied to the new material. The Rapidox O2 sensor is a highly accurate 
and reliable sensor that provides rapid, real-time O2 monitoring. The sensor model used can 
only support one chamber sampling at the same time, but the parallel chamber sampling 
through the three-way connection allowed the use of one sensor to alternate sampling 
between multiple chambers. If continuous real-time monitoring is required, then the company 
(Cambridge-Sensotec) offers other models with multichannels. Monitoring O2 concentration 
in hypoxic study is very important, and blinded units, such as the flush boxes, can have an 
undiagnosed gas leak that could result in false results, and there is no way to confirm the 
stability of the gas especially over longer durations.  
The way the connections were inserted into the wall of the box in a leak-proof manner using 
o-rings, and rubber washers, could also be used to introduce other types of electric or 
The hypoxic chamber 
 
112 
 
mechanical ports. This will allow housing other devices used in valve biology studies, like a 
bioreactor, which is a cellular stretching device.  
The chamber design allows mixing different gases, but with experience, we believe that this 
will have some level of inaccuracy when performed manually, and although the sensor will 
give a reliable fast reading, gas will take some time to mix and equilibrate in the chamber, 
and in view of the potential leaks and permeability, compensating for the gas mixture will be 
more challenging. Therefore in the current system, a premixed gas will give much higher 
accuracy, reliability and reproducibility. If gas mixing is required, then automated gas mixers 
could be considered.  
The method of continuous low flow flushing to maintain stable intra-chamber O2 
concentration allows compensating for the gas permeability. Optimising the protocol to 
quickly flush the chamber and achieve full gas exchange then continuing with the lowest 
possible flow of 0.1 L/minute, allowed using relatively small amount of gas. Yet the flush 
boxes use the smallest amount of gas anyway, but as explained above still could be associated 
with high inaccuracies, and in the other incubators like the workstations and the three-gas 
control incubators, large amounts of gas will be needed to flush and maintain the large, and 
sometimes unnecessary volumes. It is claimed that the C-Chamber can save gas, but 
compared with the very high cost of each unit, the cost savings will be questionable if at all 
possible. In our chamber, the continuous method of flushing at a low flow, will consume 6 L 
every 1 hour, and 144 L/ day. And as the M size gas cylinder contains around 10,000 L of 
gas, which will enough for nearly 70 days of continuous perfusion, and coming at a cost of 
£100–150 depending on the gas mix, which is an acceptable running cost.  
Validating the chamber has proved that a very stable O2 concentration up to 3 days was 
provided, and applying the same strategy, there is no reason why it cannot support long 
The hypoxic chamber 
 
113 
 
incubation. The downside of using chambers compared with workstations is that if cells 
require processing, like changing media, then it is not possible to perform this task without 
interrupting hypoxia.  
The chamber has also shown that it provides a stable temperature and humidity control, 
which will make culture conditions inside the chamber well controlled.  
The chamber can provide this high level of scientific accuracy and precision at a substantially 
cheap cost compared with all other rivals in the market. The cost of manufacturing one 
chamber is less than £40. And even if the cost of the Rapidox O2 sensor is taken into 
consideration, which is about £1800, it is still much cheaper than the other chambers, not to 
mention that one sensor was able to support six chambers, a feature not present in any other 
models reviewed.  
3.4.1 Hypoxia and the mitral valve 
The O2 requirement of the MVVICs are not known and it is also not known how much O2 is 
delivered by diffusion and how much by leaflet vessels. It is also not known what level of O2 
is regarded “normal” or physiological for those cells. Therefore it was important to study the 
effect of hypoxia over a range of values rather than one level.  
The selected levels of hypoxia used in this study were based on the known valve physiology 
and the previous studies addressing the effect of hypoxia (Ke et al. 2006). The MV is 
surrounded by blood with a maximum O2 concentration in the body. 
The normal O2 partial pressure (PO2) in atmospheric conditions is 21% of the atmospheric 
pressure, which is 760 mmHg (101.3 kPa), which makes it 160 mmHg (21.3 kPa). The O2 
concentration goes through a gradient cascade down the respiratory tree and the alveolar 
membrane to reach 100 mmHg (13.3 kPa), which is nearly 13% O2 in the fully oxygenated 
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arterial blood. The partial pressure of O2 in the venous blood is about 40 mmHg (5.33 kPa), 
which is nearly 5% O2. In between, O2 diffuses through the vascular tree into the tissues at 
various rates depending on the tissue’s degree of vascularisation, tissue characteristics and O2 
requirements. Some tissue will require as little as 1% of O2 (Simon et al. 2008). 
Cells cultured in vitro are normally cultured under atmospheric levels of O2 (21%) with 5% 
CO2, making the actual O2 level around 19–20%. So, in reality, cells cultured in vitro are 
cultured in hyperoxic conditions. As this level represents the gold standard of laboratory cell 
culture (Chester et al. 2007; Taylor et al. 2000), we decided to use it as a control rather than 
using the 10–13% level, which corresponds to in vivo normoxia. Previous hypoxia studies 
appear to focus on three ranges of hypoxia: mild (4–6%), moderate (1–3%) and severe (0.1– 
0.8%) hypoxia (Semenza 2006; van Vlimmeren et al. 2010), therefore a point in the middle 
of each of range was chosen, namely 5% O2, 2% O2 and 0.5% O2.  
The present hypoxic chamber design made it possible to have three chambers to run parallel 
to each other, and therefore allow more comparable samples incubated at the same time under 
different levels of hypoxia to be obtained.  
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4.1 BACKGROUND 
Mammalian cells depend critically on a continuous supply of O2 to survive, function and 
maintain energy balance, but the level of O2 needed varies largely between different cells and 
tissues (varez-Tejado et al. 2001). Tight control (whether abundance or lack) of the O2 
microenvironment is crucial for cellular function (Martorell et al. 2009). 
 
Hypoxia is a very important and fundamental environmental stimulus that can affect cellular 
behaviour (Wang et al. 1993). Cells can be exposed to hypoxia under physiological 
conditions; for example, hypoxia promotes the differentiation of the embryonic stem cells to 
cardiomyocytes (Ng et al. 2010), or pathological situations like vascular ischaemia, tissue 
injury and cancer (Luan et al. 2013; Sluimer et al. 2008). The cellular response to hypoxia 
varies between different cells depending on various factors (Bracken et al. 2006) including 
the type of cells affected, their function and whether or not they are designed to be exposed to 
hypoxia. Other factors include the level of O2 and duration of exposure and the presence of 
an adaptive mechanism, the purpose of which is to tolerate hypoxia or restore O2 supply. 
Hypoxia can have a wide range of effects on cells, tissue and the organisms. It can affect cell 
proliferation, cell death, apoptosis (Martorell et al. 2009; varez-Tejado et al. 2001), cell 
phenotype, differentiation and activation of various functional pathways (Suda et al. 2011). 
 
VICs are a dynamic population of cells. Their basic biology, phenotype and characteristics 
have attracted a lot of attention in recent years in an attempt to understand their specialised 
features, especially with the increasing evidence of their role in mediating leaflet function in 
health and disease. While their phenotype (Black et al. 2005; Taylor et al. 2000), secretory 
properties (Fayet et al. 2007), response to growth factors, hormones, drugs (Hafizi et al. 
2000), contractile and mechanical properties (Chester et al. 2000; El-Hamamsy et al. 2009; 
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Grande-Allen et al. 2011) have been widely studied, the effect of differing O2 concentrations 
of the behaviour of these cells has not been investigated. As discussed earlier, the O2 
requirements of MVICs are unknown, and it could be possible for MVICs to exist under 
hypoxic conditions either under physiological or pathological conditions. In addition, O2 
supply and demand to those cells can vary with changes to O2 supply through diffusion or 
leaflet microvessels, and increased demand during stress and injury. Therefore it is essential 
to study the effect of hypoxia on MVICS.  
 
4.1.1 Aims and objective 
This chapter aims to study the effect of hypoxia on the viability, morphology and phenotype 
of MVICs. This will be achieved by primarily isolating porcine MVICs, incubating them 
under three different levels of hypoxia and assessing the effect of hypoxia on cell 
proliferation, cell death, morphology and phenotypes relative to atmospheric control.  
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4.2 METHODS 
4.2.1 Tissue collection of porcine mitral valves 
Porcine hearts (18–30 months old) were obtained from a commercial slaughterhouse (Cheale 
Meats, Essex, UK), were placed in ice-cold Hanks solution (Sigma UK) within 15 minutes of 
removal from the animal, and they were used within 4 hours of sacrifice.  
 
4.2.2  Cell isolation and culture  
The porcine hearts were dissected under sterile conditions and the MV leaflets were removed 
from the annulus with a scalpel blade and placed in fresh media. Only leaflet tissue was used, 
and attachments of the ChT tendineae were removed. The margin of the leaflets with the 
annulus was also carefully dissected avoiding any visible muscular tissue. MVICs were then 
isolated from those leaflets under sterile conditions using enzymatic digestion with 
collagenase as previously described (Johnson et al. 1987; Taylor et al. 2000). Dissected 
valves were washed three times with PBS. Valve leaflets were incubated with 10 ml 
collagenase II (Sigma, UK), and agitated for 5 minutes in a water bath at 37°C to remove the 
VECs. The leaflets were removed and washed with fresh PBS, cut into fine pieces using a 
sterile blade and placed in a fresh tube containing 10 ml collagenase and then agitated in 
fresh collagenase solution for 45–60 minutes in the same manner as before. Following 
incubation with collagenase, the valve tissue and the suspension was strained through a 
40 µm cell strainer. Following this, another 10 ml of culture media were added to the tube 
and centrifuged at 620 g for 5 minutes at 4°C. The supernatant was then discarded and the 
pellet was re-suspended in fresh Dulbecco’s Modified Eagle Medium (DMEM) supplemented 
with 150 U/ml P/S and 2 mM L-glutamine, and 10% heat-inactivated foetal bovine serum 
(FBS) (all from Invitrogen, Paisley, UK). Cells were inspected for growth daily and medium 
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was changed two to three times a week until cells reached confluence. Once the cell had 
reached confluence they were passaged by washing the cells with PBS, and then detached by 
incubation with 0.5% Trypsin-EDTA (Invitrogen, UK) for 5 minutes at 37°C. When the cells 
were detached, an equal volume of media were added to inactivate the trypsin’s enzymatic 
activity, and transferred to a sterile 50 ml falcon tube. Tubes were centrifuged as above, 
supernatant discarded and the pellet re-suspended in fresh media and plated in new tissue 
culture flask at 1:3 ratio. Cells were used for experiments between passage numbers 2 and 6 
(P2-P6).  
4.2.3 Preparing cells for experiments 
Cells were allowed to grow and multiply until they became sufficient for running the 
experiments. In order to determine the cell number, cells were passaged using Trypsin, 
centrifuged, the supernatant discarded and the cell pellet re-suspended initially in 1 ml of 
fresh DMEM culture media. Cell number was then assessed using the Trypan blue cell 
viability assay. A haemocytometer was loaded with 20 µl of a mixture of equal volumes of 
cell suspension and Trypan blue. Viable cells, which do not take up the Trypan blue, were 
counted on the grid under the microscope and the number of the live cells was calculated. A 
known number of cells were then plated in the tissue culture plate in preparation for the 
experiment. Cells were then left in an air and 5% CO2 incubator maintained at 37
oC to for 24 
hours to allow them to attach to culture plate. After 24 hours, cells were assessed for 
attachment and growth and the media changed with fresh DMEM supplemented with 10% 
FBS, P/S and L-glutamine as described above, and cells were incubated as required.  
 
 
Effect of hypoxia on mitral valve interstitial cell viability, morphology and phenotype 
 
120 
 
4.2.4 Hypoxic incubation protocol 
Eight culture plates were generally used per experiment and placed in the corresponding 
hypoxic chamber. Experiments were carried out over 1 and 3 days (24 and 72 hours), and at 
three levels of hypoxia: mild (5% O2), moderate (2% O2) and severe (0.5% O2) as well as 
atmospheric conditions (21% O2), which served as a control. 
 
4.2.5 Assessment of the effect of hypoxia on cell proliferation 
Cell proliferation was assessed using the CellTiter 96® AQueous Non-Radioactive Cell 
Proliferation Assay referred to as a 3-(4, 5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay (Promega, 
Southampton, UK). It is a colorimetric method for determining the number of viable cells in 
proliferation assays. It is composed of two solutions of a novel tetrazolium compound MTS 
and an electron-coupling reagent (phenazine methosulphate [PMS]). MTS is bioreduced by 
cells into a formazan product that is soluble in tissue culture medium by dehydrogenase 
enzymes found in metabolically active cells. The quantity of formazan product as measured 
by the amount of 490 nm absorbance is directly proportional to the number of living cells in 
culture.  The number of living cells can be calculated from a standard curve that plots the 
optical absorbance for a known number of cells.  This study did not use a standard curve, but 
relied on using the absolute values of optical absorbance as it provides a measure of changes 
in cell number in the hypoxic groups relative to the control group.  The term proliferation was 
used to describe the increases (or lack of) in cell number relative to the control.  
pMVICs were plated in 96 well plates at a density of 5 x 103 cells per well with six duplicates 
of each sample. Cells were allowed to grow for 1 day, then the media were changed with 
100 µl of fresh DMEM culture medium supplemented with 10% FBS. Nine identical 96 well 
plates were  
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prepared at the same time. One plate was used to assess the baseline of viable cells at day (0), 
and eight plates were incubated under the following O2 concentrations: 20%, 5%, 2% and 
0.5%. Four plates were assessed at day 1, and the other four at day 3. At the end of the 
experiment, the plates were removed from the incubator, the old media were removed and 
100 µl of fresh culture media supplemented with 20 µl of MTS/PMS solution were added to 
each well. The reagent was prepared by mixing 20 ml of MTS with 1 ml of PMS, aliquoted 
and stored in the dark at -20°C until use.  The plate was incubated at 37°C for 1 hour, and the 
absorbance was read at 490 nm using the µQuant plate reader (BioTek Instruments, Vermont, 
USA).  
4.2.6 Assessment of the effect of hypoxia cell death  
Cell death was measured by the Promega CytoTox 96 Non-Radioactive Cytotoxicity Assay 
(Promega, UK). It is a colorimetric method that quantitatively measures LDH, which is a 
stable cytosolic enzyme that is released upon cell death and lysis. The assay is made of a 
tetrazolium salt, which will react with LDH released in culture media through a coupled 
enzymatic assay to form a red formazan product measured at 490 nm. The amount of colour 
produced is proportional to the number of lysed cells.  
 
pMVICs were plated in 96 well plates at a density of 5 x 103 cells per well with six duplicates 
per sample. Cells were allowed to grow for 24 hours then the media were replaced with 
100 µl of fresh medium containing 5% FBS. Three identical 96 well plates were then 
incubated in the hypoxic chambers at O2 concentrations of 5% O2, 2% O2 and 0.5% O2, in 
addition to two plates incubated under 20% O2 for 1 day. At the end of the incubation, 50 µl 
of the supernatant were removed and put in a new plate corresponding to the original one. In 
order to assess total cell death (and thereby calculate the percentage cell death), the remaining 
live cells in the wells were washed with PBS and then 100 µl of PBS containing 1% Triton X 
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was added to the wells and incubated at 37°C for 60 minutes. The plates were then 
centrifuged at 250 g for 4 minutes at 4°C. Then 50 μl of the substrate buffer was added to 
50 μl of supernatants from the experimental samples and the Triton X-treated cells and 
incubated for 30 minutes at RT in the dark. At the end of the 30-minute incubation, 50μl of 
the stop solution (1M acetic acid) was added to each well and the plate optical density 
(absorbance) was read at 490 nm on a µQuant plate reader (BioTek Instruments, Vermont, 
USA). The total cell death was calculated by adding the absorbance from the media and the 
live cells lysate. The percentage cell death was calculated by dividing the absorbance of the 
media over the total cell death using following equations: 
 Total cell death  = LDH in media + LDH from live cell lysate 
 
 Percentage cell death  = LDH in media/ total cell death 
 
4.2.7 Phenotypic changes of VICs under hypoxia.  
Porcine MVICs were phenotypically characterised using a panel of antibodies against 
specific cell surface and cytoskeletal proteins and visualised by immunofluorescence 
staining. Cells were plated on 13 mm round glass cover slips at a density of 5 x 103 cells and 
placed in six well plates. Cells were initially suspended in 400 µl of DMEM media 
supplemented with 10% FBS, and placed over the cover slips. They were given 2–3 hours to 
attach and then flooded with another 2 ml of media. Plates were given 24 hours to stabilise, 
and the media were changed and plates were incubated under hypoxia as described above 
(20%, 5%, 2%, 0.5% for 1 and 3 days). 
At the end of each experiment, the media were removed. Wells were washed with PBS twice, 
and cover slips were incubated with 4% paraformaldehyde (PFA) for 15 minutes. The PFA 
was removed and the slides were washed with PBS twice and then kept in PBS at 4°C until 
staining. For staining, the PBS was drained out, and the cover slips were permeabilised with 
Effect of hypoxia on mitral valve interstitial cell viability, morphology and phenotype 
 
123 
 
0.5% Triton X (VWR, UK) in PBS for 3 minutes followed by PBS containing Tween-20 
(PBS-T) wash, after which 3% BSA in PBS-T was added and incubated for 30 minutes to 
block non-specific binding sites. BSA was removed and cover slips were incubated in the 
following primary antibodies: αSMA, vimentin, SM22, SMM, CD31 and vWF. The source, 
dilution used, host and manufacturer are shown in (Table 4.1). Cover slips were incubated in 
primary antibody for 1 hour at RT on a shaker, then the antibodies were drained and plates 
washed with PBS-T three times before adding the secondary antibodies. For mouse 
antibodies, goat anti mouse Alexia 594 (Invitrogen, UK) antibody was used and for rabbit, a 
goat anti rabbit Alexa 594 was used. Plates were incubated at RT for one hour, wrapped in 
foil and placed on a shaker. The antibodies were then drained and the cover slips washed with 
PBS twice and then incubated with 4',6-diamidino-2-phenylindole (DAPI) at 1:20,000 
concentration in PBS-T (Sigma, UK) for two 5-minute periods. Finally cover slips were 
removed from the plates and mounted on glass slide in inverted fashion using PermaFlour 
(Thermo Fisher, Loughborough, UK)  
Table ‎4.1 - pMVICs phenotypic markers details  
 
Antibody Marker Dilution Host Supplier 
αSMA Myofibroblastic 1:200 Mouse DAKO 
Vimentin Myofibroblastic 1:100 Mouse DAKO 
SM22 Smooth muscle 1:4000 Rabbit Abcam 
SMM Smooth muscle 1:200 Mouse DAKO 
CD31 Endothelial 1:40 Mouse DAKO 
vWF Endothelial 1:400 Rabbit DAKO 
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4.2.8 Semi-quantitative analysis of phenotypic markers 
Cover slips stained for phenotypic markers were viewed under the inverted confocal 
microscope. Two independent observers examined the slides and assessed the level of 
expression using a semi-quantitative scale based on the percentage of positively stained cells 
(see Table 4.2).  
Table ‎4.2 - Semi-quantitative analysis scale for pMVICs phenotypes 
 
Level of expression Percentage of positive cells 
Negative 0% 
Weakly positive 1 - 25% 
Moderately positive 26 - 75% 
Strongly positive 76 - 100% 
 
4.2.9 Effect of hypoxia on MVICs morphology 
The effect of hypoxia on MVICs morphology was assessed using the Phalloidin 
immunofluorescence technique. MVICs were prepared, incubated and stained as described in 
section 4.2.7. Cells were stained by Oregon Grenn 488 Phalloidin (Invitrogen, UK). Slides 
were viewed using Zeiss Axio Scope fluorescence microscope (Carl Zeiss, Jena, Germany) 
connected to computer software NIS elements V 3.0 (Nikon, UK). The software is able to 
measure cell demographics using colour thresholding. Individually identifiable cells were 
selected for measurement. Fifty cells per condition were pooled from three animals and 
analysed. Representative pictures of each animal/condition were taken using the Zeiss LSM-
510 inverted confocal microscope (Carl Zeiss, Germany). 
4.2.10 Data analysis 
Data were presented by mean ± SEM. The groups were compared using one-way analysis of 
variance (ANOVA) with Dunnett post hoc test using GraphPad Prism 5 software.  
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4.3 RESULTS 
4.3.1 Effect of hypoxia on cell proliferation  
The effect of hypoxia on the proliferation of MVICs was assessed using the MTS assay. 
MVICs (n=6) were grown under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric O2 concentrations (20% O2) for 24 (day 1) and 72 (day 3) 
hours and compared with the start of the incubation (day 0). After 1 day there was no 
significant difference in cell proliferation of all the groups compared with day 0 and there 
was no difference between the three hypoxic groups and the 20% O2 control (Figure 4.1). 
After 3 days all groups apart from the 5% O2 showed increased proliferation compared with 
day 0 (*P<0.05) but there was no significant difference between the three hypoxic groups 
compared with the 20% O2 control.  
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Figure ‎4.1 - The effect of hypoxia on cell proliferation  
Porcine MVICs were plated and incubated for 1 and 3 days under mild (5% O2), moderate 
(2% O2) and severe (0.5% O2) hypoxia and atmospheric control (20% O2).  Cell proliferation 
was assessed using the MTS assay.  Results were compared to day 0 (D0) using a one-way 
ANOVA with Dunnet post hoc test.  There was no significant growth at day 1, but at day 3 
all groups apart from 5% O2 had significantly increased in cell number compared with the D0 
(*P<0.05). There was no significant difference between the groups at either day 1 or day 3. 
n=6.  
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4.3.2 Effect of hypoxia on cell death 
The effect of hypoxia on death of MVICs was assessed using the LDH cytotoxicity assay. 
MVICs (n=3) were grown under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as 20% O2 control for 1 and 3 days. 
After 1 day there was no significant difference in cell death between the three hypoxic 
conditions compared with the atmospheric control (Figure 4.2). Percentage cell death was 
8.09% ± 0.97 at 20% O2, 5.97% ± 1.04 at 5% O2, 6.56% ± 0.93 at 2% O2 and 5.75% ± 1.71 at 
0.5% (P>0.05). After 3 days, percentage cell death was significantly reduced to 6.25% ± 
0.24* under 2% O2 and to 4.02 ± 0.45%* under 0.5% O2 compared with control of 10.65% ± 
1.72 at 20% O2, and no difference of 8.5% ± 1.0 at 5% O2 (*P<0.05).  
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Figure ‎4.2 - The effect of hypoxia on cell death  
Porcine MVICs were plated and incubated for 1 and 3 days under mild (5% O2), moderate 
(2% O2), and severe (0.5% O2) hypoxia and atmospheric control (20% O2). Cell death was 
assessed using the LDH assay. Groups were compared at day 1 and day 3 separately using a 
one-way ANOVA with Dunnett post hoc test comparing the three hypoxic groups to the 20% 
control. There was no significant difference in cell death at day 1, but at day 3, cells 
incubated under moderate and severe hypoxia had significantly reduced cell death compared 
to the atmospheric control. (*P<0.05). n=3.  
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4.3.3 Effect of hypoxia on morphology of porcine MVICs 
The effect of hypoxia on morphology of pMVICs was assessed using immunofluorescence 
staining with Phalloidin. MVICs (n=3) were grown under mild (5% O2), moderate (2% O2) 
and severe (0.5% O2) hypoxia as well as 20% O2 control for 1 and 3 days (Figure 4.3).  
After 1 day there was no significant difference in cellular area after exposure to the three 
hypoxic conditions compared with the atmospheric control. Cellular area (Figure 4.4A) was 
1403 ± 176.4 µm2 for (20% O2), 1341 ± 96.98 µm
2 for (5% O2), 1355 ± 90.10 µm
2 (2% 
O2) and 1261 ± 81.10µm
2 (0.5% O2) (P>0.05). Similarly, after 3 days, the cellular area was 
not different between normoxia and hypoxia. Cell area was 2170 ± 173.1 µm2 (20% O2), 
2013 ± 167.5 µm2 (5% O2), 1920 ± 164.4 µm
2 (2% O2) and 2215 ± 110.7 µm
2 (0.5% O2).  
After 1 day there was no significant difference in MVICs’ cellular length (Figure 4.4B) under 
the three hypoxic conditions compared with the atmospheric control. Cellular length was 
107.2 ± 8.37 µm (20% O2), 103.7 ± 7.00 µm (5% O2), 116.3 ± 5.87µm (2% O2) and 129.2 ± 
6.51 µm for (0.5% O2) (P>0.05).  
Similarly, after 3 days, cellular length was not different between normoxia and hypoxia 
conditions. Cellular length was 148.0 ± 8.49 µm (20% O2), 147.7 ± 10.57µm (5% O2), 141.2 
± 7.80 µm (2% O2) and 164.4 ± 7.06 µm (0.5% O2) (P>0.05).  
Regarding cell width (Figure 4.4C), after 1 day cell width was 9.861 ± 0.4443 µm* under 
0.5% O2, which was significantly reduced compared with 12.86 ± 0.8411 µm under 20% O2, 
but there was no difference under 5% O2 where cell width was 13.07 ± 0.5101 µm, or under 
2% O2 where it was 11.81 ± 0.5868 µm (*P<0.05). After 3 days there was no difference in 
MVICs’ cellular width under the three hypoxic conditions compared with the atmospheric 
control. Cellular width was 14.60 ± 0.6572 µm for 20% O2, 13.90 ± 0.5130 µm for 5% O2, 
13.39 ± 0.6792 µm (2% O2) and 13.53 ± 0.4983µm for 0.5% O2 (P>0.05). 
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Figure ‎4.3 - The effect of hypoxia on MVICs’ morphology 
Porcine MVICs were seeded on a glass cover slip and incubated under mild hypoxia (5% O2), 
moderate (2% O2) and severe (0.5% O2) as well as atmospheric control (20% O2) for 1 and 3 
days. Cells were stained with Phalloidin, and assessed for changes in cellular morphology. 
Pictures showing representative views of each condition using confocal microscope. 
Qualitative observation by two individual assessors showed no obvious difference in cellular 
morphology between groups. (n=3). 
 
Day 1 Day 3 
20% 
5% 
2% 
0.5% 
Effect of hypoxia on mitral valve interstitial cell viability, morphology and phenotype 
 
129 
 
20
% 5% 2% 0.5
%
20
% 5% 2% 0.5
%
0
1000
2000
3000
Day 1 Day 3
C
el
l a
re
a 
( 
m
)2
A
 
20
% 5% 2% 0.5
%
20
% 5% 2% 0.5
%
0
50
100
150
200
Day 1 Day 3
C
el
l l
en
gt
h 
( 
m
)
B
 
20
% 5% 2% 0.5
%
20
% 5% 2% 0.5
%
0
5
10
15
20
Day 1 Day 3
*
C
el
l w
id
th
 (

m
)
C
 
Figure ‎4.4 - The effect of hypoxia on MVICs’ cell dimensions 
Porcine MVICs were seeded on glass cover slips and incubated under mild (5% O2), 
moderate (2% O2) and severe (0.5% O2) hypoxia as well as atmospheric control (20% O2) for 
1 and 3 days.  Cells were stained with Phalloidin, and assessed for changes in cellular 
morphology.  Cell dimensions were measured using NIS elements computer software.  
Groups were compared at day 1 and day 3 separately using a one-way ANOVA with Dunnett 
post hoc test comparing the 3 hypoxic groups to the 20% control. There was no significant 
difference in cell area or cell length at day 1 or day 3 (P>0.05). Cell width was significantly 
reduced under severe hypoxia (0.5% O2) after day 1 (*P<0.05), but at day 3 there was no 
difference in cell width between all of the groups.  
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4.3.4 The effect of hypoxia on phenotype of porcine MVICs: 
The effect of hypoxia on the phenotype of pMVICs was assessed using immunofluorescence 
staining of cells.  Cells were incubated under hypoxic conditions and control for 1 and 3 days 
and stained for the myofibroblastic markers Vimentin and αSMA, the SMC markers SM22 
and SMM, and endothelial cell markers CD31 and vWF.  
MVICs strongly express myofibroblastic markers Vimentin (Figure 4.5) and αSMA (figure 
4.6) under normoxic and hypoxic conditions.  There appeared to be no difference in the 
number of positively stained cells both after 1 and 3 days.  There was weak expression of the 
SMC markers SMM (Figure 4.7) and SM22 (Figure 4.8) in a small number of cells, but the 
level of expression did not change under any of the hypoxic conditions.  All cells were 
negative for endothelial cell markers CD31 and vWF (Figure 4.9). 
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Figure ‎4.5 - The effect of hypoxia on MVICs' vimentin expression 
Porcine MVICs were seeded on glass cover slips and incubated under mild (5% O2), 
moderate (2% O2) and severe (0.5% O2) hypoxia as well as atmospheric control (20% O2) for 
1 and 3 days.  Cells were stained with vimentin.  Semi-qualitative observation by two 
individual assessors using a fluorescence microscope showed that MVICs strongly expressed 
Vimentin, and there was no difference in number of cells or intensity of staining between all 
groups. The images show representative views of each condition using confocal microscope. 
(n=3). 
 
Day 1 Day 3 
20% 
5% 
2% 
0.5% 
Effect of hypoxia on mitral valve interstitial cell viability, morphology and phenotype 
 
132 
 
 
Figure ‎4.6 - The effect of hypoxia on MVICs' αSMA expression 
Porcine MVICs were seeded on glass cover slip and incubated under mild (5% O2), moderate 
(2% O2) and severe (0.5% O2) hypoxia as well as atmospheric control (20% O2) for 1 and 3 
days.  Cells were stained with αSMA.  Semi-qualitative observation by two individual 
assessors using a fluorescence microscope showed that MVICs strongly expressed αSMA, 
and there was no difference in number of cells or intensity of staining between all groups. 
The images show representative views of each condition using confocal microscope. (n=3). 
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Figure ‎4.7 - The effect of hypoxia on MVICs' SMM expression 
Porcine MVICs were seeded on glass cover slips and incubated under mild (5% O2), 
moderate (2% O2) and severe (0.5% O2) hypoxia as well as atmospheric control (20% O2) for 
1 and 3 days.  Cells were stained with SMM.  Semi-qualitative observation by two individual 
assessors using a fluorescence microscope showed that there was a weak expression  of SMM 
by the MVICs.  There was no difference in number of cells or intensity of staining between 
all groups. The images show representative views of each condition using confocal 
microscope. (n=3). 
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Figure ‎4.8 - The effect of hypoxia on MVICs' SM22 expression 
Porcine MVICs were seeded on glass cover slips and incubated under mild (5% O2), 
moderate (2% O2) and severe (0.5% O2) hypoxia as well as atmospheric control (20% O2) for 
1 and 3 days.  Cells were stained with SM22.  Semi-qualitative observation by two individual 
assessors using a fluorescence microscope showed that there was a weak expression of SM22 
by the MVICs.  There was no difference in number of cells or intensity of staining between 
all groups. The images show representative views of each condition using confocal 
microscope. (n=3). 
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Figure ‎4.9 - The effect of hypoxia on MVICs' CD31/vWF expression 
Porcine MVICs were seeded on glass cover slips and incubated under mild (5% O2), 
moderate (2% O2) and severe (0.5% O2) hypoxia as well as atmospheric control (20% O2) for 
1 and 3 days.  Cells were stained with CD31/vWF.  Semi-qualitative observation by two 
individual assessors using a fluorescence microscope showed that CD31/vWF was negative 
in all the groups. The images show representative views of each condition using confocal 
microscope. (n=3). 
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4.4 DISCUSSION 
 
This study demonstrates the effect of hypoxia on MVICs proliferation, viability and 
morphological and phenotypic characteristics. pMVICs cultured under hypoxia for 3 days 
showed an overall significant increase in cell proliferation compared with the beginning of 
the experiment, with no difference between hypoxic groups and control. At the same time, 
cell death was significantly reduced under moderate and severe hypoxia. MVICs generally 
retained their morphological appearance, and showed no change in expression of the 
phenotypic markers for MFBs (vimentin and αSMA) or SMC markers (SMM and SM22) 
under hypoxic conditions.  
 
Hypoxia can have a significant effect on cellular proliferation and viability. This role varies 
depending on different cellular O2 requirement and sensitivity to hypoxia. The cellular effects 
of hypoxia start at early stages of normal embryonic development where tissue hypoxia plays 
a critical role in organogenesis, including cardiogenesis. Mammalian development occurs in a 
hypoxic environment, with O2 concentration in the uterine environment is about 1–5% O2, 
and many parts of the maternal placenta remains under hypoxic conditions of less than 2% 
O2. During later stages in embryonic development after the foetal circulation is established, 
considerable parts of the foetus continue to develop under hypoxia (Dunwoodie 2009). 
 
Heart valves also are believed to develop under hypoxic conditions. It has been shown that 
the endocardial cushions (the precursors for the tricuspid and the MVs) are formed under 
hypoxic conditions (Dunwoodie 2009). Subsequently endocardial cells undergo EMT to 
proliferate and populate those cushions giving rise to the interstitial cell. This process is 
dependent on hypoxic pathways including HIF-1α and VEGF (Liu et al. 2007). Further study 
of the chick embryos (Wikenheiser et al. 2009) showed that during cardiac morphogenesis, 
Effect of hypoxia on mitral valve interstitial cell viability, morphology and phenotype 
 
137 
 
other parts of the heart including the atria and the interventricular septum were subjected to 
differential hypoxia, and this differential process helped to guide the morphogenesis of the 
heart and especially the coronary arteries, as this differential hypoxia will lead the 
development of the coronary arteries. 
 
In this study, hypoxia did not affect pMVICs proliferation, and cells continued to grow under 
different levels of hypoxia in same manner as the control up to 3 days. Cell death was 
significantly reduced under moderate and severe hypoxia after 3 days. Nevertheless, the 
percentage of reduction of cell death was small: from 10.65% to 6.25%. These findings 
indicate that pMVICs were able to tolerate various levels of hypoxia and remain viable. It 
seems that pMVICs were able to retain their embryonic ability to exist and continue to grow 
under hypoxic conditions.  
The ability of pMVICs to tolerate different levels of hypoxia is also present in some other 
types of cells. Such cells continue and maybe have increased proliferation under hypoxic 
conditions as well as reduced cell death or apoptosis and improved overall survival. Rat 
subcutaneous fibroblasts that when cultured under 5% and 2% hypoxia, showed no difference 
in cell proliferation while there was a 2-fold reduction in apoptosis (Modarressi et al. 2010) 
and pulmonary artery fibroblasts of human and bovine lungs that were found to have 
increased proliferation after being exposed for 24 hours to 2% O2 (Mortimer et al. 2007). 
Cells like cardiac fibroblasts that are the most prevalent cell type in the heart and play an 
essential role in maintaining the structure and function of the heart even have increased 
proliferation under hypoxia and reduced cell death or apoptosis (Porter et al. 2009).  
 
On the other hand, some other cells are sensitive to hypoxia and their proliferation and 
viability is reduced with reduction of O2 levels. T-cell lymphocytes that when grown under 
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2% O2 have significantly lower proliferation and higher apoptosis rates compared with 21% 
O2 (Larbi et al. 2010), and rat pheochromocytoma cells (PC12 cells) had increased apoptosis 
when cultured under hypoxia for more than 36 hours (varez-Tejado et al. 2001). This feature 
of O2 sensitivity is used by some cells, such as the endothelial cells, glomus cells in the 
carotid body and cells in the neuroepithelial bodies in the lung, to allow them to act as the 
primary O2 sensor for the body. Minor changes in O2 levels will get detected by these cells, 
and subsequently induce systematic changes aimed at restoring O2 levels for the whole body, 
like increased cardiac output, pulmonary vasoconstriction and hyperventilation (Guadall et al. 
2011; varez-Tejado et al. 2001).This capacity to tolerate and survive hypoxic conditions is an 
important feature that will allow those cells to function under ischaemic conditions 
(Sangeetha et al. 2011), resist injury and serve to facilitate tissue repair (Turner et al. 2013). 
The ability to tolerate hypoxia is attributed to activating various cellular pathways. These 
pathways will improve cellular growth as in HIF-1α and VEGF (Street et al. 2009), reduce 
the rate of cell death and apoptosis like the FBLN5 (Guadall et al. 2011) and the neuron-
derived orphan receptor 1 (NOR-1) (Martorell et al. 2009) and improve cellular metabolism 
under hypoxia, like isocitrate dehydrogenase (Wise et al. 2011).  
 
Phenotype and morphology 
The study also looked at effect of hypoxia on the phenotype and morphology of pMVICs. It 
confirmed that under normal O2 levels, pMVICs strongly expressed αSMA and vimentin. 
There was weak expression of the smooth muscle markers SMM and SM22 and there was no 
expression of the endothelial markers CD31 and vWF. pMVICs showed mixed morphologies 
of elongated and cuboidal cells. Hypoxia did not have any effect on the expression of the 
phenotypic markers studied. The shape of the cells was also generally maintained under 
different levels of hypoxia.  
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It is widely accepted that the VICs found in the healthy valves represent the quiescent valve 
interstitial cell (qVIC) that are believed to maintain the structural integrity of the valve (Liu et 
al. 2007; Rabkin et al. 2001). Under certain circumstances these cells can be activated to 
become MFB, acquiring features of both fibroblasts and SMCs. They are characterised with 
increased contractility and prominent stress fibres. These MFBs play a significant role in 
injured or diseased valves by mediating functional biochemical and mechanical adaptation of 
the valve (Schoen 2005), via increased proliferation, migration, contraction, secretion of 
matrix enzymes and the synthesis and release of ECM proteins (Taylor et al. 2000). 
 
The other type of cells present within the valve represent a smaller population (1–5%) of 
SMCs (Latif et al. 2014; Yip et al. 2011). They express SMM. Some people believe that 
these cells come from the arteriole and venules present in the leaflet (Mulholland et al. 1996; 
Taylor et al. 2003) or from SMCs present at the base of the leaflet as extensions from the 
annulus (Disatian et al. 2008), but on the other hand there is some evidence from electron 
microscopy studies on the existence of smooth muscle system “network” inside the valve 
leaflet (Cimini et al. 2003). It was recently shown that smooth muscle markers including 
SMM and SM22 were significantly increased in calcific aortic valve disease (Latif et al. 
2014).  
 
Under light microscopy, VICs have two well-recognised morphologies: one is of cuboidal, 
stellate or cobblestone appearance; the other spindle-shaped, elongated with a swirling 
pattern (Taylor et al. 2003). This elongated morphology is associated with prominent stress 
fibres and the expression of αSMA, while the rounded morphology has prominent granules, 
and is believed to be more associated with the production of collagen and other ECM 
components. Although these features are indicative of either qVICs or MFB, but they are 
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neither sensitive nor specific enough to differentiate between them due to variability in level 
of αSMA expression and the presence of both morphologies (Liu et al. 2007; Rabkin et al. 
2001). 
Hypoxia was shown to affect the phenotype and morphology of other cells. For example, 
αSMA expression was increased by lung and liver fibroblasts (Modarressi et al. 2010) and 
rheumatoid synovial fibroblast when cultured under hypoxia (Li et al. 2013), meanwhile it 
was reduced expression in rat dermal fibroblasts (Modarressi et al. 2010). In pMVICs, 
hypoxia has affected neither the expression of the phenotypic markers nor the morphology of 
the cells. pMVICs strongly expressed αSMA, which is an artefact of the widely recognised 
culturing process and occurs to different types of fibroblast including VICs where cells 
quickly express αSMA once cultured in vitro (Cimini et al. 2002; Rohr 2011; Taylor et al. 
2000). Nevertheless, hypoxia did not further increase or decrease αSMA expression. Smooth 
muscle markers were weakly expressed by pMVICs similar to previously reports (Latif et al. 
2014; Yip et al. 2011) and they did not change under either in culture or under hypoxia.  
 
It is important to remember that this study looked at the isolated effect of hypoxia on 
pMVICs in the absence of mechanical stimulus like stretch or other biological mediators like 
TGF-β that were shown to modulate VICs phenotype expression and differentiation (Thayer 
et al. 2011; Waxman et al. 2012).  
 
 
In conclusion, this study has shown that pMVICs maintain stable viability, morphology and 
phenotype under different levels of hypoxia. This suggests that they are able to reside in these 
conditions; however, hypoxia may be capable of affecting the secretory properties of the 
cells.  In addition, this study defines that any observed changes in MVICs function under 
hypoxic conditions, will not be attributed to changes in cells number or viability.  
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5.1 INTRODUCTION 
The ECM provides the main structural backbone of the valve leaflet. Made of three distinct 
but interacting layers, the ECM plays an important role in determining the physical and 
mechanical properties of the valve (Taylor et al. 2006). The main constituents of these three 
layers are collagens, GAGs (and their associated PGs) and elastin. Although present in each 
layer, there is a predominance of collagen in the fibrosa, GAGs and PGs in the spongiosa and 
elastin in the ventricularis (or atrialis) (Latif et al. 2005a).  
In addition to its structural role, the ECM also forms complex interactions with the cells 
within and on the surface of the valve, affecting their phenotype and their function in 
maintaining the ECM and the integrity of the valve. The ECM is a reservoir to many 
biologically active molecules like growth hormones, cytokines, matrix remodelling enzymes 
like MMPs and TIMPs (Bowers et al. 2010; Visse et al. 2003) and cell communication 
proteins like integrins, selectin and adhesion molecules (Latif et al. 2005b).  
Valve leaflets serve a complex function of timely, coordinated opening and closing to guide 
the unidirectional blood flow inside the heart. In doing so they withstand high levels of 
dynamic changes of stress and pressure throughout each cardiac cycle (Hinton et al. 2011). 
Therefore, maintaining the integrity of the ECM and subsequently the valve leaflet structure 
is a crucial and important biological function. Failure to do that can result in loss of optimum 
valve function, with subsequent significant cardiovascular morbidity and mortality. Most of 
the valvular pathologies share the common feature of disruption of the leaflet structure and 
destruction of the ECM (Hinton et al. 2011; Salhiyyah et al. 2011). 
VICs are important to maintain the structure of the ECM. Their main function is to produce 
ECM components especially collagen, GAGs and elastin. They also contribute to the ECM 
remodelling and repair that occur subsequent to mechanical stress by secreting various 
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mediators like matrix remodelling enzymes. As discussed earlier, hypoxia is a potential 
condition that can affect MVICs under normal or pathological circumstances. The study so 
far has shown that pMVICs remained viable and retained their cell morphology and 
phenotypes under different levels of hypoxia and up to 3 days. It is not known whether 
hypoxia can affect the MVICs functional capacity to produce and maintain the valve ECM 
and especially that hypoxia was shown to affect the production of other tissues’ ECMs 
(Gilkes et al. 2013; Myllyharju et al. 2010).  
5.1.1 Aims and objectives 
The aim of this chapter is to study the effect of hypoxia on the functional ability of pMVICs 
to produce different ECM components. This will be achieved by incubating primarily isolated 
pMVICs under different levels of hypoxia, and assessing the production of collagen through 
measuring the amount of total collagen produced and the gene expression of Collagens I and 
III, the amount of total sulphated GAGs as well the gene expression of relevant genes. 
Measuring the gene expression of the matrix enzymes MMP-2, MMP-9, TIMP-1 and TIMP-2 
will assess the effect of hypoxia on matrix remodelling potential.  
 
 
 
Effect of hypoxia on ECM production 
 
144 
 
5.2 METHODS 
5.2.1 Tissue collection of porcine mitral valves 
Porcine hearts (18–30 months old) were obtained from a commercial slaughterhouse (Cheale 
Meats, Essex, UK). The hearts were placed in ice-cold Hanks solution (Sigma, UK) within 15 
minutes of removal from the animal, and they were used within 4 hours from animal 
sacrifice.  
5.2.2 Cell isolation and culture 
Porcine MVs were dissected and VICs were isolated and grown as described in section  4.2.2. 
Cells were used for experiments between passage numbers 2 and 6 (P2–P6). Cells were 
allowed to grow and multiply until they became sufficient for running the experiments. Cells 
were passaged and of which a known number were plated in the appropriate tissue culture 
plate in preparation of each experiment as described in section  4.2.3.  
 
5.2.3 Hypoxic incubation protocol 
Appropriate cell culture plates for each experiment were incubated in the hypoxic incubator 
described in Chapter 3. Each plate was placed in the corresponding hypoxic chamber, and 
experiments were carried out in four different conditions: 20%, 5%, 2% and 0.5% O2 over 1 
± 3 days as explained later for each experiment.  
 
5.2.4 The effect of hypoxia on porcine MVICs’ collagen production 
The effect of hypoxia on pMVICs collagen production was measured using the Collagen 
SircolTM assay (Biocolor, Northern Ireland, UK). It is a dye-binding method designed for the 
analysis of acid- and pepsin-soluble collagens. The Sircol Assay is suitable for monitoring 
collagen produced in situ or during in vitro cell culture and in vitro ECM. It measures type I 
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to V of mammalian collagens, and can be used for ex vivo measurement of total collagen-like 
collagens, soluble in cold acid or pepsin, recovered from mammalian soft tissues, cartilages 
and fluids, and for collagens released into cell culture medium in vitro during cell growth and 
cell maintenance. It is unable to discriminate between different types of collagen.  
 
The assay consists of collagen isolation & concentration reagent that contains polyethylene 
glycol in a TRIS-HCl buffer, pH 7.6, dye reagent that contains Sirius Red in picric acid and 
has been formulated for specific binding to collagen. The kit comprises an acid-salt wash 
reagent, which contains acetic acid, sodium chloride and surfactants; an alkali reagent, that 
contains 0.5M sodium hydroxide and is used to release Sircol dye from the collagen-dye 
complex; and a reference standard, which is a sterile solution of cold acid-soluble bovine 
skin collagen type I in 0.5M acetic acid at a concentration of 500 μg/ml.  
pMVICs were plated in six well plates at a density of 200 x 103 cells per well. Cells were 
allowed to grow for 1 day then the media were changed with fresh 2.5 ml medium containing 
10% FBS. Eight identical six well plates were prepared at the same time. The plates were 
incubated under the following O2 concentrations: 20%, 5%, 2% and 0.5%. Four plates were 
assessed after 24 hours (day 1), and the other four were assessed after 72 hours (day 3) 
exposure to the different O2 concentrations. 
  
At the end of the incubation, the media from the plates were collected in 1.5 ml eppendorf 
tubes. The exact amount of media were measured and recorded. To a fresh tube, 1 ml of the 
media was transferred, 200µl of cold isolation and concentration reagent were added and the 
tubes inverted for mixing. The tubes were placed in half-filled container of ice water 
overnight at 4°C. The tubes were then centrifuged at 13,000 rpm for 10 minutes. An invisible 
pellet was formed at the bottom of the tube. The supernatant was carefully aspirated, and 1 ml 
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of Sircol dye reagent was added to each tube. Blank tubes were prepared using 100 µl of 
distilled water, and collagen standards were prepared by adding 5, 10 and 15 µg of soluble 
bovine skin collagen type I made up to 100 µl using distilled water. After adding the Sircol 
dye reagent, the tubes were placed on shaker to mix the dye with the collagen for 30 minutes. 
They were centrifuged at 13,000 for 10 minutes. The supernatant was then drained very 
carefully without disturbing the pellet. The tubes were gently washed with 750 µl of ice-cold 
acid-salt wash to remove unbound dye from the surface of the pellet and the inside of the 
tube. The tubes were centrifuged and drained as before and finally 250 µl of alkali reagent 
was added. The tubes were vortexed to dissolve the collagen-dye bound and the absorbance 
was read at 555 nm using a spectrophotometer (Eppendorf, Germany). The collagen 
standards were used to generate a standard curve (Figure 5.1), which was subsequently used 
to calculate the amount of collagen produced by the cells.  
 
 
Figure ‎5.1 - Collagen standard curve  
Collagen standards supplied with the Sircol kit were made up at three different concentration by 
adding  5, 10 and 15 µg of soluble bovine skin collagen type I and made up to 100 µl using distilled 
water in addition to a reagent blank.  Standards were processed as per the Sircol kit protocol and 
optical absorbances for each concentration were used to generate the standard curve.  
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5.2.4.1 Data analysis  
Data are expressed as mean ± SEM. Differences between groups for each test were assessed 
using one-way ANOVA followed by Dunnett post hoc test.  
5.2.5 Effect of hypoxia on sGAG production  
The amount of sulphated GAGs (sGAG) produced by the MVICs was assessed using the 
BlyscanTM assay (Biocolor, Northern Ireland, UK).  It is a quantitative dye-binding method 
for the analysis of sulphated PGs and sGAG. The assay is made of a dye label that is 1,9-
dimethylmethylene blue. This dye is employed under conditions that provide a specific label 
for the sulphated polysaccharide component of PGs or the protein free sGAG chains. The 
assay is able to measure an extensive range of mammalian PGs including the following 
sGAGs either still attached to the peptide/protein chain or as free chains: chondroitin sulphate 
(CS), keratan sulphate (KtS), dermatan sulphate (DS) and heparan sulphate (HS) (including 
heparins), but it is not able to detect hyaluronan (HA). Soluble components such as proteins 
and neutral carbohydrates present in tissue extracts do not interfere with the assay. The assay 
can be used to measure sGAGs present in soluble form like ECM components that may be 
released by live cells into the culture medium, or different biological materials like cartilage 
or cultured cells following papain extraction.  
 
pMVICs were plated in six well plates at a density of 200 x 103 cells per well. Cells were 
allowed to grow for 24 hours then the media were changed with fresh 2.5 ml medium 
containing 10% FBS. Eight identical six well plates were prepared at the same time. The 
plates were incubated under the following O2 concentrations: 20%, 5%, 2% and 0.5%. Four 
plates were assessed after 24 hours (day 1), and the other four were assessed after 72 hours 
(day 3) exposure to the different O2 concentrations. At the end of the experiment, the culture 
media were collected and frozen at -80°C. Cells were washed with PBS once with extra care 
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taken to drain all excess PBS, and the cells were incubated with 400 µl of fresh extraction 
buffer. The extraction buffer was prepared by making a 0.2M sodium phosphate buffer 
(NaH2PO4) at pH 6.4, to which the following agents were added: 0.1M sodium acetate, 
0.01M ethylenediaminetetraacetic acid-disodium salt (Na2EDTA) and 0.005M L-cysteine 
hydrochloride, and just before use Papain was added at a concentration of 8 μl per 1 ml (all 
from sigma, UK). Plates were incubated with the extraction buffer for 10 minutes at 37°C 
until all the cells have detached, and confirmed under light microscope, and were collected 
using a cell scrapper to a 1.5 ml eppendorf tube. Tubes were then incubated at 65°C for 30 
minutes, centrifuged at 13,000 rpm for 10 minutes and supernatant collected to be used for 
the Blyscan assay. Of this cell extract, 100 µl were transferred to a fresh 1.5 ml eppendorf 
tube for each sample. GAG standard were also prepared by adding 1, 2, 3, 4 and 5 µg of 
bovine tracheal CS made up to 100 µl with distilled water. Reagent blank was of 100 µl of 
distilled water. To each of those tubes 1 ml of dye reagent was added. Tubes were placed on 
an orbital shaker at RT for 30 minutes. Tubes were then centrifuged at 13,000 rpm for 10 
minutes. The dye binds to sGAG forming an insoluble purple complex that precipitates at the 
bottom of the tube. The unbound dye then was very carefully removed with extra care not to 
disturb the pellet or to lose any small particles. After that 1 ml of a dissociation reagent was 
added to each tube. The tubes were then vortexed until all the dye pellet had dissolved. The 
absorbances of the samples were measured 650 nm using a spectrophotometer (Eppendorf, 
Germany) after calibration with distilled water.  
 
The reagent standards were used to generate a standard curve (Figure 5.2), which was 
subsequently used to calculate the amount of sGAG present in the cells.  
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Figure ‎5.2 - sGAG standard curve 
GAG standards supplied with the Blyscan kit were made up at five different concentrations by adding  
1, 2, 3, 4 and 5 µg of bovine tracheal CS and made up to 100 µl using distilled water in addition to a 
reagent blank.  Standards were processed as per the Blyscan kit protocol and optical absorbances for 
each concentration were used to generate the standard curve.  
 
The culture media that were collected at the end of the experiments were used to measure the 
amount of sGAGs secreted into culture media. They were placed in 15 ml falcon tubes and 
were freeze dried for 24 hours. The dried material was then re-suspended by the addition of 
400 µl of distilled water and the assays were performed as above loading 100 µl in each test 
similar to cell suspension.  
 
5.2.5.1 Data analysis 
Total sGAG produced by the MVICs was calculated by adding the amount of sGAGs 
produced in the cells and the amount secreted in the culture media. The percentage of the 
sGAG secreted in media were calculated by dividing the secreted sGAGs over the total 
amount. Data were presented by mean ± SEM. Groups were compared using one-way 
ANOVA with Dunnett post hoc test using GraphPad Prism 5 software.  
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5.2.6 Effect of hypoxia on gene expression using quantitative real-time polymerase 
chain reaction 
5.2.6.1 Samples 
In order to examine the effect of hypoxia on ECM gene expression, pMVICs were cultured 
and prepared as described above in section  4.2.2. Cells were plated in P10 Petri dish until 
they reached 70–80% confluent. Media were replaced with fresh DMEM media 
supplemented with 10% FBS as mentioned previously and incubated under the same three 
hypoxic conditions and the atmospheric control for one day only. At the end of the 
incubation, the media were removed and cells were washed twice with sterile PBS before 
RNA extraction.  
5.2.6.2 RNA extraction 
RNA extraction was achieved using the RNeasy extraction kit (Qiagen Ltd, Manchester, UK) 
according to the manufacturer’s guidelines. Briefly, cells were lysed in 350 µl RLT buffer 
supplemented with β-mercaptoethanol at a concentration of 10 µl/1 ml and homogenised 
using the Qiashredder tube (Qiagen Ltd, UK) by centrifuging at 800 g (13,000 rpm) for 2 
minutes. Another 350µl of 70% ETOH were added to the lysate and mixed gently. The 
mixture was then transferred to the RNeasy mini column and centrifuged for 15 seconds at 
13,000 rpm. The flow through was discarded as the RNA binds to the column membrane. The 
column was washed with 350µl of RW1 buffer to remove contaminants. A DNase digestion 
was then performed to remove any residual DNA contamination. This was achieved by 
adding 80 μL of DNase in RDD buffer (Qiagen, UK), made according to manufacturer’s 
guidelines, to the column membrane and keeping it for 15 minutes at RT. The column was 
washed with another 350 µl of RW1 buffer, spun for 15 seconds at full speed and the flow 
through was discarded. The column was then washed twice with 500 µl of RPE buffer and 
centrifuged for 15 seconds and then 2 minutes to eliminate the ETOH. The mini column was 
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placed into a new 2 ml collection tube and centrifuged for 1 minute to ensure all ETOH was 
removed. The mini column was transferred again to a new RNase-free 1.5 ml eppendorf, and 
40 µl of Ambion RNase-free water (Life Technologies, UK) was added. The column was 
centrifuged at 13,000 rpm for 1 minute. The eluted RNA was placed immediately on ice and 
stored at -80°C.  
 
5.2.6.3 Quantification of total RNA 
Absorption spectroscopy was performed to assess the purity and concentration of the isolated 
RNA. In 70 μl of Tris-EDTA (TE) buffer (10mM Tris; 1mM EDTA; pH 8.0) (Sigma, UK) 5 
μl of RNA was diluted and OD readings were taken at 260 nm and 280 nm using a 
spectrophotometer (Eppendorf, Germany). RNA concentration was calculated based on the 
equation that at 260 nm, the OD of 1 equals an RNA concentration of 40 µg/ml. Since the 
samples were DNase treated the chance that the calculation could be affected by any single- 
or double-stranded DNA (which also absorbs at 260 nm) was reduced. The purity of the RNA 
from any protein contamination was measured by the A260/A280 ratio, which should be 2.0 in 
a clean preparation. And since proteins also absorb light at 280 nm, if the A260/A280 ratio is 
less than 2.0 this indicates protein contamination. Using these results the RNA was diluted to 
100 ng/μl in 10 μl aliquots and stored at -80°C. 
 
5.2.6.4 cDNA synthesis 
Complementary DNA (cDNA) was synthesised from total RNA by using TaqMan Reverse 
Transcriptase Kit (Applied Biosystems, UK) according to manufacturer’s instructions. All 
RNA samples, reagents and steps were thawed, kept and performed on ice. Samples were 
briefly vortexed and centrifuged. The enzymes were kept at -20°C until immediately before 
use. All steps were performed on ice. A master mix was prepared by mixing the reagent (as 
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shown in Table 5.1), and aliquoting 9 µl into 0.5 ml eppendorf tube. Then 1 μl of RNA at 10 
ng/ul was added and the mixture briefly vortexed and centrifuged. The reactions were 
transferred to a standard thermal cycler and incubated at 25 °C for 10 minutes (enable primer 
binding), 48°C for 30 minutes (primer extension) and 95°C for 5 minutes (enzyme 
inactivation). Following cDNA synthesis the samples were diluted from 10 ng/μL to 2 ng/μL 
by the addition of 40 μL of RNase-free water. The cDNA samples were then stored at -20°C 
until required. 
 
Table ‎5.1 - TaqMan Reverse Transcriptase master mix components for 10 μl reaction 
Reagent Final Concentration Volume (µl)  
10x RT buffer 1x 1.0 
25mM MgCl2 5.5mM 2.2 
dNTPs 500µM each 2.0 
Random Hexamers 2.5µM 0.5 
RNase inhibitor 0.4U/µl 0.2 
Multispribe RT 1.25U/µl 0.625 
RNA-free Water   2.475 
Sample RNA 10 ng/µl 1.0 
 
 
5.2.6.5  Real-time TaqMan PCR 
The relative levels of the genes of interest were quantified using an ABI Prism 7500 (Applied 
Biosystems, Warrington, UK) using TaqMan probes. TaqMan PCR uses a fluorogenic probe 
to detect the specific gene of interest (GOI) product during the PCR reaction. It has a reporter 
fluorescent dye that is attached to the 5’ end and a quencher dye attached to the 3’ end. The 
proximity of the quencher dye to the fluorescent dye reduces the fluorescence emitted from 
the reporter dye. During PCR reaction, the probe attaches downstream from the primer site 
and is cleaved by the 5’ nuclease activity of the Taq DNA polymerase as the primer is 
extended. The cleavage of the probe separates the reporter dye from the quencher dye so that 
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the reporter dye fluorescent is increased. This signal is detected by a detector in the PCR 
machine and its intensity is proportional to the amount of amplicon, and thus the relative 
expression of the GOI (Livak et al. 1995). Pre-designed, pre-optimised assays containing 
PCR primers and TaqMan probe for all genes of interest and the 18S rRNA were purchased 
from Applied Biosystems (UK); however, the company cannot provide us with the sequence 
of primers, for reasons of confidentiality. The GOI and the housekeeping gene assays were 
labelled with different dyes to allow duplex PCR. 18S rRNA was selected as the 
housekeeping gene as it was commonly used as a control gene under hypoxic conditions in 
various cells (Kimura et al. 2008a; Nagelkerke et al. 2010). Table 5.2 shows the GOI used 
and their catalogue numbers. 
 
Table ‎5.2 - PCR genes assay details  
Gene Name Assay ID Details RefSeq Amplicon 
length 
COL1A1 Collagen, type I, alpha 1 Ss03375690_u1 AJ289757.1 140 
COL3A1 Collagen, type III, alpha 1 Ss03375691_g1 AJ289758.1 136 
C-4-S Chondroitin 4 Sulphate Ss03374044_m1 DQ400920.1 69 
HAS-2 Hyaluronan synthase 2 Sc03393798_m1 NM_214053.1 62 
MMP-2 Matrix metalloproteinase 2 
(gelatinase A) 
Ss03394318_m1 NM_214192.1 77 
MMP-9 Matrix metalloproteinase 9 
(gelatinase B) 
Ss03392100_m1 NM_001038004.1 58 
TIMP-1 TIMP metalloproteinase 
inhibitor 1 
Ss03381944_u1 NM_213857.1 105 
TIMP-2 TIMP metalloproteinase 
inhibitor 2 
Ss03375440_u1 NM_001145985.1 77 
18S 18S Ribosomal RNA Hs03928992_g1 NR_003286.2 104 
 
All PCR plasticware and reagents including PCR Fast Master Mix were from Applied 
Biosystems, and performed according to their guidelines. The RT-PCR assays were 
performed in a 20 μl reaction containing 3 μl cDNA (2 ng/μl), 10 μl of TaqMan universal 
PCR Master Mix (2x), 1 μl of target gene assay (20x), 1 μl of 18S assay (20x) and 5 μl of 
RNA-free water (Table 5.3). cDNA samples were thawed and kept on ice. The primers were 
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kept in the dark until immediately before use. The samples were vortexed and centrifuged 
briefly. Reactions were performed in duplicates. 17 µl of master mix were loaded onto an 
optical 96 well plate first and then 3 µl of cDNA were added next (Table 5.3). The plate was 
centrifuged at 400 g for 1 minute before running the PCR reaction.  
 
Table ‎5.3 – Real-time PCR reaction components for a 20 µl reaction 
Reagent  Concentration Volume (µl) 
Fast Advanced Master 
Mix 
2x 10 µL 
GOI 20x 1 µL 
18S 20x 1 µL 
H2O – 5 µL 
cDNA 2ng/µl 3 µL 
 
 
Real-time PCR was performed using the ABI Prism 7500 Fast Sequence Detection System 
(Applied Biosystems, UK).  Cycling conditions are shown in (Table 5.4). Data were collected 
and analysed using Sequence Detection Software (Applied Biosystems, UK). The software 
set baseline and thresholds automatically. Data were exported into Excel and analysed using 
the comparative Ct method. 
 
Table ‎5.4 - PCR cycling conditions  
Step Temperature Time Purpose 
First hold  95°C 20 seconds Activate DNA polymerase 
    
40 cycles 95°C 5 second cDNA denature  
 
 
60°C 30 seconds Primer binding and cDNA 
extension 
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5.2.6.6 Data analysis 
PCR experiments were designed and performed according to the MIQE guidelines (Bustin et 
al. 2009). The analysis was performed using the comparative Ct method, which is a relative 
quantification technique that uses mathematical formulas instead of standard curves (Livak et 
al. 2001). The formula to convert the Ct values for target and endogenous control genes into a 
meaningful measure is 2-ΔΔCt, where ΔΔCt = ΔCt of test sample – ΔCt of calibrator sample 
and ΔCt = target gene Ct – endogenous control gene Ct. Essentially, the formula calculates 
the abundance of target messenger RNA (mRNA), normalised to an endogenous control and 
relative to a calibrator. The mean relative expression of each gene was calculated from all 
isolates. 
 
5.2.6.7 Statistical analysis  
Data are expressed as mean ± SEM. Differences between groups for each test were assessed 
using one-way ANOVA followed by Dunnett post hoc test.  
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5.3 RESULTS 
5.3.1 Effect of hypoxia on collagen production 
The effect of hypoxia on total collagen production by pMVICs was assessed using the 
Collagen Sircol assay (n=6). After 24 hours (day 1) of incubation, there was no difference in 
the total amount of collagen produced under a different level of hypoxia and 20% O2 
atmospheric control (Figure 5.3). Total amount of collagen produced by 200,000 cells was for 
25.01 ± 4.32 µg (20% O2), 25.78 ± 3.18 µg (5% O2), 26.55 ± 1.77µg (2% O2) and 26.18 ± 
4.16 µg (0.5% O2) (P>0.05). But after 72 hours (day 3) the total amount of collagen produced 
was significantly reduced to 37.23 ± 1.89µg* at (5% O2) and to 33.12 ± 2.73µg* at (0.5% O2) 
compared with 46.17 ± 2.24µg at (20% O2). There was no difference at between 20% and 
(2% O2), which produced 42.21 ± 1.95µg (*P<0.05).  
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Figure ‎5.3 - Effect of hypoxia on total collagen production 
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2), and severe (0.5% 
O2) hypoxia as well as atmospheric control (20% O2) for 1 day and 3 days. Culture media 
were collected and analysed for the amount of total Collagen present using the Sircol assay. 
Groups were compared separately at day 1 and day 3 using one-way ANOVA with Dunnett 
post hoc test comparing the three hypoxic groups to 20% control. After 1 day, there was no 
difference in the amount of collagen produced by all groups (P>0.05), but after 3 days, there 
was a significant reduction in the amount of collagen produced under mild (5% O2) and 
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severe (0.5% O2) hypoxia but not moderate (2% O2) compared with atmospheric control. 
(*P<0.05). n=6. 
 
5.3.2 Effect of hypoxia on COL1A1 and COL3A1 gene expression 
The effect of hypoxia on COL1A1 and COL3A1 gene expression by the pMVICs was 
assessed through quantitative real-time PCR (qRT-PCR) and normalised against 18s rRNA 
(n=6). There was neither a statistically significant difference in the levels of gene expression 
of COL1A1 nor COL3A1 between hypoxic conditions and control for 24 hours (day 1). For 
COL1A1 the relative gene expression was 1.17 ± 0.25 under 20% O2, 1.37 ± 0.15 (5% O2), 
1.74 ± 0.15 (2% O2) and 1.53 ± 0.22 (0.50% O2) (Figure 5.4A). The relative gene expression 
for COL3A1 was 1.13 ± 0.23 was 20% O2, 1.16 ± 0.17 (5% O2), 1.14 ± 0.18 (2% O2) and 
1.44 ± 0.45 (0.50% O2) (Figure 5.5A). There was no significant difference in the expression 
of 18s rRNA in all groups (P>0.05) (Figures 5.4B and 5.5B).  
 
20
% 5% 2%
0.5
0%
0.0
0.5
1.0
1.5
2.0
Conditions
R
el
at
iv
e 
E
xp
re
ss
io
n 
of
 C
ol
 1
A
1
A
 
20
% 5% 2%
0.5
0%
0.0
0.5
1.0
1.5
Conditions
R
el
at
iv
e 
E
xp
re
ss
io
n 
of
 1
8s
 r
R
N
A
B
 
Figure ‎5.4 - The effect of hypoxia on MVICs’ COL1A1 gene expression  
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2), and severe (0.5% 
O2) hypoxia as well as atmospheric control (20% O2) for 1 day. mRNA was extracted using 
RNeasy extraction kit, then cDNA was synthesised using TaqMan Reverse Transcriptase kit. 
The relative expression of COL1A1 (A) and 18S rRNA (B) was quantified using real-time 
TaqMan PCR. The data were analysed using the comparative Ct method relative to 
atmospheric control. The data represent mean relative expression ± SEM (n=6). Groups were 
compared using one-way ANOVA with Dunnett post hoc test. There was no significant 
difference in COL1A1 gene expression between the groups.   
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Figure ‎5.5 - Effect of hypoxia on MVICs’ COL3A1 gene expression  
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2), and severe (0.5% 
O2) hypoxia as well as atmospheric control (20% O2) for 1 day. mRNA was extracted using 
RNeasy extraction kit, then cDNA was synthesised using TaqMan Reverse Transcriptase kit. 
The relative expression of COL3A1 (A) and 18S rRNA (B) was quantified using real-time 
TaqMan PCR. The data were analysed using the comparative Ct method relative to 
atmospheric control. The data represent mean relative expression ± SEM (n=6). Groups were 
compared using one-way ANOVA with Dunnett post hoc test. There was no significant 
difference in COL3A1 gene expression between the groups.  
 
5.3.3 The effect of hypoxia on sGAG production by porcine MVICs 
The effect of hypoxia on total sGAG production by pMVICs was assessed using the Blyscan 
assay (n=4). After 24 hours (day 1) of incubation, there was no difference in the total amount 
of sGAG produced under a different level of hypoxia and the 20% O2 atmospheric control 
(Figure 5.6). Total amount of sGAG produced by 50,000 cells was 6.72 ± 1.07 µg (20% O2), 
5.54 ± 1.13 µg (5% O2), 5.25 ± 1.03 µg (2% O2) and 5.21±1.03µg (0.50% O2) (P>0.05). 
After 72 hours (day 3) the total amount of sGAG was significantly reduced to 4.63 ± 0.39 
µg* (2% O2) and 3.55 ± 0.88 µg* (0.50% O2) compared with 7.81 ± 0.51 µg (20% O2) 
(*P<0.05), and there was no statistical difference of 5.93 ± 0.78 µg produced (5% O2). 
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Figure ‎5.6 - Effect of hypoxia on total sGAG production 
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric control (20% O2) for 1 day and 3 days. The amount of total 
sGAG produced was measured in both the cells and the culture media using Blyscan assay. 
The groups were compared separately at day 1 and day 3 using one-way ANOVA with 
Dunnett post hoc test comparing the three hypoxic groups to 20% control. After 1 day, there 
was no difference in the total amount of sGAG produced by all groups, but after 3 days, there 
was a significant reduction in the amount of sGAG produced under moderate (2% O2) and 
severe (0.5% O2) hypoxia compared with atmospheric control. (*P<0.05). n=6. 
 
The amount of total sGAG represents the amount of sGAG isolated from the cells plus the 
amount of sGAG secreted into the media. Therefore, the percentage of the amount of sGAG 
secreted into the media is calculated for two reasons: the first is to see if the hypoxia affects 
the production and secretion preferentially, and, second, to identify if measuring the sGAG in 
the cells will be representative of the total amount of sGAG produced. There was no 
significant difference in the percentage of sGAG secreted into the media under hypoxia 
compared with control after 24 hours (day 1): 36.71 ± 1.50% (20% O2), 30.88 ± 5.13% (5% 
O2), 26.40 ± 3.14% (2% O2) and 23.63 ± 4.46% (0.50% O2) (P>0.05) (Figure 5.7). Similarly 
there was no significant difference in secreted sGAG between the different levels of hypoxia 
after 72 hours (day 3) of incubation: 56.99 ± 3.64% (20% O2), 49.62 ± 9.59% (5% O2), 61.09 
± 3.58% (2% O2) and 57.80 ± 7.25% (0.50% O2) (P>0.05). However, it was noticed that there 
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was significantly more sGAG secreted into the media after 3 days compared with 1 day in all 
the groups. At 20% O2, the percentage of sGAG secreted at day 3 was 56.99 ± 3.64% 
compared with 36.71 ± 1.50% after day 1 (P=0.0143) 
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Figure ‎5.7 - Effect of hypoxia on sGAG secretion into culture media 
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric control (20% O2) for 1 day and 3 days. The amount of sGAG 
produced was measured in both the cells and the culture media using Blyscan assay. The 
percentage of sGAG secreted into media from the total amount of sGAG produced was 
calculated. The groups were compared separately at day 1 and day 3 using one-way ANOVA 
with Dunnett post hoc test comparing the three hypoxic groups with 20% control. There was 
no difference in the percentage of sGAG secreted to the media relative to the total amount of 
sGAG produced by all groups both after 1 day and 3 days. (P>0.05). n=6. 
 
5.3.4 Effect of hypoxia on C-4-S and HAS-2 gene expression 
The effect of hypoxia on chondroitin-4-sulphate (C-4-S) (Figure 5.8) and HAS-2 (Figure 5.9) 
gene expression by pMVICs was assessed through qRT-PCR and normalised against 18s 
rRNA (n=6). There was no statistically significant difference in the levels of gene expression 
of C-4-S. The relative level of gene expression of C-4-S was 1.07 ± 0.16 under (20% O2), 
1.80 ± 0.76 (5% O2), 1.3 ± 0.32 (2% O2) and 2.2± 0.99 (0.5% O2).  The relative gene 
expression of HAS-2 was significantly reduced to 0.24 ± 0.07* under (0.5% O2) compared 
with 1.16 ± 0.26 at (20% O2) (*P<0.05%), while there was no significant difference of 0.81 ± 
Effect of hypoxia on ECM production 
 
161 
 
0.23 under (5% O2) or 0.61± 0.28 (2% O2). There was no significant difference in the 
expression of 18s rRNA in all groups (P>0.05). 
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Figure ‎5.8 - The effect of hypoxia on MVICs’ C-4-S gene expression  
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric control (20% O2) for 1 day. mRNA was extracted using 
RNeasy extraction kit, then cDNA was synthesised using TaqMan Reverse Transcriptase kit. 
The relative expression of C-4-S (A) and 18S rRNA (B) was quantified using real-time 
TaqMan PCR. Data were analysed using the comparative Ct method relative to atmospheric 
control. The data represent mean relative expression ± SEM (n=6). Groups were compared 
using one-way ANOVA with Dunnett post hoc test. The study did not show a significant 
difference in C-4-S gene expression between the groups (P>0.05).  
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Figure ‎5.9 - The effect of hypoxia on MVICs’ HAS-2 gene expression  
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric control (20% O2) for 1 day. mRNA was extracted using the 
RNeasy extraction kit, then cDNA was synthesised using TaqMan Reverse Transcriptase kit. 
The relative expression of HAS-2 (A) and 18S rRNA (B) was quantified using real-time 
TaqMan PCR. The data were analysed using the comparative Ct method relative to 
atmospheric control. The data represent mean relative expression ± SEM (n=6). Groups were 
compared using one-way ANOVA with Dunnett post hoc test. There was significant 
reduction in HAS-2 gene expression under severe (0.5% O2) hypoxia compared to control 
(20%O2) *P<0.05.  
Effect of hypoxia on ECM production 
 
162 
 
5.3.5 Effect of hypoxia on ECM remodelling enzymes 
The effect of hypoxia on the gene expression of the ECM remodelling enzymes produced by 
the pMVICs was assessed through qRT-PCR and normalised against 18s rRNA (n=6). The 
enzymes assessed were MMPs 2 and 9, and their tissue inhibitors, TIMPs 1 and 2.  
The relative gene expression of MMP-2 (n=6) was significantly increased to 1.406 ± 0.1834* 
fold under 0.50% O2 compared with 0.9549 ± 0.06035 fold at 20% O2 (*P<0.05), while there 
was no significant difference of 0.9678± 0.1252 fold under (5% O2) or 1.028±0.07446 fold 
(2% O2). There was no significant difference in the expression of 18s rRNA in all groups 
(P>0.05) (Figure 5.10). 
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Figure ‎5.10 - The effect of hypoxia on MVICs’ MMP-2 gene expression  
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric control (20% O2) for 1 day. mRNA was extracted using 
RNeasy extraction kit, then cDNA was synthesised using TaqMan Reverse Transcriptase kit. 
The relative expression of MMP-2 (A) and 18S rRNA (B) was quantified using real-time 
TaqMan PCR. The data were analysed using the comparative Ct method relative to 
atmospheric control. The data represent mean relative expression ± SEM (n=6). Groups were 
compared using one-way ANOVA with Dunnett post hoc test. There was a significant 
increase in MMP-2 gene expression under severe (0.5% O2) hypoxia compared with control 
(20%O2) *P<0.05.  
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The relative gene expression of MMP-9 (n=6) was significantly increased to 2.905 ± 0.6151* 
fold under 0.50% O2 compared with 0.8161 ± 0.3291 fold (20% O2) (*P<0.05), while there 
was no significant difference of 1.342 ± 0.4644 fold under 5% O2 or 1.995 ± 0.6842 fold (2% 
O2). There was no significant difference in the expression of 18s rRNA in all groups (P>0.05) 
(Figure 5.11). 
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Figure ‎5.11 - The effect of hypoxia on MVICs’ MMP-9 gene expression  
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric control (20% O2) for 1 day. mRNA was extracted using 
RNeasy extraction kit, then cDNA was synthesised using TaqMan Reverse Transcriptase kit. 
The relative expression of MMP-9 (A) and 18S rRNA (B) was quantified using real-time 
TaqMan PCR. The data were analysed using the comparative Ct method relative to 
atmospheric control. The data represent mean relative expression ± SEM (n=6). The groups 
were compared using one-way ANOVA with Dunnett post hoc test. There was significant 
increase in MMP-9 gene expression under severe (0.5% O2) hypoxia compared with control 
(20% O2) *P<0.05.  
 
 
The relative gene expression of TIMP-1 (n=6) was significantly increased to 2.979± 0.5815* 
fold under 0.50% O2 compared with 1.495 ± 0.4066 fold (20% O2) (*P<0.05), while there 
was no significant difference of 1.705± 0.2402 fold under 5% O2 or 2.259 ± 0.2715 fold (2% 
O2). There was no significant difference in the expression of 18s rRNA in all groups (P>0.05) 
(Figure 5.12). 
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Figure ‎5.12 - The effect of hypoxia on MVICs’ TIMP-1 gene expression  
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric control (20% O2) for 1 day. mRNA was extracted using 
RNeasy extraction kit, then cDNA was synthesised using TaqMan Reverse Transcriptase kit. 
The relative expression of TIMP-1 (A) and 18S rRNA (B) was quantified using real-time 
TaqMan PCR. The data were analysed using the comparative Ct method relative to 
atmospheric control. The data represent mean relative expression ± SEM (n=6). The groups 
were compared using one-way ANOVA with Dunnett post hoc test. There was a significant 
increase in TIMP-1 gene expression under severe (0.5% O2) hypoxia compared with control 
(20% O2) *P<0.05.  
 
The relative gene expression of TIMP-2 (n=6) was significantly increased to 1.995 ± 0.4659* 
fold under 0.50% O2 compared with 0.9924 ± 0.1603 fold (20% O2) (*P<0.05), while there 
was no significant difference of 1.068 ± 0.1412 fold under 5% O2 or 1.339 ± 0.1370 fold (2% 
O2). There was no significant difference in the expression of 18s rRNA in all groups (P>0.05) 
(Figure 5.13). 
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Figure ‎5.13 - The effect of hypoxia on MVICs’ TIMP-2 gene expression  
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric control (20% O2) for 1 day. mRNA was extracted using 
RNeasy extraction kit, then cDNA was synthesised using TaqMan Reverse Transcriptase kit. 
The relative expression of TIMP-2 (A) and 18S rRNA (B) was quantified using real-time 
TaqMan PCR. The data were analysed using the comparative Ct method relative to 
atmospheric control. The data represent mean relative expression ± SEM (n=6). Groups were 
compared using one-way ANOVA with Dunnett post hoc test. There was a significant 
increase in TIMP-2 gene expression under severe (0.5% O2) hypoxia compared with control 
(20% O2) *P<0.05.  
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5.4 DISCUSSION 
This study demonstrates the effect of hypoxia on the production of ECM components by 
MIVCs. The study showed that mild levels of hypoxia had little or no effect on the 
expression of ECM components. Reductions in the release and/or expression were seen in 
total collagen, total sGAGs and HAS-2 after 3 days of exposure of severe levels of hypoxia 
(0.5% O2). By contrast, the expression of MMP-2, MMP-9, TIMP-1 and TIMP-2 were all 
increased after exposure to 0.5% O2 for 1 day. Hypoxia had no effect on the gene expression 
of COL1A1, COL3A1 or C-4-S.  
Collagen  
Collagen is the main component of heart valves’ ECM. It accounts for more than 60% of 
valve leaflet dry weight (Kunzelman et al. 1993). The collagen subtypes present in valve 
leaflets are collagen I (74%), collagen III (24%) and collagen IV (2%) (Cole et al. 1984). 
Collagen fibres are present throughout the leaflet from base to coapting edge in all three 
layers of the leaflet, with a maximum density at the fibrosa layer where they are thick, 
parallel with interweaving pattern that run in the circumferential direction. In the other layers, 
collagen fibres are associated with the PGs in the spongiosa, and with elastin in atrialis, but 
are generally thinner with a punctuate pattern with occasional crimping of fibres (Latif et al. 
2005a). Collagen gives the valve leaflet its mechanical strength and forms the load-bearing 
backbone of the valve leaflet. The pattern of distribution of collagen fibres allows the valve to 
expand during closure in order withstand the haemodynamic force of the blood during systole 
(Grande-Allen et al. 2011).  
The study used the Sircol biochemical assay kit to measure that amount of total collagen 
secreted by the pMVICs. It is a widely used method of measuring total collagen (Bigg et al. 
2013; Schenke-Layland et al. 2003). The assay measures total collagen of subtypes I–V, 
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without being able to differentiate between them. In order to gain information on the collagen 
isoforms affected by hypoxia, the study also looked at the gene expression of the commonest 
collagen subtypes in the valve, namely collagen I and III. Culturing pMVICs under severe 
hypoxia resulted in a reduction of the amount of total collagen secreted by those cells. At the 
same time, same level of hypoxia did not affect the gene expression of collagens I and III. 
Cellular response to hypoxia with regards to collagen production can be different depending 
on different factors like species and cell type, level and duration of hypoxic exposure, the 
presence of other biological mediators and experimental design like continuous or 
intermittent hypoxia. For example, the normal function of chondrocytes in producing 
collagen and maintaining cartilage ECM is enhanced by hypoxic conditions (Coyle et al. 
2009; Gelse et al. 2008a; Gelse et al. 2008b), but the effect of hypoxia on cells that normally 
require higher levels of O2 can increase the level of collagen production into maladaptive 
pathological levels associated with conditions of tissue fibrosis, like liver fibrosis (Copple et 
al. 2009; Moon et al. 2009), kidney fibrosis (Kimura et al. 2008a) pulmonary fibrosis 
(Schreier et al. 2013) and myocardial fibrosis (Casals et al. 2013). The data presented for the 
effects of hypoxia on MVICs suggest that these cells are different from other fibroblast-like 
cells in that they reduced their production of collagen. The results obtained are unlikely to be 
due to changes in cell number under hypoxia since the observations made in Chapter 4 
showed the cells remained viable at O2 levels as low as 0.5%.  
In this study, hypoxia did not affect the level of gene expression of COL1A1 or COL3A1, but 
there was a reduction in the total amount of collagen produced. It could be that hypoxia 
affects other subtypes of collagen, or it could be due to hypoxia affecting post-translational 
changes of collagen synthesis, that reduce the levels of the mature protein. For example, 
culturing the 3T3-L1 cell line under 1% hypoxia resulted in enhancement of type IV collagen 
secretion but without an increase in gene expression of COL4A1 or COL4A2 (Tajima et al. 
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2001), and in foetal rat lung fibroblasts cultured under hypoxia, mRNA levels of procollagen 
I were not affected by hypoxia incubation for 5 days, but there was increased expression and 
of prolyl-4-hydroxylase, which accelerated the deposition of collagen (Horino et al. 2002). In 
addition, this study has shown that there is increased expression of the matrix remodelling 
enzymes. This could explain the reduction in the total collagen compared with stable gene 
expression.  
The study has used a clear experimental protocol and a validated hypoxic incubator with a 
real-time monitoring that guaranteed the tight control of the hypoxic conditions as shown in 
Chapter 3. Hypoxic incubation was limited to 3 days to avoid the need for changing culture 
media and expose cells to intermittent re-oxygenation, which could affect the reproducibility 
of the results. This was seen in a series of experiments from a group who looked at the effect 
of hypoxia on human vascular MFB with regards to the production of ECM in the context of 
valve tissue engineering. They first cultured MFBs from human saphenous veins that were 
seeded on a polyglycolic acid scaffold coated with poly-4-hydroxybutyrate and cultured for 2 
and 4 weeks under 7% hypoxia with or without insulin. This resulted in increased collagen 
and GAG levels compared with 20% O2 (Balguid et al. 2009). Then they examined same 
cells in monolayer cultures under variable levels of hypoxia below 7% O2 down to 0.5% for 1 
and 4 days. Relative gene expression of mRNA of procollagen I and III were significantly 
increased at 2%, 1% and 0.5%. After 4 days, protein levels using immunohistochemistry 
showed no difference for collagen I, but collagen III levels were significantly reduced at 
0.5% (van Vlimmeren et al. 2010). Finally they tested the tissue-engineered constructs from 
the first study using the lower O2 levels from the second study. This time there was no 
difference in the production of ECM under 7% and 4%, while there was moderate and severe 
reduction of collagen and GAG. The authors decided to re-investigate the results of the first 
study but they could not re-produce the same results. They believe this could be attributed to 
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inadequate control of the experimental conditions including subjecting the cells to 
intermittent hypoxia (van Vlimmeren et al. 2012).  
It is important to remember that this study looked at the isolated effect of hypoxia on MVICs 
without any addition of other mediators or stimuli. The presence of different mediators could 
modulate the cellular response to hypoxia. For example, both TGF-β1 and hypoxia were 
individually shown to increase the production of procollagen I in human cardiac fibroblasts, 
but when the two conditions were combined, the induction effect was reversed and no 
difference was seen compared with control (Agocha et al. 1997). In addition, TGF- β1 
(Merryman et al. 2007) and mechanical stretch (Ku et al. 2006; Merryman et al. 2007) were 
shown to increase collagen production by VICs. The study aim was to demonstrate the effect 
of hypoxia on pMVICs. Further experiments should be designed to assess the impact of 
various biological mediators on hypoxia, but adding such mediators to the culture media of 
the cells or subjecting cells to mechanical stimulation.  
GAGs 
The effect of hypoxia on the sGAG production by the pMVICs was also examined. There 
was no difference in the amount of total sGAG produced by the cells at one day under the 
three hypoxic conditions used, but after 3 days, there was a significant reduction under 
moderate (2% O2) and severe (0.5% O2) hypoxia compared with the atmospheric control. The 
total sGAG measured was sum of the sGAG in the media and in the cell layer. There was 
significant increase in the percentage of sGAG secreted to the media from the total sGAGs 
after three days compared to day 1, but there was no difference in this percentage between 
different levels of hypoxia and atmospheric control.  
GAGs and their associated PGs are essential components of heart valve ECM, and play an 
important role in the normal structure and function of heart valves. GAGs are negatively 
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charged which gives them the capacity to attract and retain water. This makes them highly 
flexible, forming a gel like matrix that is able to resist compression and absorb stress (Wight 
2002). GAGs were also found to be important for valve embryogenesis, development and 
remodelling through facilitating and guiding cell–matrix interactions allowing cell 
proliferation and differentiation (Stephens et al. 2012). GAGs also have important 
interactions with other ECM components: decorin was found to be associated with collagen 
fibrillogenesis, and biglycan plays a role with decorin in elastogenesis through binding to 
tropoelastin (Reinboth et al. 2002). Veriscan interacts and binds to a variety of matrix 
proteins like fibrillin, collagen I and fibronectin (Carthy et al. 2012).  
GAGs are predominantly found in the spongiosa layer of the leaflet (Latif et al. 2005a) and 
within the chordeae (Grande-Allen et al. 2004). But their presence in the leaflet is not 
confined to the spongiosa. They also appear to be distributed throughout the leaflet (Latif et 
al. 2005a) with higher staining intensity towards the base of the leaflet that reduces towards 
the coapting edge. They were found to fill up some gaps in fibrosa and atrialis layers (Gupta 
et al. 2009a). The types of GAGs present in heart valves are HA, DS, CS (4 and 6 sulphated), 
keratin sulphate and HS. Apart from HA, all GAGs are attached to a protein core-forming 
PGs. The PGs present in heart valves are biglycan (a CS/DS PG), decorin (CS/DS PG) and 
Veriscan (large CS PG) (Dainese et al. 2007; Latif et al. 2005a; Reinboth et al. 2002; 
Stephens et al. 2011). GAGs and PGs make up about 30% of the aortic valve leaflet 
(Stephens et al. 2008a), yet the relative proportion of the individual classes vary between 
different reports due to variability in GAG content between different regions of the valve and 
across age (Stephens et al. 2008a) and within different regions of the same valve where, for 
example, areas subjected to higher tensions have increased amounts of biglycan and decorin 
(Grande-Allen et al. 2004). In addition, their levels also vary in the different heart valves. It 
has been reported that HA is the most abundant GAG comprising 50–60% of the aortic valve 
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GAGs (Murata 1981), while it represents only 37% of GAGs in the posterior leaflet of the 
MV (Dainese et al. 2007). 
The Blyscan biochemical assay kit was used in this study to measure the total amount of 
sGAG produced by the pMVICs, which has previously been used to measure sGAGs in valve 
tissue and cells (Lacerda et al. 2012; Schenke-Layland et al. 2009; Singelyn et al. 2009). The 
assay measures the sulphated GAGs only, which include all GAGs but not HA. Therefore, 
the study also looked at the gene expression of HAS-2 and C-4-S. HAS-2 is one of the major 
enzymes that synthesizes HA, and would reflect the effect of hypoxia on HA. The level of 
expression of HA had a similar pattern to the total GAGs: it was significantly reduced under 
severe hypoxia (0.5% O2) compared with control. The gene expression of C-4-S was also 
examined under hypoxia. It was selected as it was one of the commonest types of sGAG 
present in valves. It is normally present across all layers, but has been shown to have strong 
expression in the inflow and outflow layers of the leaflet. In the spongiosa, it is more 
diffusely distributed, and entirely absent in some regions (Latif et al. 2005a). The mRNA 
expression of the C-4-S was analysed and showed no difference in expression under hypoxia. 
The reduction in total sGAG could be due to decreased synthesis of other GAG subtypes 
similar to HA, or due to increased breakdown especially with increases in matrix remodelling 
enzymes, including MMP-2 and MMP-9, that will lyse the PGs and make the free GAGs 
more susceptible for enzymatic destruction. In this study, the importance of hypoxia as a 
stimulus that affects GAG production by MVICs was limited by not looking at a wider 
spectrum of GAGs and their associated PGs.  
The effect of hypoxia on GAG production is important under both physiological and 
pathological conditions. Whereas cartilage tissue, which is very rich in GAGs is normally 
avascular and maintained under hypoxic conditions (Coyle et al. 2009), increased GAGs 
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production and deposition was linked to other conditions like atherosclerosis (Asplund et al. 
2010) and lung fibrosis (Papakonstantinou et al. 2000; Papakonstantinou et al. 2002).  
The GAG family contains a heterogeneous group of compounds with variable structures and 
protein associations. Hypoxia has a differential effect on different types of GAGs. In this 
study, hypoxia reduced the expression of HAS-2 and total sGAG but had no effect on C-4-S. 
Previous studies that looked at the effect of hypoxia on cellular synthesis, production and 
secretion of GAGs reported variable results depending on the type of cells, species, level of 
hypoxia and duration and the presence of other mediators (Figueroa et al. 1999). Asplund et 
al. (Asplund et al. 2009; Asplund et al. 2010) showed that reducing levels of O2 did not affect 
macrophage capacity to produce veriscan or perlecan down to 2% O2, but at 0.5% O2 there 
was a significant and sharp increase in the levels of both GAGs and PGs (Asplund et al. 
2010). On the other hand, this has significantly reduced the synthesis of HS-PG (syndecan) 
and contributed to increased macrophage motility. A similar effect was seen by Hashimoto 
and colleagues (Hashimoto et al. 2006) where hypoxia significantly increased the level of HA 
synthesis at 10% and 5% O2 by bovine articular chondrocytes, but at 1% O2 there was a 
significant reduction compared to 21% O2. Some type of cells showed increased production 
of total PGs under 2% O2 up to 10 days in culture (Coyle et al. 2009). Human meniscal 
fibrochondrocytes cultured under 3% O2 for 3 weeks, did not show any difference in the total 
amount of GAG produced, yet, the mRNA expression of the PG veriscan was significantly 
reduced (Adesida et al. 2012). Similarly total GAG synthesis by human lung fibroblasts were 
not affected but there was an increase in the relative amount of HS (Papakonstantinou et al. 
2000). 
Aside from its effect on GAG synthesis, hypoxia can also affect their secretion from some 
cells as well. In human pulmonary vascular SMCs (VSMCs) cultured under 3% O2 with 
PDGF, VSMCs GAG synthesis was not changed compared to 21% O2, but its secretion into 
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the media were delayed up to 48 hours, with a relative reduction in the amount of hyaluronic 
acid. In human lung fibroblasts, hypoxia also did not affect the total GAG synthesis, but 
increased their secretion in a time-dependent manner (Papakonstantinou et al. 2000). In this 
study, there was reduction in total sGAG produced by pMVICs under hypoxia, as both the 
cellular and secreted sGAGs were measured. Hypoxia did not affect the ability of pMVICs to 
secrete the sGAGs in the same proportion of the amount present in the cells. With time, there 
was increase in the percentage of secreted sGAG compared with the cellular content 
indicating that even if the cells reduce sGAG production, they continue secreting it to the 
ECM at a steady rate.  
Similar to collagen, the production and secretion of GAGs can be affected by the presence of 
other mediators like TGF-β. For example, in human lung fibroblasts cultured with different 
isoforms of TGF-β, hypoxia induced GAG production in a differential manner where more 
hyaluronic acid and chondroitin were secreted in the media, and more HS in the cell layer 
(Papakonstantinou et al. 2002).  
MMPs and TIMPs 
Relative gene expression of MMP-2 and MMP-9, and the tissue inhibitors TIMP-1 and 
TIMP-2, assessed the effect of hypoxia on matrix remodelling and turnover. Under severe 
hypoxia (0.5% O2), there was a significant increase in the expression of all of these genes.  
MMPs, also called matrixins, are members of a metzincin group of proteinases characterised 
by having three main domains: a propeptide domain that contains a cysteine switch that 
connects it to a zinc catalytic domain and a haemopexin domain. There are 23 different 
MMPs in humans. They are located in six groups based on similarities in structure and their 
substrate. These include collagenase (like MMPs 1, 8 and 13), gelatinases (MMPs 2 and 9) 
stromelysins and others. MMPs 2 and 9 also have repeats of type II fibronectin that allow 
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them to bind to collagen. They act on gelatines, collagen, laminin, PGs and others (Visse et 
al. 2003). The main function and feature of the MMPs family is the degradation of ECM 
structural components through proteolysis. They can also regulate and modify the activity of 
signalling molecules growth factors and cytokines. Their action is also useful to release 
ECM-bound growth factors such as TGF-β (Nagase et al. 1999; Yu et al. 2000). MMPs were 
found to have significant role in many physiological processes like embryonic development 
and morphogenesis (Kleinman et al. 2003), tissue repair and remodelling and they are very 
important to regulating and maintaining tissue architecture. The timely breakdown of ECM is 
essential for the success of these biological processes as it creates a space for cells to migrate 
(Giannelli et al. 1997), differentiate (Streuli 1999) and induce EMT (Page-McCaw et al. 
2007).  
The activity of the MMPs is tightly controlled, and loss of this control was found to be 
associated with various pathological conditions like CVD, arthritis (Visse et al. 2003) and 
cancer (Egeblad et al. 2002). One of the mechanisms that contribute to this control is the 
TIMPs. TIMPs are endogenous specific MMP inhibitors. There are four TIMPs known 
(TIMP 1, 2, 3 and 4). They are composed of two domains N- and C-domain. The N-domain 
binds to the zinc catalytic domain of the MMP and is capable of inhibiting it (Brew et al. 
2010). TIMPs are believed to inhibit almost all MMPs. They also have other biological 
functions not related to their MMP inhibitory function like cell-growth promoting activities 
(Iyer et al. 2012). Similar to MMPs, TIMPs expression and activity are regulated during 
development and tissue remodelling, and they play an important role in controlling MMPs 
especially in pathological conditions when their expression is upgraded (Murphy 2011; Visse 
et al. 2003). TIMPs are attracting increased attention because of their role in CVD and cancer 
as potential therapeutic targets (Murphy 2011). 
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Heart valves express a range of MMPs and TIMPs. While different studies have reported 
variable expression of MMPs, most of the studies agree on the expression of MMP-1, -2, -9 
and 13 and TIMP-1 and -2 by valve cells. Dregger et al. (Dreger et al. 2002) showed the 
expression of MMP-1, TIMP-1 and TIMP-2 in all heart valves, while MMP-2 was expressed 
in semi-lunar valves, but there was no expression of MMP-9. Rabkin reported the presence of 
MMP-1, MMP-2, MMP-9 and MMP-13 in normal human MVs. Normal aortic valves were 
showed to express MMP-2, MMP-9, TIMP-1 and TIMP-2 (Fondard et al. 2005; Koullias et 
al. 2004), and mild expression of MMP-1 and MMP-13 (Aikawa et al. 2006). The expression 
of MMPs is generally affected (both enhanced or inhibited) by a variety of factors and 
mediators like growth factors and interleukins (Porter et al. 2009; Turner et al. 2012). In 
human semilunar valves the expression of MMP-1, MMP-13 were significantly reduced with 
age (Aikawa et al. 2006). 
Severe hypoxia induced the expression of matrix enzymes MMP-2, MMP-9, TIMP-1 and 
TIMP-2 by pMVICs. The hypoxic effect on production and regulation of MMP and TIMPs is 
species and cell-type specific (Riches et al. 2009; Semenza 2003). Whilst hypoxia is known 
to induce certain MMPs, such as MMP-2 and MMP-9, others are inhibited by hypoxia like 
MMP-3 (Steinbrech et al. 1999). Hypoxia up-regulates MMP-2, TIMP-1 and TIMP-2 in 
murine fibroblasts (Misra et al. 2010). In human aortic smooth muscles cells, hypoxia up-
regulated both MMP-2 and MMP-9 (Erdozain et al. 2011). Even in the same type of cells, 
hypoxic conditions also affect MMPs. MMP-2 is induced by acute hypoxia in cardiac 
fibroblasts, but under chronic hypoxic conditions it is inhibited (Riches et al. 2009)  
The activation of MMP-2 and MMP-9 and their tissue inhibitors TIMP-1 and TIMP-2 was 
only seen under severe hypoxia, similar to the effects on collagen and GAG levels seen 
earlier. This supports that observation that pMVICs were able to tolerate hypoxia down to 2% 
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O2. Only under severe hypoxia did pMVICs have an effect on the production and 
maintenance of different ECM components. The induction of the metalloproteinases 
indicated that there is increased breakdown of the ECM components, but at the same time, 
the induction of the tissue inhibitors indicates that the increase in catabolic effect of the 
MMPs is counteracted in an attempt to maintain the level of activity at the baseline. Yet it is 
difficult to know or quantify the net effect of those two opposing actions. The increased 
breakdown secondary to increased metabolic activity could explain some of the effects seem 
on the ECM component. The reduction of the total amount of collagen despite no change in 
the gene expression of collagens I and III could be due to increased breakdown of collagen 
that is not met by increased production.  
Elastin  
The other important component of ECM is elastin. It accounts for about 10% of the leaflet 
content and is organised in fine interweaving fibres mainly in the atrialis layer and gives the 
valve leaflet its elasticity. Elastic fibres are also found in the other valve layers, the spongiosa 
and fibrosa, and they appear to have a more complex function in maintaining a network with 
the other valve component to contribute further to the optimum mechanical properties of the 
leaflet (Latif et al. 2005a; Stephens et al. 2008a; Tseng et al. 2011). There is increased 
interest in elastin as part of the tissue-engineered scaffolds and constructs (Balguid et al. 
2009). Despite the important role of elastin, the effect of hypoxia on elastin production was 
not examined, in view of the fact that elastin usually takes a long time to be synthesised 
(Hoerstrup et al. 2000) and significantly affected by the presence of various growth factors 
and mechanical stimulation (Patel et al. 2006). 
In summary, this study shows the significant effect of hypoxia on the production and 
maintenance of the MV ECM by the VICs. Severe hypoxia resulted in reduction in the total 
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amount of collagens and sGAGs produced by MVICs. It also reduced the gene expression of 
the HAS-2, and increased the expression of valve metabolic enzymes MMP-2, MMP-9, 
TIMP-1 and TIMP-2.  
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Chapter 6: Expression and role of HIF-1α in the 
response of mitral valve interstitial cells to hypoxia  
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6.1 INTRODUCTION: 
O2 homeostasis is tightly controlled in mammals, which have sophisticated mechanisms to 
ensure cells receive the optimal level of O2 to maintain their structure and function (Semenza 
2009). The different constituents of the cardiovascular system work in a coordinated way to 
ensure the delivery of the correct amounts of O2 to meet the varying demands of different 
organ and tissues. The level of O2 concentration in different tissues in humans ranges from 
about 10% all the way down to below 1% (Simon et al. 2008). Significant changes to the 
levels of O2 needed by each type of cell are associated with cellular dysfunction, and may 
have pathological consequences. For example, high levels of O2 can result in acute lung 
injury, while reduction in the O2 supply to the heart causes cellular ischaemia and, 
potentially, cell death. Mammals have different intrinsic mechanisms to respond to changes 
in the level of O2 either in the surrounding environment or at the tissue/cell level that allow 
them to compensate for acute or chronic changes in O2 concentration. For example, reduction 
of blood O2 levels due to being at high altitude is sensed by specialised O2-sensing cells in 
the carotid body, which triggers increased ventilation thus driving more O2 into the body. If 
low O2 levels persist, chronic adaptation will occur with various modifications like increasing 
O2-carrying capacity through increased heme synthesis and erythropoiesis (Chepelev et al. 
2011; Rolfs et al. 1997). 
At the cellular level, one of the master regulators in the O2 homeostasis is the HIF-1α. HIF-
1α, discovered by Prof Greg Semenza and Guang Wang from Johns Hopkins in 1992 
(Semenza et al. 1992; Wang et al. 1993), is a factor that is induced by hypoxia and induces a 
several hundredfold increased transcriptional expression of EPO mRNA, through binding to 
3’ enhancer sequence, later defined as hypoxia response element (HRE) (Semenza et al. 
1996).  
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HIF-1α belongs to the basic helix-loop-helix (bHLH)-PAS protein superfamily (Wang et al. 
1995a). In addition, it has an oxygen-dependent degradation domain (ODDD), which 
mediates its O2-regulated stability (Figure 6.1). On this domain, there are two prolene 
residues (P402 and P564) and one lysine residue (K532) that are important for this function. 
It also has other two transactivation domains (TADs), a C-TAD and an N-TAD, which have 
an asparagine residue (N803) that interacts with coactivators like p300/CBP to activate gene 
transcription once HIF-1α is stabilised (Lando et al. 2002; Pugh et al. 1997; Ruas et al. 
2002). 
 
 
Figure ‎6.1 - Structure of HIF-1α 
The simplified figure showing the domain structure of the HIF-1α protein; HIF-1α belongs to 
the bHLH-PAS protein superfamily. In addition, it has an ODDD, which mediates its oxygen-
regulated stability through two prolene residues (P402 and P564) and one lysine residue 
(K532). It also has other two transactivation domains, a C-TAD and an N-TAD, which have 
an asparagine residue (N803) that interacts with coactivators like p300/CBP to activate gene 
transcription once HIF-1α is stabilised. Figure modified from (Ke et al. 2006; Lee et al. 
2004) 
 
Under normoxic conditions, HIF-1α gets degraded very quickly with a short half-life of about 
1 minute (Wang et al. 1995a). This process is initiated by PHD (Figure 6.2), which is 2-
oxoglutarte (2-OG)-dependant dioxygenase that requires both O2 and Fe2+ for the reaction, 
while it hydroxylases the two prolene residues on the HIF-1α (Ivan et al. 2001; Jaakkola et 
al. 2001). There are three isoforms of PHD with diferent bioavailability. PHD plays a critical 
role in the HIF-1α pathway and due to its dependence on O2, it is regarded a master O2 sensor 
(Bruick et al. 2001; Masson et al. 2003). Another two steps contributing to HIF-1α 
modification include hydroxylation of the asparagine residue by asparaginyl hydroxylase, 
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also called factor inhibiting HIF (FIH-1), which is similar in function to the PHDs (Lando et 
al. 2002) and acetylation of a lysine residue by arrest-defective-1 (ARD-1) acetyltransferase, 
which differs from the other enzymes in that it is independent of the level of O2 (Jeong et al. 
2002). These modifications to HIF-1α, and especially the hydroxyprolene, will attract and 
bind to the product of von Hippel-Lindau (pVHL). The latter will form a multiprotein E3 
ligase complex resulting in polyubiquitination of HIF-1α. The polyubiquitin tagged HIF-1α 
will then be a target for proteosomal degradation. Hydroxylation of asparagine also 
contributes to this effect but can also block the HIF-1α CAD activity and inhibit the binding 
to coactivators like the p300/CBP (Bruick et al. 2001; Ivan et al. 2001; Jaakkola et al. 2001; 
Masson et al. 2003; Maxwell et al. 1999). Under hypoxic conditions, O2-dependent PHD will 
not be able to hydroxylate the prolene residues on HIF-1α and consequently, binding to 
pVHL and will be inhibited. Stable HIF-1α present in the cytoplasm will translocate to the 
nucleus. There, it will form a dimer with a closely related subunit, the HIF-1β, also known as 
the aryl hydrocarbon nuclear translocator (ARNT). The active dimer of HIF-1α and HIF-1β 
will then recruit various transcriptional co-activators like CBP/p300 through the TAD. This 
will allow the HIF complex to bind to specific HRE sequences in the enhancer or promoter 
regions of various target genes and activate their transcription. The activation of target genes 
will create a cascade of cellular events that will help the cell counteract and adapt to the 
reduction in O2. Effects of HIF-1α activation include improved glucose metabolism, cellular 
survival and angiogenesis (Lee et al. 2004). Unlike HIF-1α, HIF-1β is also constitutively 
expressed (Wang et al. 1995a) and is not affected by the level of O2 both at gene and protein 
levels (Kallio et al. 1997). 
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Figure  6.2 - Changes to HIF-1α under both hypoxic and normoxic conditions 
Under normoxia, 2 proline (P)  residues 402 and 564 of HIF-1α are hydroxylated (OH) by PHD as it transforms 
(2-OG) to CO2 succinate in an  O2 and  Fe2+ dependent manner.  FIH wil hydroxylate asparagine 803 (N).  In addition lysine  532 (K)  wil  be acylated (A)  by  ARD which  partialy  dependent  on  O2.  Hydroylated  HIF-1α 
binds to pVHL and forms a complex with E3 ubiquitin (Ub) ligase, leading to proteasomal degradation. Under 
hypoxia, lack of O2 wil inhibit the funciton of PHD and FIH. Unhydroxylated HIF-1α wil not be able to bind 
pVHL-E3 Ubiquitin, and gets stablised. Stable HIF-1α translocates to the nucleus and binds to HIF-1β forming 
a dimer. Coactivator CBP/p300 wil bind to the dimer through nonhydroxylated (N). The HIF dimer wil atach 
to hypoxia response elements (HRE) and induce transcription of target genes. Adapted from (Ke et al. 2006). 
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This study so far has shown that human MV leaflets have a variable degree of 
vascularisation, which is also altered under different disease conditions, suggesting that some 
areas of the MV leaflets and subsequently VICs could exist under hypoxic conditions in 
various circumstances. pMVICs cultured under different levels of hypoxia remained viable 
and continued to grow, while retaining their morphology and phenotype, while severe 
hypoxia induced some changes in the production of various ECM components by those cells.   
HIF-1α is a master mediator of most of the biological processes that involve hypoxia and 
changes to O2 homeostasis. The expression and role of HIF-1α in MV pathophysiology are 
unknown.  
6.1.1 Aims and objectives 
The aim of this chapter was to study the expression of HIF-1α in samples of human MV 
affected with different pathologies and attempt to determine if HIF-1α mediates the 
functional changes seen in VICs in response to hypoxia. 
This was achieved by assessing the level of expression of HIF-1α in normal and diseased 
human MV leaflets. Then examining the capacity of the pMVIC to express HIF-1α, and 
defined the temporal pattern of expression in relation to different levels and durations of 
hypoxia. It also examined the HIF-1α gene expression by pMVICs. Lastly, using selective 
pharmacological tools it examined the role of HIF-1α in mediating some of the functional 
responses of pMVICs seen under hypoxia.  
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6.2 METHODS 
6.2.1 Expression of HIF-1α in normal and diseased human valves 
The expression of HIF-1α in human valves was assessed through immunohistochemical 
staining of the anterior leaflets of valves from healthy donors, and valves explanted at time of 
surgery from rheumatic disease and myxomatous degeneration. These valves were collected 
as described in section  2.2.5 and included normal valves (n=6), rheumatic valves (n=6) and 
myxomatous valves (n=4). Valves were fixed and paraffin embedded as described in  2.2.6 
and processed in a similar way using HIF-1α primary antibody at 1:50 (Novus Biological, 
Colorado, USA). 
6.2.2 Effect of hypoxia on HIF-1α expression in porcine MVICs using qRT-PCR 
pMVICs were isolated and cultured as described in sections  4.2.1 and  4.2.2 Cells were plated 
on Petri dishes, and incubated under three different levels of hypoxia and normoxic control 
for 1 day (24 hours). The relative gene expression of HIF-1α was measured using qRT-PCR 
as described in  5.2.6 using HIF-1α primer (Table 6.1). Data were analysed using the 
comparative Ct method relative to normoxic control. Data represent mean relative expression 
± SEM (n=6). Groups were compared using one-way ANOVA with Dunnett post hoc test.  
 
Table ‎6.1 - HIF-1α PCR gene assay details 
Gene Name Assay ID Details RefSeq Amplicon 
length 
HIF-1α Hypoxia-inducible factor 
1, alpha subunit  
Ss03390447_m1 NM_001123124.1 111 
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6.2.3 Expression of HIF-1α in HeLa cells under hypoxia using immunofluorescence 
staining 
In order to optimise the immunofluorescence staining for HIF-1α and to validate the 
antibodies used, a HeLa cell line was used as a positive control. HeLa cells were supplied as 
a courtesy of Ms Ann McCormack (Transplant Immunology Group, Harefield, UK). Cells 
were grown and plated on glass square cover slips at a density of 10,000 cells per cover slip 
in a six well plate and allowed to grow for 24 hours. Culture media were replaced with fresh 
DMEM media supplemented with 10% FBS and plates were incubated under severe hypoxia 
only (0.5% O2) and atmospheric control (20% O2) for 6 hours. At the end of the incubation, 
media were removed completely and cover slips were washed with cold PBS twice and 
incubated in 4% PFA for 15 minutes at RT. They were then washed twice with PBS and kept 
in it at 4°C until staining. Immunofluorescence staining was performed as described in  4.2.7. 
The primary antibody used was HIF-1α at 1:100 (Thermo Fisher Scientific, UK). The 
secondary antibody was Alexa 549 at 1:1000 (Invitrogen, UK). Slides were viewed using 
Zeiss Axio scope fluorescence microscope (Zeiss, Germany) connected to NIS elements 
software (Nikon, UK). 
6.2.4 Expression of HIF-1α in porcine MVICs under hypoxia using immunofluorescence 
staining 
The expression of HIF-1α in pMVICs was assessed using immunofluorescence staining. 
Porcine MIVCs were isolated, cultured and passaged as described above  4.2.2. Once ready 
for the experiment, cells were plated on square glass cover slips at 10,000 cells per cover slip 
in the same way as described for the HeLa cells above. Cells were allowed 24 hours to attach, 
and media were replaced with fresh media containing 10% FBS, and incubated under 
different levels of hypoxia as described earlier. In the first series of experiments the 
expression of HIF-1α at different levels of hypoxia (5%, 2% and 0.5% O2) compared with 
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20% O2 was assessed. In a second series of experiments the expression of HIF-1α over time 
(6, 24 and 72 hours) was assessed. At the end of the incubation, cells were fixed in 4% PFA 
and stained as mentioned earlier for HeLa cells.  
6.2.4.1 Quantification of HIF-1α staining 
The expression of HIF-1α under different levels of hypoxia and over time was quantified by 
measuring the intensity of the immunofluorescent staining. This was performed using Zeiss 
Axio scope fluorescence microscope (Zeiss, Germany) connected to NIS elements v 3.0 
software (Nikon, UK). Photos from 10 random HPFs for each condition were taken for both 
the HIF-1α staining and corresponding nuclear DAPI staining. The HIF-1α staining was 
quantified by defining the threshold of the staining using the software, which then measured 
the mean fluorescence area and calculated this as the area fraction per HPF, which is the ratio 
of the mean fluorescence area to the total field area. The DAPI pictures were used to count 
the number of cells using a similar principle. Finally, the intensity of the HIF-1α staining is 
normalised to the cell number by dividing the area fraction by the number of cells for each 
individual field.  
6.2.5 The expression of HIF-1α by porcine MVICs using Western blotting 
The expression of HIF-1α by pMVICs under hypoxia and control conditions was assessed 
using Western blotting. Primary isolates of pMVICs were cultured and passaged as 
mentioned earlier  4.2.2. They were plated in 10 cm Petri dish until they reached about 80% 
confluence. The media were replaced with fresh DMEM media supplemented with 10% FBS. 
The plates were then incubated under three different levels of hypoxia and 20% O2 control as 
described earlier for 6 hours. At the end of the incubation period, the dishes were removed 
from the hypoxic incubator very quickly and placed on ice. The media were removed and the 
cells were washed with cold PBS twice and removed. A lysis buffer was added to the cells 
(60 µl/dish). The buffer used was radioimmunoprecipitation assay (RIPA) buffer (Sigma, 
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UK) freshly supplemented with protease inhibitor cocktail (Roche, UK) (one tablet per 5 ml 
RIPA buffer) and 1 mM of phenylmethanesulphonyl fluoride (PMSF). Cells were solubilised 
and homogenised in the lysis buffer using a rubber scraper and frequent pipetting, then were 
transferred to 1.5 ml eppendorf tubes placed on ice and were frozen immediately at -80°C for 
at least 10 minutes. Then they were allowed to thaw on ice and centrifuged at 13,000 rpm for 
10 minutes at 4°C. The supernatant was transferred to a fresh tube and stored at -80°C until 
use.  
6.2.5.1 Protein assay using bicinchoninic acid  
The concentration of the protein in the cell lysate was assessed using the bicinchoninic acid 
assay (BCA). Alkaline Cu (II) is reduced by proteins to Cu (I) in a concentration-dependent 
manner. BCA is a highly specific chromogenic reagent for Cu (I) forming a purple complex 
with an absorbance maximum at 562 nm, and therefore the absorbance measured is directly 
proportional to the protein concentration in the lysate. This assay is performed by preparing 
standard samples of BSA at concentrations ranging from 0.5 to 50 µg/ml of protein. The cell 
lysates at a concentration of 1:50 and 50 µl of the standard samples were loaded in duplicates 
in a 96 well plate. The BCA solution was freshly prepared by adding CuSO4 (Sigma, UK) to 
BCA at 1:50 and adding 200 µl of the mixture to each well. The plate was then incubated at 
37°C for 30 minutes, and read at 562 nm using a Quant spectrophotometer (Pharmacia 
Biotech, UK). The BCA samples were used to draw a standard curve (Figure 6.3), which was 
used to calculate the protein concentrations in the lysate samples.  
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Figure ‎6.3 - BCA standard curve 
An example of BCA standard curve generated by blotting at optical absorbance of known 
concentrations of BSA protein assayed using the BCA. The equation of the curve was used to 
calculate the concentration of protein in samples.  
6.2.5.2 Western blotting 
Cell lysate samples were initially prepared for Western blotting by adding an equivalent 
volume containing 100 µg of protein to a 0.5 ml eppendorf-containing dithiothreitol (DTT) 
(10x) and NuPAGE LDS (4x). The mixture was made up to a final volume of 30 µl using 
Millipore water. All tubes were made up to the same volume using variable amounts of 
water. A molecular weight marker tube was also made by loading 4 µl of full range rainbow 
marker (Amersham, UK), and DTT (10x), LDS (4x) and water as for the rest of the samples. 
All samples were then denatured by heating at 70°C for 10 minutes in a water bath. Samples 
were then loaded onto a NuPAGE Novex 10% Bis-Tris gel (Invitrogen). The gel was loaded 
to the chamber and was immersed in sodium dodecyl sulphate (SDS) running buffer 
(Invitrogen, UK), and the gel was run at 200 volts, 125 mA per gel for 60 minutes at RT, 
after which, the gel was carefully removed from its cassette. It was placed in the transfer 
module in the following arrangement: first, two sponge pads previously well soaked in 
transfer buffer and squeezed to get rid of all air bubbles were laid down, two layers of filter 
paper briefly soaked in transfer buffer, the gel, nitrocellulose hybond C membrane 
(Amersham, UK), another two filter papers and another two or three well-soaked sponge pads 
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until the module could close tightly. Extra care was taken to ensure all air bubbles were 
removed. The transfer module was then placed in the chamber and filled with transfer buffer. 
Outside the chamber, the unit was filled with distilled water. The transfer buffer used was 50 
ml of 20x NuPAGE transfer buffer (Invitrogen, UK) diluted with 200 ml of methanol and 750 
ml of distilled water. Protein transfer was performed at 30 volts for 60 minutes.  
Following the transfer, the membrane was carefully removed and cut according to the 
molecular weight marker. It was placed in small plastic bag and blocked for 1 hour with 5% 
non-fat dried milk (NFDM) made with PBS with 0.1% Tween-20 (PBS-T). It was then 
incubated with the primary HIF-1α antibody (Thermo Fisher Scientific, UK) at 1:2000 for 1 
hour at RT. The housekeeping control protein was glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) at 1:60,000 (Chemicon, Abingdon, UK). Antibodies were also 
prepared in the 5% NFDM prepared in 0.1% PBS-T. Membranes were washed briefly with 
PBS-T, and were incubated with horseradish peroxidise (HRP) conjugated rabbit anti mouse 
secondary antibody at 1:1000 (Dako, UK) for 1 hour at RT. They were then washed with a 
copious amount of PBS-T for four times each for 15 minutes. After washing, the membranes 
were drained and incubated with super signal west pico chemiluminescent substrate (Pierce, 
Thermo Fisher, UK) for 5 minutes, placed on a glass plate, covered in Saran wrap and 
developed using GE film (Amersham, UK) for variable durations (10 seconds to 5 minutes) 
until the optimum exposure was reached.  Western blot films were scanned and quantified 
using Quantity one (Biorad, Hemel Hempstead, UK). OD was normalised to GAPDH.  
6.2.6 Pharmacological stimulation and inhibition of HIF-1α 
HIF-1α was chemically induced in pMVICs using two separate stimulants: CoCl2 (Sigma, 
UK) and deferoxamine (DFO) (Sigma, UK) under normoxic conditions (Wang et al. 1995a). 
HIF-1α was also blocked chemically under severe hypoxia (0.5% O2) using two different 
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blockers: 2-methoxyestradiol-2 (2ME-2, Sigma, UK) (Mabjeesh et al. 2003) and CAY10585 
(Cayman Chemical, Michigan, USA) (Lee et al. 2007). Three different concentrations of each 
pharmacological agent were used: 10 µM, 100 µM and 1000 µM were used for CoCl2 and 
DFO; 1µM, 10µM and 100µM were used for 2ME-2 and CAY10585.  
The effects of the chemical stimulants and blockers on the pMVICs were assessed for their 
effect on pMVICs proliferation using the MTS assay as described in section  4.2.5 and cell 
death using the LDH assay described in section 4.2.6. pMVICs were treated with three 
different concentrations of each agent and compared with untreated control Groups were 
incubated at 20% O2 for 3 days. Subsequently, their ability to induce or block HIF-1α was 
assessed using immunofluorescence as described above, where cells were treated and 
incubated at 20% O2 for stimulant and under 0.5% O2 for the blocker for 6 hours. The groups 
were compared with a positive and negative control of untreated cells incubated both at 20% 
O2 and 0.5% O2.    Finally their effect on pMVICs production of sGAGs was assessed using 
the sGAG Blyscan assay as described in section  5.2.5.  pMVICs were treated with the same 
concentrations and incubated at 20% O2 for stimulant and under 0.5% O2 for the blocker for 3 
days. The groups were compared with a positive and negative control of untreated cells 
incubated both at 20% O2 and 0.5% O2.  
6.2.7 Data analysis 
Data are expressed as mean ± SEM. Differences between groups for each test were assessed 
using one-way ANOVA followed by Dunnett post hoc test.  
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6.3 RESULTS 
6.3.1 Expression of HIF-1α in normal and diseased human valves 
Normal (Figure 6.4) and myxomatous (Figure 6.5) mitral valves show little or no staining of 
HIF-1α. There were few scattered positive cells with weak staining seen in both VICs and 
VECs.  
 
Figure ‎6.4 - Expression of HIF-1α in a normal human mitral valve 
Normal human anterior mitral valve leaflets were paraffin fixed, sectioned and stained for 
HIF-1α at 10x (Panel A) and 40x (Panel B). Valve sections were overall negative (n=6). 
 
 
 
 
Figure ‎6.5 - Expression of HIF-1α in a myxomatous human mitral valve 
Myxomatous human anterior mitral valve leaflets were paraffin fixed, sectioned and stained 
for HIF-1α at 10x (Panel A) and 40x (Panel B). Valve sections were overall negative (n=4). 
 
 
In rheumatic MVs, four out of six valves had shown positive HIF-1α staining with the 
antibody against HIF-1α. HIF-1α was strongly expressed by the VICs, with some sections 
showing diffuse HIF-1α expression in VICs across the section (Figure 6.6B), while others 
A B 
A B 
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showed intense expression in localised regions (Figure 6.6A), with the reminder of the leaflet 
showing either weaker diffuse expression or even no expression at all. It was also noticed that 
HIF-1α expression was also co-localised within walls of the thickened neo-vessels (Figure 
6.6C) that were previously described in section  2.3.2.2.2. 
 
 
Figure ‎6.6 - Expression of HIF-1α in a rheumatic human mitral valve 
Rheumatic human anterior mitral valve leaflets were paraffin fixed, sectioned and stained for 
HIF-1α at 10x (Panel A) and 40x (Panel B). Valve sections showed different patterns of 
strongly positive staining. Panel 1 shows a localised area of strongly positive cells. Panel 2 
shows a valve section with diffuse staining and Panel 3 shows cells staining positive for HIF-
1α associate with neo-vessels of the leaflet (n=6). 
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6.3.2 Effect of hypoxia on HIF-1α expression in porcine MVICs using qRT-PCR 
The effect of hypoxia on HIF-1α gene expression by the pMVICs was assessed using qRT-
PCR and normalised against 18s rRNA (n=6). After 1 day exposure to hypoxia there was no 
significant difference in the levels of gene expression in any of the groups compared with 
20% O2 (Figure 6.7).  The level of relative gene expression of HIF-1α was 1.03±0.13 fold 
under 20% O2, 0.92±0.16 fold under 5% O2, 0.82±0.10 fold under 2% O2 and 0.64±0.065 
under 0.50% O2. There was no significant difference in the expression of 18s rRNA in all 
groups (P>0.05). 
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Figure ‎6.7 - The effect of hypoxia on pMVICs’ HIF-1α gene expression 
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric control (20% O2) for 1 day. mRNA was extracted using 
RNeasy extraction kit, then cDNA was synthesised using TaqMan Reverse Transcriptase kit. 
The relative expression of HIF-1α (A), and 18S rRNA (B) were quantified using real-time 
TaqMan PCR. Data were analysed using the comparative Ct method relative to atmospheric 
control. The data represent mean relative expression ± SEM (n=6). The groups were 
compared using one-way ANOVA with Dunnett post hoc test. There was no significant 
difference in HIF-1α gene expression between the groups (P>0.05).  
 
6.3.3 Expression of HIF-1α in HeLa cells under hypoxia using immunofluorescence 
staining 
The expression of HIF-1α under hypoxia was assessed using immunofluorescence staining. 
HeLa cells that were incubated under severe hypoxia (0.5% O2) for 6 hours showed positive 
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nuclear staining for HIF-1α compared with the same cells incubated under atmospheric O2 of 
20%, which were completely negative (Figure 6.8). 
 
Figure ‎6.8 - The effect of hypoxia on HeLa cells HIF-1α expression using 
immunofluorescence staining 
HeLa cells were seeded on glass cover slips and incubated under severe (0.5% O2) hypoxia as 
well as atmospheric control (20% O2) for 6 hours. Cells were stained with HIF-1α and 
assessed using a fluorescence microscope. Cells incubated under hypoxia showed positive 
staining for HIF-1α (red) localised at the nucleus. Positive cells appeared purple when co-
visualised with DAPI (blue). (n=2)  
 
6.3.4 Expression and quantification of HIF-1α in porcine MVICs under hypoxia using 
immunofluorescence staining: 
Immunofluorescence staining was used to confirm and subsequently quantify the levels of 
HIF-1α expression in pMVICs. Firstly, pMVICs were incubated under different levels of 
hypoxia and atmospheric control for 6 hours. There was very weak positive staining (almost 
negative) for HIF-1α under 20% O2. Under hypoxia, there was positive HIF-1α staining by 
the pMVICs. Positive cells showed nuclear staining similar to what is seen in HeLa cells. 
Both the intensity of the staining and the number of positive cells were increased with a 
HIF1α HIF1α + DAPI 
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reduction in O2 levels. Immunofluorescence staining quantification showed mean area 
fraction per cell was 0.00033±0.0001 for 20% O2, 0.0009±0.0001* (5% O2), 0.0010±0.0002* 
(2% O2) and 0.00130±0.0002* (0.50% O2) (*P<0.05) n=3. 
 
 
HIF1α HIF1α + DAPI 
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2% 
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Figure ‎6.9 - The effect of hypoxia on pMVICs’ HIF-1α expression 
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as well as atmospheric control (20% O2) for 6 hours. The cells were stained with 
HIF-1α. Immunofluorescence staining was quantified by measuring the area fraction per cell. 
Groups were compared using one-way ANOVA with Dunnett post hoc test and showed a 
significant increase in HIF-1α expression in the hypoxia groups compared with atmospheric 
control (P*<0.05). n=3. 
 
In the second series of experiments, the expression of HIF-1α over time was examined. 
Severe hypoxia was selected because it induced the maximum HIF-1α expression (Figure 
6.9). pMVICs were incubated under 0.5% O2 for 6, 24 and 72 hours. There was a strong HIF-
1α expression at 6 hours, but the expression decreased over time to become very weak after 
72 hours (Figure 6.10). Immunofluorescence staining quantification showed mean area 
fraction per cell was 0.00130±0.00016 at 6 hours, 0.00066±0.00007* at 24 hours and was 
0.00018±0.00003* at 72 hours (*P<0.05) n=3. 
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Figure ‎6.10 - The effect of severe hypoxia (0.5% O2) on pMVICs’ HIF-1α expression 
over time 
Porcine MVICs were incubated under severe (0.5% O2) hypoxia for 6, 24 and 72 hours. Cells 
were stained with HIF-1α. Immunofluorescence staining was quantified by measuring the 
area fraction per cell. Groups were compared using one-way ANOVA with Dunnett post hoc 
test and showed a significant decrease in HIF-1α expression with increased duration of 
incubation compared with 6 hours. (*P<0.05) n=3. 
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6.3.5 Expression of HIF-1α by pMVICs under hypoxia by Western blotting 
 
Western bloting was used to assess the expression of HIF-1α protein by pMVICs under 
hypoxic conditions (Figure 6.11). pMVICs were incubated under diferent levels of hypoxia 
as wel as the atmospheric control for 6 hours. There was no HIF-1α expression seen under 
20% O2 with OD of 0.22±0.13 units and 5% O2 with 0.29±0.17 units. There were some faint 
HIF-1α bands seen at 2% O2 0.31±0.16 OD units, but the significant efect was seen at 0.5% 
O2 with OD of 1.5±0.43* units (*P<0.05) n=4. 
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 Figure ‎6.11 - Expression of HIF-1α by pMVICs using Western bloting 
Porcine MVICs were incubated under mild (5% O2), moderate (2% O2) and severe (0.5% O2) 
hypoxia as wel as atmospheric control (20% O2) for 6 hours. Cels were lysed and Western 
blot was performed (A). Blots were quantified using OD measurement (B). Groups were 
compared using one-way ANOVA with Dunnet post hoc test and showed a significant 
increase in HIF-1α expression at severe hypoxia groups compared with atmospheric control 
(*P<0.05) n=3. 
 
A 
B 
Expression and role of HIF-1α in the response of mitral valve interstitial cells to hypoxia 
 
199 
 
6.3.6 Pharmacological Modulation of HIF-1α 
6.3.6.1 Stimulators of HIF-1α 
6.3.6.1.1 Effect of DFO and CoCl2 on cell proliferation and cell death 
The effect of DFO and CoCl2 on the viability of pMVICs was initially assessed using the 
MTS assay (n=3). Cells were treated with three different concentrations of DFO or CoCl2 and 
were compared with untreated control. All were incubated under 20% control for 3 days. 
DFO (Figure 6.12A) and CoCl2 (Figure 6.13A) had no effect on cell proliferation compared 
with the control, with the exception of 1000 uM of CoCl2 that induced a marked reduction in 
cell viability. The optical absorbance for control was 0.14±0.02* for (1,000 µM) compared 
with 0.72±0.13 for untreated control (P<0.05). 
 
The effect of DFO and CoCl2 on pMVICs death was assessed using the LDH assay (n=3). 
Cells were treated with three different concentrations of DFO or CoCl2 and were compared 
with untreated control. All were incubated under 20% control for 3 days. There was no 
statistically significant difference between the percentages of cell death from the cells treated 
with DFO and the control (Figure 6.12B). This was also the case for lower concentrations of 
CoCl2, but at 1000 µM of the drug there was a significant increase in the percentage of dead 
cells (Figure 6.13B). The percentage of cell death for cells treated with CoCl2 at (1,000 µM) 
was 40.19%±1.378* compared with 13.08%± 3.931 for untreated control cells (*P<0.05). 
 
6.3.6.1.2 The effect of DFO and CoCl2 on HIF-1α expression of pMVICs 
The effect of DFO on pMVICs HIF-1α expression was assessed using immunofluorescence 
staining (n=3). Cells were treated with three different concentrations of DFO or CoCl2 and 
were compared with two untreated controls. The treated cells and one control were incubated 
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under 20% O2. The second control was incubated under 0.5% O2 in the absence of DFO or 
CoCl2 as positive control to check that cells were capable of inducing the expression of HIF-
1α as described earlier. All groups were incubated for 6 hours. There was a significant 
increase in HIF-1α expression by the untreated cells under severe hypoxia (0.5% O2) 
compared with untreated cells maintained under atmospheric conditions (20% O2). Area 
fraction was 0.00084±0.00009* compared with 0.00031±0.00005, respectively (*P<0.05).  
Cells incubated with 10 µM DFO did not have a significant increase in HIF-1α expression. 
The area fraction was 0.00044±0.00007 compared with 20% O2 (Figure 6.12C). Cells 
incubated under 100 µM and 1,000 µM DFO showed significant induction of HIF-1α. Area 
fractions were 0.00071±0.00008* and 0.00096±0.00007*, respectively (*P<0.05) n=3. 
Regarding the effect of CoCl2 on pMVICs HIF-1α expression, cells incubated with all 3 
different concentrations of CoCl2, 10 uM, 100 uM, 1,000 uM significantly expressed HIF-1α 
compared with 20% O2. Area fraction was 0.00059±0.00008* for (10 µM), 
0.00104±0.00007* for (100 µM) and 0.00118±0.00007* for (1000 uM) (*P<0.05) n=3. 
 
6.3.6.1.3 The effect of DFO and CoCl2 on pMVICs sGAG production 
The effect of DFO on pMVICs sGAG production was measured using the Blyscan assay 
(n=3). Cells were treated with three different concentrations of DFO or CoCl2 and were 
compared with two untreated controls. The treated cells and one untreated control were 
incubated under 20%. The second control was incubated under 0.5% O2 in the absence of 
DFO or CoCl2 as a positive control. All groups were incubated for 3 days. There was a 
significant reduction in the amount of sGAG produced by the untreated (0.5% O2) control 
that was 1.71±0.27 µg* compared with 4.86±0.95 µg for the 20% O2 control (*P<0.05).  
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All three concentrations of DFO (Figure 6.12D) resulted in a significant reduction in the 
amount of sGAG produced by the MVICs which was 3.00±0.67µg* (10 µM), 2.04±0.18 µg* 
(100 µM) and 2.12±0.07 µg* (1,000 µM) (*P<0.05). Similarly, there was a significant 
reduction in the amount of sGAG produced by CoCl2-treated pMVICs (Figure 6.13D), which 
was 2.57±0.59 µg* at (100 µM) and 0.45±0.22µg* (1,000 µM) (*P<0.05), but there was no 
difference for 4.21±0.65 µg produced by cells incubated with (10 µM) (*P<0.05).  
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Figure  6.12 - Effect of DFO on MVICs 
DFO was not shawn to have a significant effect on MVICs proliferation (A) or cell death (B). 
It induced HIF-1α at 100 µM and 1,000 µM (C), and all concentrations resulted in a 
reduction in the amount of sGAG produced similar to severe hypoxia (D). 
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Figure  6.13 - Effect of CoCl2 on MVICs 
The experiment did not show a signifiant effect of CoCl2 on MVICs proliferation at small and 
moderate concentrations, but at 1,000 µM it resulted in significantly reduced cell 
proliferation (A), which also corresponded in an increase in cell death (B). All concentrations 
of CoCl2 induced the expression of HIF-1α (C) and concentrations 100 µM and 1,000 µM 
resulted in reduced sGAG production similar to the effect of severe hypoxia (D).  
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6.3.6.2 Inhibitors of HIF-1α  
6.3.6.2.1 Effect of 2ME-2 and CAY10585 on cell proliferation and cell death 
The effect of 2ME-2 and CAY10585 on pMVICs proliferation was assessed using the MTS 
assay (n=3). Cells were treated with three different concentrations of 2ME-2 or CAY10585 
and were compared with an untreated control. All groups were incubated under 20% O2 for 3 
days. There was a significant reduction in cell proliferation for the cells treated with 2ME-2 
(Figure 6.14A). Optical absorbance was 0.45±0.05* at 10 µM and 0.40±0.70* at 100 µM 
compared with 0.75±0.11 for the untreated control (*P<0.05). There was no significant 
difference at 1µM. CAY10585 has no effect on cell proliferation compared with the control 
at all concentrations tested (Figure 6.15A). 
 
The effect of 2ME-2 and CAY10585 on pMVICs death was assessed using the LDH assay 
(n=3). Cells were treated with three different concentrations of 2ME-2 or CAY10585 and 
were compared with the untreated control. All were incubated under 20% O2 for 3 days. 
There was no statistically significant difference between the percentages of cell death from 
the cells treated with 2ME-2 at low concentrations (Figure 6.14B). Cell death was 
15.74%±3.85 at 1 µM and 18.43%±3.9 at 10µM compared with the untreated control of 
12.82%±3.59. While at 100 µM there was a significant increase in the percentage of cell 
death of 42.39%±2.25* (*P<0.05) on the other hand there was no statistically significant 
difference between the percentages of cell death from the cells treated with CAY10585 and 
the control (Figure 6.15B). 
 
6.3.6.2.2 The ability of 2ME-2 and CAY10585 to block HIF-1α expression in pMVICs 
The ability of 2ME-2 and CAY10585 to block HIF-1α expression in pMVICs was assessed 
using immunofluorescence staining (n=3). Cells were treated with three different 
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concentrations of 2ME-2 or CAY10585 and were compared with two untreated controls. The 
treated cells and one control were incubated under 0.5% O2. The second control was 
incubated under 20% O2 in the absence of 2ME-2 or CAY10585 to act as a negative control. 
All groups were incubated for 6 hours. There was a significant increase in HIF-1α expression 
by the untreated cells under severe hypoxia (0.5% O2) compared with untreated cells 
maintained under atmospheric conditions (20% O2). The area fraction was 0.00084±0.00009* 
compared with 0.00031±0.00005, respectively (*P<0.05). 
Cells incubated with different concentrations of 2ME-2 continued to express HIF-1α similar 
to the 0.5% untreated control, and remained significantly different from the 20% control 
(Figure 6.14C). The area fraction was 0.00072±0.00008* for 1 µM, 0.00114±0.00013* for 10 
µM and 0.00084±0.00011* for 100 µM (*P<0.05). Similarly, cells incubated with different 
concentrations of CAY10585 continued to express HIF-1α similar to the 0.5% untreated 
control, and remained significantly different from the 20% control (Figure 6.15C). The area 
fraction was 0.00065±0.00006* for 1 µM, 0.00070±0.00005* for 10 µM and 
0.00087±0.00009* for 100 µM (*P<0.05). 
 
6.3.6.2.3 The effect of 2ME-2 and CAY10585 on pMVICs sGAG production 
The effect of 2ME-2 and CAY10585 on pMVICs sGAG production was measured using the 
Blyscan assay (n=3). Cells were treated with three different concentrations of 2ME-2 and 
CAY10585 and were compared with two untreated controls. The treated cells and one control 
were incubated under 0.5% O2. The second control was incubated under 20% O2 in the 
absence of 2ME-2 or CAY10585 as a negative control. All groups were incubated for 3 days. 
There was a significant reduction in the amount of sGAG produced by the untreated (0.5% 
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O2), which was 2.11±0.22µg* compared with 4.71±0.66µg under (20% O2) control 
(*P<0.05).  
MVICs incubated with all three concentrations of 2ME-2 had a significant reduction in the 
amount of sGAG produced by the MVICs compared with the 20% O2 (Figure 6.14D). The 
amount of sGAG produced was 2.05±0.23* µg at (1 µM), 1.63±0.26* µg at (10 µM) and 
1.61±0.24* µg at 100 µM (*P<0.05), but there was no difference compared with the 0.5% O2. 
Similarly, there was a significant reduction in the amount of sGAG produced by all the 
CAY10585-treated groups compared with 20% O2 (Figure 6.15D), which were 1.89±0.22µg* 
for 1 µM, 1.89±0.12µg* for 10 µM, 1.80±0.33µg* for 100 µM, but there was no difference 
compared to the untreated 0.5% O2 control (P>0.05).  
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Figure  6.14 - Effect of 2ME-2 on MVICs 
2ME-2 reduced MVICs proliferation at 10 µ and 100 µM (A) and increased cell death at 100 
µM (B). None of the used concentrations were able to block the expression of HIF-1α when 
incubated under severe hypoxia (C) and similarly they had no effect on the reversing the 
effect of severe hypoxia on sGAG production (D).  
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Figure  6.15 - Effect of CAY10585 on MVICs 
CAY10585 has no effect on MVICs proliferation (A), cell death (B), blocking HIF-1α 
expression under hypoxia (C) or reversing the effect of hypoxia on sGAG production (D).  
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6.4 DISCUSSION 
This study showed the expression of HIF-1α by the MVICs. Immunohistochemical analysis 
of normal, rheumatic and myxomatous anterior human MV leaflets showed that HIF-1α is 
expressed in rheumatic MVs. pMVICs expressed HIF-1α protein in vitro in a concentration-
dependent manner, similar to HeLa cells, in response to reductions in O2 concentration. HIF-
1α protein expression was reduced over time. However, hypoxia did not affect expression of 
the HIF-1α mRNA. In addition, the study showed that HIF-1α at least partially mediates the 
decrease in sGAG production by pMVICs under hypoxia.  
HIF-1α is considered a master regulator of O2 homeostasis that allows all metazoan species to 
have O2 delivered and utilised by their multicellular structures. The HIF-1α system is very 
sensitive to changes in levels of O2, it is universally expressed by all metazoal cells and 
directly regulates more than 1,000 human genes controlling functions like O2 delivery, 
angiogenesis, glucose metabolism, O2 and redox homeostasis and many others (Semenza 
2013).  
Hypoxic stimuli start affecting cells during the early stage of development, as most of the 
embryogenesis occurs in the hypoxic uterine environment (Simon et al. 2008). HIF-1α 
mediates most of the cellular pathways essential for organogenesis, and further development 
of the biological system that will maintain O2 delivery to cells like the cardiovascular system. 
HIF-1α is critical for this step as complete HIF-1α deletion is lethal to mice in the early 
embryonic stage (Compernolle et al. 2003; Iyer et al. 1998). On the other hand, although 
mice with heterozygote HIF-1α (HIF1α+/-) survived and developed apparently normally, they 
had impaired response to hypoxia and had delayed development of polycythemia, right 
ventricular hypertrophy, pulmonary hypertension and pulmonary vascular remodelling (Yu et 
al. 1999). 
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In this study, the expression of HIF-1α in normal and in two disease entities of human MVD 
(rheumatic and myxomatous) was examined. Normal and myxomatous valves were overall 
negative for HIF-1α with some scattered positive cells both in interstitial and endothelial 
areas. These positive cells could represent a true positive expression of HIF-1α, or could be 
have been seen due to excised valves being exposed to a period of hypoxia between removal 
from the patient and fixation in the laboratory. On the other hand, rheumatic valves showed a 
significant increase in HIF-1α staining. Yet, not all rheumatic valves stained for HIF-1α, and 
the positive valves appeared positive in certain areas or clusters. Of interest is that HIF-1α 
staining co-localised with areas of increased angiogenesis as described in Chapter Two.  
Vascular development and angiogenesis is one of the main functions of the HIF-1α pathway 
in response to hypoxia, which is the main stimulus that drives angiogenesis through inducing 
the expression of virtually all critical angiogenic growth factors, including VEGF (Forsythe 
et al. 1996). VEGF, which is considered the most potent endothelial-specific mitogen that 
stimulates endothelial cell proliferation and participates directly in angiogenesis, is strongly 
induced by HIF-1α. In addition many other factors like stromal cell-derived factor-1 (SDF-1) 
(Ceradini et al. 2004), placental growth factor (PGF), angiopoietin-1 (ANGPT1) and 
ANGPT2 are directly induced by HIF-1α and contribute to the complex organised process of 
angiogenesis and vascular remodelling (Kelly et al. 2003). HIF-1α induces secreted 
angiogenic cytokines that mobilise and recruit pro-angiogenic factors from distal sites like the 
endothelial progenitor cells and mesenchymal stem cells (Hirota et al. 2006; Rey et al. 2010).  
The increased levels of HIF-1α expression in rheumatic valves could explain the increase in 
valve vessels seen in the specimens examined. It is possible that as part hypoxia could 
contribute to the pathological process that mediates RVD, resulting in increased HIF-1α 
expression, which will subsequently stimulates angiogenesis, similar to what is seen in 
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humans with severe pulmonary hypertension (Tuder et al. 2001). The reduction in valve 
vessels seen earlier in myxomatous valves was associated with baseline levels of HIF-1α. 
One possible explanation is that myxomatous degeneration is a consequence of ageing where 
either MVICs O2 requirement is reduced with age and therefore both the expression of HIF-
1α and valve vessels are reduced, or that MVICs capacity to express HIF-1α is reduced with 
age as previously reported (Semenza 2010). Another theory that is the over-expression of the 
anti-angiogenic mediator Chm-I in myxomatous valves could have a HIF-1α inhibitory effect 
as well. Chm-1 was found to be markedly downregulated in rheumatic and atherosclerotic 
aortic valve disease, which were associated with angiogenesis (Yoshioka et al. 2006). There 
was no expression of HIF-1α in normal valves. HIF-1α is not seen in normal tissues, due to 
its rapid degradation under normoxic conditions. Occasional weak staining can be expected 
in normal tissue due to collection artefacts because of the delay in fixing the samples. 
Nevertheless, the same valves, showed large areas of little or no vascularisation (chapter II) 
suggesting that some of those areas within the valve could exist under hypoxic conditions, yet 
there was no HIF-1α expression in those areas. Similar to myxomatous valves, this can be 
explained by reduced O2 requirement with age, or that part of the valves are expected and 
adapted to exist under hypoxic conditions, and therefore they do not express HIF-1α. 
 This study showed that HIF-1α gene expression by pMVICs was expressed under normoxic 
conditions and that expression did not change under different levels of hypoxia, unlike the 
changes of protein expression. These results are consistent with previous studies on the HIF-
1α gene expression as it was found to be constitutively expressed in most types of cell lines 
under normoxic conditions and the level of expression was not changed under hypoxic 
conditions (Gradin et al. 1996; Kallio et al. 1997). HIF-1α modification and stabilisation 
occurs at a post-translational protein level (Kallio et al. 1997). The control of HIF-1α at 
transcriptional level is not well understood (Semenza 2013) especially in some cell lines 
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where the HIF-1α mRNA is induced under hypoxia (Lemus-Varela et al. 2010; Semenza 
2013), and even though there are significant differences between gene and protein expression 
under hypoxia is some cells (Zhang et al. 2012). 
The detection of HIF-1α protein was very challenging: HIF-1α is very unstable under 
normoxia as it has a half-life of 1 to 5 minutes (Kallio et al. 1997; Wang et al. 1995b). It 
translocates to the nucleus under hypoxia, and becomes diluted when the cells are lysed, thus 
requiring very high protein loading to be detected by Western blotting. Also, HIF-1α 
expression is variable across time, and although it is highly stabilised under hypoxia over a 
short period of time, the level of expression is reduced over time. Another problem presented 
by HIF-1α is the variability in the quality of the commercially available HIF-1α antibodies. 
Initial extensive efforts to detect HIF-1α by Western blotting were unsuccessful. Thus 
detecting HIF-1α by immunofluorescence staining was performed. HeLa cells, a cell line that 
was known to express HIF-1α in response to hypoxia were used as a positive control, and 
helped to optimise the experimental and staining protocol, as well as the choice of antibody. 
The expression of HIF-1α by HeLa cells in this study was consistent with previous literature 
(Hofer et al. 2002; Kallio et al. 1997; Wang et al. 1995b).  
After extensive optimisation of the Western blot protocol, progress was then possible with 
detection of HIF-1α protein. Total cell lysate from pMVICs incubated under different levels 
of hypoxia for 6 hours showed expression of HIF-1α. There was no expression of HIF-1α 
under normoxic conditions or under 5% O2. At 2% there were some weak bands seen in some 
specimens, but there was a very clear strong expression at 0.5%. The Western blot findings 
generally agree with the immunofluorescence staining, especially at 20% O2 where there was 
no expression in both techniques and at 0.5% O2 where there was very strong significant 
expression in both techniques. Regarding the mild and moderate hypoxia, 
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immunofluorescence staining was able to show the increased expression of intra-nuclear 
staining, which was also statistically significant when the staining was quantified. The 
intensity of staining was proportional with the level of hypoxia. Western blot was unable to 
detect any difference in HIF-1α expression in mild and moderate hypoxia, although some 
bands were seen at 2% O2. This is possibility due to the nature of HIF-1α that it degrades 
very quickly, and that large concentrations are required to detect it in total cell lysate. Nuclear 
extract isolation was attempted – and did not lead to reliable results. It requires a long time 
and multiple preparation steps, which could also contribute to the degradation of the protein 
and difficulty in detecting it.  
Although cell lysates for Western blot were prepared very quickly (in about 1 minute), fixing 
cells for immunofluorescence staining was even quicker and possibly the protein remained 
more stable, in addition, there was no further processing for the protein. Therefore, 
immunofluorescence appeared to be a slightly more sensitive technique to detect the 
expression of HIF-1α in the mild to moderate hypoxic range. On the other hand, the 
immunofluorescence technique can be limited by the non-specific staining, nevertheless, due 
to careful optimisation, non-specific staining was reduced. The other concern with using the 
immunofluorescence technique is the accuracy of the quantification. Using a standard 
threshold and increasing the sample size of the field to minimise the error also optimised this. 
The results shown were reproduced from different experiments, and correlated well with 
Western blot under severe hypoxia.  
Different cell types have variable response to hypoxia in terms of level of hypoxia and 
duration of exposure. It is important to analyse the HIF-1α response to hypoxia as this could 
present different biological features, including different O2 sensitivity or different metabolic 
rates (Bracken et al. 2006). This study shows the response and pattern of expression of HIF-
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1α by pMVICs across the O2 gradient is similar to most other cell lines like HeLa cells for 
example (Jiang et al. 1996).  
HIF-1α has a significant response in acute hypoxia with a rapid increase following a few 
hours exposure to hypoxia. However, this response is different under chronic or prolonged 
hypoxia, where its level starts to drop down to baseline and even becomes undetectable after 
1 to 7 days in many cells like HeLa cells or cultures of human dermal fibroblasts (Ginouves 
et al. 2008). In HeLa cells, this phenomenon is seen across different O2 levels though it is 
more attenuated with reduced O2 level especially at extreme hypoxic levels (0.1%) (Ginouves 
et al. 2008). This phenomenon is mediated primarily by PHDs (and their isoforms) as chronic 
hypoxia increases the expression and over-activates the PHDs. It also increases intra-cellular 
O2 availability through inhibition of mitochondrial respiration. This could result in a negative 
feedback loop that will limit the HIF-1α activity and lead to adaption to ambient O2 
availability (Ginouves et al. 2008; Willam et al. 2006). The baseline expression of PHDs 
(and their isoforms) is variable between different types of cells and tissue, for example PHDs 
is most abundant in the heart, and the different PHD isoforms are regulated differently under 
hypoxia.  In addition, in a rat myocardial infarction model, both HIF-1α as well as PHDs 2 
and 3 are up-regulated, most significantly at 7 days (Willam et al. 2006). This may explain 
the variability seen in cellular response to different levels and duration of hypoxia in MVICs 
response to hypoxia. 
The HIF (alpha) family has two other isoforms in addition to the 1α: HIF-2α and HIF-3α. 
HIF-2α shares about 50% of the amino acid sequence with HIF-1α, as well as some 
functional features like heterodimerisation with HIF-1β and the HREs, and activation of 
target genes, but unlike HIF-1α it is not ubiquitously expressed, and the level of expression 
varies from one cell type to another, for example, it is more expressed in endothelial cells and 
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lung pneumocytes. In addition, both HIF-1α and HIF-2α can have differential function, for 
example loss of the O2 sensing ability of the carotid body cells in HIF-1α-deficient mice were 
not rescued by over-expression of HIF-2α (Hu et al. 2003; Semenza et al. 2012; Wiesener et 
al. 1998). HIF-3α is another isoform that shares fewer features with HIF-1α. It is closely 
related to a splice variant called inhibitory PAS (IPAS) that is believed to be a negative 
regulator of HIF-1α, but both are not widely expressed and are not well studied (Ke et al. 
2006). None of these isoforms were examined in this study, but should be the subject of 
further investigation in the future. 
As seen in Chapter Five, hypoxia has a functional effect on pMVICs. At the same time, 
pMVICs express HIF-1α in a classic pattern, and therefore, this study examined whether HIF-
1α mediates the functional changes of the MVICs especially in terms of ECM. In order to do 
that, MVICs were treated with HIF-1α stimulants and inhibitors and assessed for sGAG 
production. The amount of sGAG produced was chosen because it has a significant change 
under hypoxia as shown in Chapter Five. It is also one of the essential valve ECM 
components that is affected by ageing and by valve disease. sGAGs also are mostly 
concentrated in the middle layer of the valve, which is a region more likely to become 
hypoxic.  
First pMVICs were incubated under normoxic conditions and HIF-1α was chemically 
induced by two stimulants separately: CoCl2 and DFO. Both agents are well-established HIF-
1α stimulants (Wang et al. 1995a). CoCl2 is an inorganic compound and heavy metal, while 
DFO (C25H48N8O8) is an iron-chelating agent that is medically used to remove excess iron 
from the body. They stabilise HIF-1α through their effect on PHDs, which require both O2 
and Fe to target HIF-1α degradation. Both CoCl2 and DFO block the function of PHDs by 
either replacing the Fe binding site or diminishing the availability of Fe2+ (Bruick et al. 2001; 
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Masson et al. 2003). They induce HIF-1α in a dose-response manner. CoCl2 is also toxic at 
higher doses and causes increased cell death. The study tested various concentrations of HIF-
1α modulators to determine the optimum concentration. First the effect of these agents was 
tested for their effect on cell proliferation and cell death, in order to eliminate the chance that 
any observed change in sGAG seen is not through changes in cell number. CoCl2 
significantly reduced cell proliferation and increased cell death at the highest concentration 
tested (1,000 µM), but at lower concentrations (less than 100 µM) there was no effect on the 
cellular proliferation. This is consistent with previous report in HeLa cells for example 
(Wang et al. 1995b). At 100 µM, CoCl2 showed a reduction in the amount of sGAG produced 
by pMVICs similar to what is seen by hypoxia alone. DFO did not show any effect on cell 
proliferation or death but showed dose-response increase in HIF-1α expression, and similar to 
CoCl2, it reduced the amount of sGAG produced by pMVICs.  This demonstrates that 
reduction in sGAG production seen under hypoxia is mediated by HIF-1α.  
The choice of HIF-1α inhibitors was more difficult.  Vast number of compounds have been 
screened as potential HIF-1α inhibitors, and identified hundreds of inhibitors. The interest in 
finding a perfect HIF-1α inhibitor stems from the fact that HIF-1α is over-activated in many 
cancers and blocks it is a potential treatment target. Yet, these agents still lack specificity and 
their effect does not translate to significant clinical efficacy (Xia et al. 2009). The two HIF-
1α inhibitors chosen were 2ME-2 and CAY10585. 2ME2 is an endogenous metabolite of 
oestrogen that was initially found to inhibit proliferation and migration of endothelial cells 
resulting in anti-angiogenic effect. 2ME-2 was found to be a HIF-1α inhibitor. It is believed 
that 2ME-2 inhibits HIF-1α through binding to tubulin, inhibiting polymerisation and causing 
microtubule disruption and arrest which subsequently inhibits HIF-1α stability (Mabjeesh et 
al. 2003; Xia et al. 2012). Another proposed mechanism of action is through inhibition of 
mitochondrial respiration, and therefore increasing intra-cellular O2 availability (Hagen et al. 
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2004). 2ME-2 inhibits cellular proliferation (Hagen et al. 2004), and increases apoptosis 
(Mooberry 2003) in a dose-dependent manner. This effect was seen in this study as well, 
where 2ME-2 inhibited cell proliferation at moderate to high concentrations, and increased 
cell death at high concentrations. However, 2ME-2 was unable to significantly block HIF-1α 
expression in response to hypoxia. There are few possible explanations for this, including that 
HIF-1α blockage occurs at a higher concentration (Hagen et al. 2004), especially in vitro 
experiments (Mabjeesh et al. 2003), or that 2ME-2 does not affect the pMVICs since it has 
been reported to have a cell-specific effect (Mooberry 2003). 2ME-2 has no effect on the 
amount of sGAG produced at any concentration, which fits with the fact that it failed to block 
HIF-1α, although the exact effect could be different in view that 2ME-2 has inhibited 
proliferation and increased cell death.  
The other inhibitor used was CAY10585, which belongs to a group of aryloxyacetylamino 
benzoic acid analogues, which is a class of HIF-1α inhibitors that block HIF-1α in a 
concentration-dependent manner (Crescini et al. 2013; Hu et al. 2013; Lee et al. 2007). In 
this study, CAY10585 did not have any effect on cell proliferation, cell death, inhibition of 
HIF-1α or the amount of sGAG produced. It is most likely that CAY10585 acts in a cell-
specific manner and has no efficacy in pMVICs.  
Thus, pharmacological modulation of HIF-1α in pMVICs shows that HIF-1α at least partially 
mediates the functional response seen under hypoxia on the sGAG production. This effect 
was shown through chemically stimulating HIF-1α and mimicking the effect of hypoxia, but 
unfortunately, blocking HIF-1α was not successful to complement the data with the activators 
of HIF. Yet, it remains unknown whether other pathways like HIF-2α play a role in mediating 
the effect of hypoxia on ECM production.  
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In conclusion this study shows the over-expression of HIF-1α in human rheumatic MV 
anterior leaflet compared with normal and myxomatous valves. pMVICs expressed HIF-1α 
protein in vitro in a classic concentration-dependent manner similar to HeLa cells, with 
reduction in the level of expression over time, but hypoxia did not affect its gene expression. 
In addition, the study showed that HIF-1α at least partially mediates the functional response 
of pMVICs sGAG production under hypoxia.  
 
 
 
 
 
 
 
 
 
 
 
 
  
Final discussion and conclusion 
 
219 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 7: Final discussion and conclusion  
  
Final discussion and conclusion 
 
220 
 
This thesis has identified hypoxia as an important signalling pathway in MV interstitial cells 
that has not been previously studied within the field of valve biology. The study has shown 
that MVICs incubated under hypoxia remained viable and continued to proliferate, while 
retaining their morphology and phenotype. On the other hand, severe hypoxia results in 
reduced production of the ECM components sGAG and collagen, while it induced matrix 
metabolism through up-regulating the gene expression of MMPs and their tissue inhibitors. 
Human rheumatic valves had greater expression of HIF-1α compared with normal or 
myxomatous valves. Porcine MVICs expressed HIF-1α under hypoxia. Stimulating the 
activation of HIF-1α chemically shows a reduction in the amount of GAGs produced by 
MVICs, similar to the effect observed under severe hypoxia. The study also confirmed the 
presence of vascular supply to the normal MV leaflets and showed that there was increased 
vascularisation in rheumatic valves, while there was loss of vessels in myxomatous valves.  
7.1 CLINICAL IMPLICATIONS OF THE STUDY  
7.1.1 Normal mitral valves 
 As discussed in Chapter 2, the thickness of the MV leaflets indicate that diffusin alone is not 
enough to cater for the O2 requirements of the MVICs based on mathematical models (Weind 
et al. 2001; Weind et al. 2002), which could indicate that some parts of the valve leaflet could 
normally exist under hypoxic conditions. However, normal valves have some vessels within 
the leaflets, but these vessels are not of a specific pattern and there are some regions within 
the valve leaflets that do not have any blood supply.  
Porcine MVICs cultured under mild hypoxia did not have any effect on their response or 
function. Under moderate (2% O2) hypoxia, most of the functions were also maintained, but 
cells started to be affected, like the reduction in cell death or reduced sGAG production, for 
example, but the most prominent effect was seen when pMIVCs were grown under severe 
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hypoxia (0.5% O2). This indicates that pMVICs can function in an environment where the O2 
levels are somewhere between 2–5% O2, which could occur in areas distant from the vascular 
supply.  
In addition, the presence of vessels in some other areas of the valve would indicate that 
MVICs do require more O2 than what could be delivered by simple diffusion. This suggests 
that although pMVICs may have relatively low O2 requirement (2-5%), there might have 
differential need for O2, that some regions would require more O2 than others. It is important 
to remember that although diffusion alone might not be enough to provide the entire O2 
requirement to the middle of the valve, MVICs are distributed at various distances from the 
surface of the valve, and therefore, different cells within same leaflet could be exposed to a 
range of O2 tensions.  
Those cells exposed to severe hypoxia were able to tolerate it. Cell proliferation was not 
affected, and cell death was reduced indicating that they can survive in such conditions. Yet, 
those cells strongly expressed HIF-1α, which appear to have a role in mediating some 
functional changes at that level, including reduced ECM production of collagen and sGAGs 
and increased matrix enzymes. Nevertheless, there was no HIF-1α expression detected in 
normal valves. In vitro experiments exposed cells to acute hypoxia. The regulation and 
expression of HIF-1α by acute and chronic hypoxia might therefore differ, especially that the 
expression of HIF-1α gets significantly reduced when MVICs were cultured under severe 
hypoxia for as little as 3 days. 
These comparisons are between human valves and porcine cells, which despite similarities 
between them they remain different. One of the main differences in this context is that 
porcine valves are more extensively vascularised compared with human valves as shown in 
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Chapter Two. One of the possibilities is that pMVICs do have higher O2 requirements than 
human cells, and that human cells will require less than 2% O2 under normal circumstances.  
The lack of vessels in areas of normal MV leaflets could be part of an age-related 
degeneration process as some previous reports showed reduction in human valve leaflet 
vascularity with age (Duran et al. 1968). This also agrees with the fact that valve GAG 
content is reduced with age (Baig et al. 1978), also some cells has reduced capacity to 
express HIF-1α with age like mouse dermal fibroblasts (Semenza 2010). 
 
7.1.2 Myxomatous mitral valve disease 
In myxomatous valve leaflets, there were no vessels were identified. This reduced vascularity 
within the leaflet compared with normal valves suggests that MVICs could potentially exist 
under hypoxic conditions. Nevertheless there was no HIF-1α expression by myxomatous 
VICs. 
One theory to explain this is that since myxomatous degeneration is a slow progressive 
disease, this process could have been proceeded by the gradual loss of leaflet vascularity with 
age like what was reported in normal valves (Duran et al. 1968), and that coincided with the 
reduced capacity of MVICs to express HIF-1α with age (Semenza 2010), or with chronic 
desensitisation of MVICs to express HIF-1α secondary to this process. Another theory is that 
the increased expression of anti-angiogenic mediators like Chm-I in myxomatous valves 
(Mariscalco et al. 2011), which could counteract HIF-1α expression and cause reduced 
vasculature.  
The effect of hypoxia on pMVICs seen in this study could explain some of the changes 
observed in myxomatous valve disease. Myxomatous disease is believed to be a 
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dyscollagenesis disorder as a consequence of destruction to the fibrosa layer and therefore 
loss of the mechanical integrity of the leaflet (Hadian 2010). In mild-to-moderate canine 
myxomatous MVD, it was shown that there was a 10% reduction in total collagen, 20% 
reduction in fibular collagen and an increase in immature reducible cross links (Hadian et al. 
2010), and interestingly, it was found that serum concentration of procollagen III is inversely 
proportional to the severity of the disease (Hezzell et al. 2012). There is also a up to threefold 
increase in the number of MVICs (Black et al. 2005; Disatian et al. 2008; Rabkin et al. 
2001).  
On the other hand, myxomatous valves have an increase in the total sGAG content compared 
with normal valves (Lis et al. 1987). There was large variability in the percentage increase 
between different studies and within the same study reaching 30–150% (Grande-Allen et al. 
2003). In this study, severe hypoxia resulted in a reduction of the total amount of sGAG, and 
also reduced the gene expression of HA. It might be that chronic gradual hypoxia has a 
different effect compared with acute events seen here, or other stimuli might override the 
reduction seen in hypoxia like mechanical stimulation or other biological mediators.  
In the present study, MMP-2 and MMP-9, as well as their tissue inhibitors TIMP-1 and 
TIMP-2, were increased. This increase in matrix enzymes indicates that there is more matrix 
turnover associated with hypoxia, similar to what is seen is valve disease. But the net effect 
of the activation of these enzymes cannot be determined since both the MMPs and their 
inhibitors are increased. MMPs and TIMPs are reported to have increased expression in 
different types of diseased valve. Soini and colleagues (Soini et al. 2001) in a study of both 
aortic and MVs from degenerative and endocarditic valves showed increased expression of 
MMP-2, MMP-9, TIMP-1 and TIMP-2 where TIMP-1 was mostly, and strongly, expressed. 
Rabkin (2006) showed a significant increase in MMP-1, MMP-2, MMP-9 and MMP-13 in 
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myxomatous MVs compared with normal ones. Disatain et al. (Disatian et al. 2008) showed 
a similar increase in MMP-1 and MMP-13 in myxomatous dog MVs. Over-expression of 
MMP-2 in transgenic mice has also reproduced myxomatous MV disease (Mahimkar et al. 
2009). Studies that looked at aortic valve disease also showed a significant increase in MMPs 
and TIMPs as well as in diseased valves (Aikawa et al. 2006; Fondard et al. 2005; Koullias et 
al. 2004). It is important to note that in addition to the study of the expression of matrix 
enzymes, their activities need to be assessed to see what net effect of their opposing effects is 
on the ECM in response to hypoxia.  
7.1.3 Rheumatic valve disease  
Rheumatic valves showed a significant increase in leaflet vascularisation with an increase in 
the number of vessels, which are larger and thicker, compared with normal valves. This was 
associated with increased expression of HIF-1α. These findings suggest that there is a 
significant hypoxic stimulus affecting these valves, which is evident due to the increased 
expression of HIF-1α. This could be secondary to the rheumatic disease process affecting the 
leaflet vessels or by inflammatory changes to the leaflet resulting in decreased O2 diffusion 
into the leaflet. Subsequently, intra-leaflet hypoxia will trigger the expression of HIF-1α by 
MVICs, which will induce further changes in an attempt to restore O2 supply by increased 
angiogenesis. Alternatively, the rheumatic inflammatory process could result in non-hypoxic 
induction of HIF-1α. This can occur through different cytokines and growth factors like 
mitogen activated protein kinase (MAPK), P42/44, p38 kinase and phosphoatidylinositol 3 
kinase (PI3K) which can activate HIF-1α independent of O2 and hypoxia, or enhance its 
hypoxic activation through phophorylation (Bruick et al. 2001; Jeong et al. 2002). 
It is well recognised that in RVD there is increased collagen synthesis and deposition 
(Rajamannan et al. 2005) with fibrotic thickening (Schoen 2008). In this study, pMVICs 
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cultured under severe hypoxia had reduced total collagen, but there was no effect on the gene 
expression of collagens I and III. This could partially agree with the changes seen in 
rheumatic disease, as collagen production is not affected under hypoxia, but maybe during 
the rheumatic process its degradation is reduced resulting in increased accumulation. Little is 
known about the collagen distribution within different areas of rheumatic valves, especially 
considering that rheumatic valves can have localised thickening, nodular changes and areas 
of calcification (Donnelly 2008; Rajamannan et al. 2005). Data from the more widely studied 
calcific aortic stenosis showed that collagen formed about 90% of the total protein in the 
grossly healthy parts of the leaflet while it dropped to 40% in the soft affected areas and 
further to 10% inside the calcific nodules. Surrounding those calcific nodules there was 
increased production of procollagen I synthesis indicating increased turnover with 
degradation exceeding synthesis (Eriksen et al. 2006). This suggests that the hypoxic 
pathway could have a more significant localised effect on the disease process.  
The hypoxic effect on the ability of MVCs to produce GAGs supports findings in RVD. Baig 
and colleagues (Baig et al. 1978) looked at acid muccupolysaccharide (GAGs) between 
normal and rheumatic MVs in different age groups and found that in young patients (less than 
20 year old), GAG content of rheumatic valves was significantly increased compared with 
normal controls. But in the other older rheumatic groups, GAG content was reduced 
compared with normal valves. In addition, there was no difference in the relative GAG 
composition in valves below 40 years of age, but after that there was a significant reduction 
in the HA content in rheumatic valves at 35% compared with 65% in normal valves 
compared with an increase in CS subtypes from 25% to 47%. In another study, Lis and 
colleagues showed a reduction in GAG content in rheumatic MVs (Lis et al. 1987). Similarly, 
when this is compared to localised changes studied in calcific degeneration of both mitral and 
aortic disease, total GAG content was found to be significantly reduced and sometimes absent 
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inside the calcific nodule, but increased in the areas surrounding the nodule and associated 
with increased lipid accumulation (Sell et al. 1965). These findings were recently confirmed 
by the Grande-Allen group (Stephens et al. 2011) who looked at three different PGs: decorin, 
biglycan and versican (as well as HA in calcific aortic valves), and showed that all of them 
were significantly reduced inside the calcific nodule but increased in the areas surrounding it 
compared with the normal valves and the reminder of the valve.  
It is very important to appreciate that hypoxia has a dynamic, changing stimulus, which has a 
broad spectrum of effects corresponding to various events or stages in health and disease, For 
example, at the early stages of a disease process, the reduction of O2 can be mild, but in an 
advanced condition, hypoxia will become severe and affect cells differently, for example, in 
atherosclerosis, where intimal thickening of blood vessels and occlusion of the vasa vasorum 
significantly reduce blood supply to the vessel wall exposing SMCs to hypoxia (Figueroa et 
al. 1999). This will recruit and retain macrophages to the site of injury, and subsequently 
contribute more to hypoxia. 
The disease process in RVD is associated with over-expression of HIF-1α as seen in this 
study. Although it is possible that this is an adaptive response to counteract a hypoxic insult, 
it could be contribute further to the disease process, evidenced by disorganised angiogenesis 
with vessels being much bigger, thicker and irregular compared with normal, possibly 
weakening the valve. In addition, HIF-1α could be mediating some observed effects, like 
reduction in GAGs, and resulting in a maladaptive response.  
 
7.2 LIMITATIONS OF THE STUDY 
The study had a number of limitations. Human MV leaflets were used for 
immnohistochemical analysis of leaflet vascularisation and the expression of HIF-1α. The 
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normal valves were from unused donor hearts, which were still deemed to be normal on 
preoperative and gross examination. Yet it is not possible to completely rule out that these 
valves had some disease in them. In addition, this normal group come from a narrow age 
range and it would have been more informative to look at the pattern of vascularisation across 
younger as well as older patients free of CVD especially with the evidence that leaflets are 
more extensively vascularised early in life. Obtaining such specimens is very difficult, if not 
impossible. Although the study clearly shows that the normal valve group has leaflet vessels 
within them, it cannot exclude whether those vessels are secondary to subclinical disease 
processes. Similarly, the lack of vessels seen in myxomatous valves could be a coincidental 
finding that valve leaflets lose their microvessels with age and it is not related to disease 
itself. The rheumatic valves used in this study were from patinets who were receiving 
treatment at the Aswan Heart Centre in Egypt, region of the world where RVD is still a major 
health issue. They lack any clinical data including age of the patient at time of surgery, and 
the level of acuteness of the disease that could have further implication on linking the 
findings in the study to clinical events. Regarding the myxomatous valves, most of the valves 
are now repaired during surgery, with only small parts of the valve occasionally resected. 
This made obtaining myxomatous valves for investigation extremely difficult. It was decided 
not to examine these small parts resected at repair, because they might not be representative 
of the whole valve architecture. Although whole anterior leaflets were examined in this study, 
it is still does not represent the whole valve structure as many changes can still occur in the 
posterior leaflet, which is usually left in place during the surgery.  
 
The study has relied on using porcine tissue, due to the difficulty in getting human specimens 
to culture cells and the speed at which these cells grow and time taken to reach confluence. 
Porcine cells were used as they are widely studied in the absence of sufficient human cells 
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and due to the similarities between porcine and human valves. In addition porcine valves are 
routinely used for valve replacements. As discussed previously, comparing the effect of 
hypoxia on pMVICs to the changes seen in human valves might not be very accurate, as 
human cells could behave differently if cultured under similar conditions.  
This study was also limited in that the in vitro assessments of pMVICs were performed under 
static conditions. Unlike many other tissues, heart valves are dynamic structures constantly 
under mechanical stress and stretch. It has been shown that mechanical changes play an 
important role in the function of vavlular cells (Arjunon et al. 2013), for example, under 
mechanical stretch, aortic VICs have increased collagen production (Ku et al. 2006) and in 
combination with pressure their phenotype is also altered (Thayer et al. 2011). It is expected 
that O2 requirement and consumption will be different for dynamic compared with static 
conditions, as dynamic cells could potentially have increased O2 demand. Yet the exact effect 
of mechanical changes in vivo will be difficult to determine. It is believed that changes in 
pressure and stress over the valve will cause compression during the cardiac cycle, and 
therefore the diffusion distance for O2 will be less. Another point is that heart valves, 
especially MVs, are not uniform in their thickness and surface topography, and therefore, 
diffusion distances and the therefore O2 availability will be different across the various areas 
of the valve. This study serves to define the effect of hypoxia on static cells, which provides a 
baseline for future investiagtions. The results of this study can therefore form a reference and 
guide for future invsestigations using dynamic models of valve function.  
Another limitation of the study is the duration of hypoxia. The maximum hypoxic time used 
was 3 days. This is the optimum duration that cells could be left without changing the media. 
The current experimental design did not allow changing culture media without intermittent 
hypoxia. Although some other studies changed culture media under normoxic conditions, this 
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will expose the cell to intermittent hypoxia and could potentially skew the results. The study 
reports robust, rigorous hypoxic control over a relatively short period of time. It will be 
interesting to further explore the effect of prolonged hypoxia on MVICs, in light of the 
changes seen by these cells, and the fact that many of the in vivo changes can happen over 
longer period of time. These cells have an adaptive response to hypoxia and potentially 
behave differently.  
This study has shown successfully that the chemical induction of HIF-1α replicated the effect 
of hypoxia on pMVICs. The inhibitors used to block the HIF-1α were unable to completely 
inhibit its expression or modulate the hypoxic effect on the cells. Therefore the study was 
able to partially show that HIF-1α mediates the changes in sGAG production by pMVICs 
under hypoxia. There is a need to search for different HIF-1α inhibitors to complete the study 
on the role of HIF-1α pathway in mediating the changes of pMVIC under hypoxia.  
 
7.3 FUTURE DIRECTIONS  
Not all areas that could have been investigated could be included in this study. In addition, 
the present thesis has shed the light on some interesting questions. Therefore future 
investigations into a number of areas related to this study are recommended.  
1. The in vitro experiments were performed on porcine MVICs. Despite the great 
similarities with human cells, it will be interesting to repeat the same experiment on 
human cells as they might behave differently under hypoxic conditions, especially in 
view of differences in leaflet vascularisation patterns between humans and pigs, and 
the fact that porcine valves are not known to suffer from MV disease unlike humans. 
In order to perform these experiments, human MVICs will need to be isolated from 
normal MV leaflets freshly obtained from unused donor hearts. These cells can be 
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then used in same experimental design described in this thesis. It will also be 
interesting to isolate hMVICs from diseased human valves and assess whether those 
cells have altered response to hypoxia.  
 
2. The experiments performed in this study were carried out under static conditions, 
which is different from the dynamic physiological conditions that MVICs exist under. 
Cellular response to hypoxia can be different if cultured under dynamic conditions as 
O2 might be different. It is important to assess the effect of hypoxia under dynamic 
conditions. This can be performed by culturing MVICs under hypoxia while there are 
subjected to stretch. Cells can be stretched using Flexercell tension system 
(Hillsborough, USA) or a similar system. The hypoxic chamber design used in this 
study will allow building a modified version that can accommodate the stretch 
machine inside it. 
 
3. This study examined the effect of hypoxia on pMVICs, and looked at the expression 
and function of a selected number of markers and mediators. The field of valve 
biology includes many other biologically active components. Future work should 
consider expanding the scope of these components, like looking at other phenotypic 
markers such as Desmin and myocardin (Latif et al. 2014), other ECM components 
present in valve leaflets like MMP-1, MMP-13 (Disatian et al. 2008) and elastin 
(Latif et al. 2005a) and dissecting further collagens (Cole et al. 1984) and sGAG 
(Dainese et al. 2007) into their subtypes. Looking at other HIF-1α isoforms like 
HIF1β and HIF2α could also expand the hypoxic mediators. In addition, it will be 
interesting to investigate the relationship of hypoxia to other mediators that can 
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potentially modulate MVICs response and function. These mediators include TGF-β 
(Agocha et al. 1997), integrins (Fayet et al. 2007) and Chm-I (Yoshioka et al. 2006).  
 
4. The role of hypoxia and HIF-1α in valve calcification has not been explored in valve 
biology. There is evidence that vascular calcification is also mediated by hypoxia and 
reactive O2 species (Towler 2007; Towler 2011). In this thesis two significant changes 
were seen in rheumatic MV disease including increased vascularisation and 
expression of HIF-1α, and since rheumatic MVs have increased calcification 
compared with other types of MV disease, hypoxia could have an important role in 
valve calcification. This could also be studied by looking at atherosclerotic aortic 
valves that were reported to have increased neovascularisation (Soini et al. 2003) in 
addition to their significant susceptibility to calcification.  
 
5. The interest in understanding valve biology is encouraged by the quest to manufacture 
self-renewable tissue-engineered heart valves. With these findings in this study on the 
role of hypoxia on heart valve cells, further experiments in valve tissue engineering 
should take hypoxia into consideration, and that including designing scaffolds that 
will allow improved O2 diffusion, consider inducing vessel formation, testing tissue 
engineered valves under hypoxic conditions and factor in the O2 requirements of the 
cells used for these valves especially for stem cells that are known to be affected by 
hypoxia more than other cells.  
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7.4 CONCLUDING REMARKS 
This study has identified the importance of hypoxia on MV interstitial cells as a signalling 
pathway that affects their function in production and maintenance of ECM. These changes 
could be linked to some of the pathological process of MV disease that also involve increased 
vascularisation and over-expression of HIF-1α. These findings open the door for the whole 
area of research in valve biology and pathogenesis.  
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4/17/2014 Re: Permission to use illustration 
https://exchange.imperial.ac.uk/owa/?ae=Item&t=IPM.Note&id=RgAAAAASvuHZSl46QY%2fMDL%2b
K5ZUUBwCoqADgsQPHQpT8VkAqEkiIAADIn6…‎ 1/2 
Re: Permission to use illustration 
CavalierHealth.org [cavalierhealth@att.net] 
Sent:17 April 2014 00:51 
To: Salhiyyah, Kareem 
Kareem: This photo does not belong to us. We found it on the web, and I cannot locate its source 
information in our files. To the extent we may grant permission to you, we hereby do so. 
Rod Russell 
editor@cavalierhealth.org 
From: "Salhiyyah, Kareem" <k.salhiyyah@imperial.ac.uk> 
To: CavalierHealth. org <cavalierhealth@att.net>; "Editor@CavalierHealth.org" <Editor@CavalierHealth.org> 
Sent: Wednesday, April 16, 2014 12:11 PM 
Subject: RE: Permission to use illustration 
Dear Rod, 
Thank you for your reply. 
The illustration is for the Myxomatous mitral valve disease in cavalier King Charles spaniel dog. 
Please find attached a copy of the illustration. 
I highly appreciate your help 
bw 
kareem 
From: CavalierHealth.org [cavalierhealth@att.net] 
Sent: 16 April 2014 02:22 
To: Salhiyyah, Kareem; Editor@CavalierHealth.org 
Subject: Re: Permission to use illustration 
Kareem, thanks for writing to www.cavalierhealth.org. Which particular illustration do you mean? 
Could you send a copy of it to me, or at least describe it, so that I can be sure who owns it? 
Rod Russell 
editor@cavalierhealth.org 
From: "Salhiyyah, Kareem" <k.salhiyyah@imperial.ac.uk> 
To: "Editor@CavalierHealth.org" <Editor@CavalierHealth.org> 
Sent: Tuesday, April 15, 2014 9:21 AM 
Subject: Permission to use illustration 
Dear Sir/Madam, 
I am a PhD student at Imperial college London, and I would like to get permission to use your 
illustration 
4/17/2014 Re: Permission to use illustration 
https://exchange.imperial.ac.uk/owa/?ae=Item&t=IPM.Note&id=RgAAAAASvuHZSl46QY%2fMDL%2b
K5ZUUBwCoqADgsQPHQpT8VkAqEkiIAADIn6…‎ 2/2 
(http://www.cavalierhealth.org/mitral_valve_disease.htm) on Myxomatous mitral valve disease in cavalier 
King Charles spaniel dog in PhD thesis. The purpose of the use is for scientific use only and has no 
commercial use. 
many thanks 
kareem salhiyyah 
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4/17/2014 RE: From Mardil Website : email from Kareem Salhiyyah 
https://exchange.imperial.ac.uk/owa/?ae=Item&t=IPM.Note&id=RgAAAAASvuHZSl46QY%2fMDL%2b
K5ZUUBwCoqADgsQPHQpT8VkAqEkiIAADIn6…‎ 1/1 
RE: From Mardil Website : email from Kareem Salhiyyah 
Jim Buck [JBuck@mardil.com] 
Sent:16 April 2014 17:45 
To: Salhiyyah, Kareem 
Sure, good luck 
Jim Buck 
President & CEO 
jbuck@mardil.com 
o. 763 568‐7815 
c. 952 255‐9043 
‐‐‐‐‐Original Message‐‐‐‐‐ 
From: Kareem Salhiyyah [mailto:k.salhiyyah@imperial.ac.uk] 
Sent: Tuesday, April 15, 2014 8:26 AM 
To: Jim Buck 
Subject: From Mardil Website : email from Kareem Salhiyyah 
Dear Sir/Madam, 
I am a PhD student at Imperial college London, and I would like to get permission to use your illustration 
(http://www.mardil.com/overview/ ) on functional mitral valve regurgitation in PhD thesis. The purpose of 
the use is for scientific use only and has no commercial use. 
many thanks 
kareem salhiyyah 
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27/4/2014 Re: Permission to use illustration 
https://exchange.imperial.ac.uk/owa/?ae=Item&t=IPM.Note&id=RgAAAAASvuHZSl46QY%2fMDL%2b
K5ZUUBwCoqADgsQPHQpT8VkAqEkiIAADIn6SsA…‎1/ 2 
Re: Permission to use illustration 
Edward C. Klatt [KLATT_EC@mercer.edu] 
Sent:21 April 2014 12:43 
To: Salhiyyah, Kareem 
Dear Kareem Salhiyyah: 
You are welcome to make use of the WebPath image for your PhD thesis. 
Sincerely yours, 
Edward C. Klatt MD 
BMP Program Director 
Professor of Pathology 
School of Medicine 
Mercer University 
On Apr 16, 2014, at 12:15 PM, Salhiyyah, Kareem <k.salhiyyah@imperial.ac.uk> wrote: 
Dear Dr Klatt, 
I am a PhD student at Imperial college London, and I would like to get permission to use your 
illustration (http://library.med.utah.edu/WebPath/CVHTML/CV061.html) in PhD thesis. The purpose 
of the use is for scientific use only and has no commercial use. 
many thanks 
kareem salhiyyah 
From: Mary McFarland [mary.mcfarland@utah.edu] 
Sent: 15 April 2014 17:32 
To: Salhiyyah, Kareem; ehsl-reference@lists.utah.edu 
Subject: RE: Permission to use illustration 
Hello Kareem 
Permissions for use of WebPath images can be directed to Dr. Edward Klatt. 
His email is Klatt_EC@mercer.edu 
Regards, 
Mary 
Mary McFarland 
Eccles Health Sciences Library 
ph: 801-581-5534 
http://library.med.utah.edu 
27/4/2014 Re: Permission to use illustration 
https://exchange.imperial.ac.uk/owa/?ae=Item&t=IPM.Note&id=RgAAAAASvuHZSl46QY%2fMDL%2b
K5ZUUBwCoqADgsQPHQpT8VkAqEkiIAADIn6SsA…‎2/ 2 
From: Salhiyyah, Kareem [mailto:k.salhiyyah@imperial.ac.uk] 
Sent: Tuesday, April 15, 2014 7:17 AM 
To: ehsl-reference@lists.utah.edu 
Subject: [ehsl-reference] Permission to use illustration 
Dear Sir/Madam, 
I am a PhD student at Imperial college London, and I would like to get permission to use your 
illustration (http://library.med.utah.edu/WebPath/CVHTML/CV061.html) in PhD thesis. The purpose 
of the use is for scientific use only and has no commercial use. 
many thanks 
kareem salhiyyah 
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4/17/2014 Thanks For Your Email About Heart Valve Surgery! 
Thanks For Your Email About Heart Valve Surgery! 
heartv6@dedicated836.inmotionhosting.com on behalf of HeartValveSurgery.com 
[adam@heartvalvesurgery.com] Sent:15 April 2014 14:32 
To: Salhiyyah, Kareem 
Hi there! 
Thanks so much for writing us. Due to an incredibly high volume of patient and caregiver emails, we 
are running a little behind in responding to everybody's questions and comments about heart valve 
surgery. (So you know, this is an auto-generated response.) 
We will do our best to get back to you as soon as possible. In the meantime, don't forget to visit the 
different sections of this website to learn more about heart valve surgery: 
Meet patients just like you at our Heart Valve Journals community 
Get the latest patient information at Adam's Heart Valve Surgery Blog Research over 1,200 patient 
recommended surgeons at the Surgeon Finder Learn about leading heart valve centers at our 
"Cardiac Clinics" section 
Read the 4th revised edition of "The Patient's Guide To Heart Valve Surgery" 
Keep on tickin! 
Adam Pick 
Patient, Author, Website Founder www.HeartValveSurgery.com email: adam@heartvalvesurgery.com 
Connect with patients right now at: 
https://exchange.imperial.ac.uk/owa/?ae=Item&t=IPM.Note&id=RgAAAAASvuHZSl46QY%2fMDL%2b
K5ZUUBwCoqADgsQPHQpT8VkAqEkiIAADIn6... 1/1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendex 
 
262 
 
4/17/2014 
Permission to use illustration 
Permission to use illustration 
Salhiyyah, Kareem Sent:15 April 2014 14:03 To: netters@elsevier.com 
Dear Sir/Madam, 
I am a PhD student at Imperial college London, and I would like to get permission to use your 
illustration (http://www.netterimages.com/image/9905.htm) in PhD thesis. The purpose of the use is 
for scientific use only and has no commercial use. 
many thanks kareem salhiyyah 
https://exchange.imperial.ac.uk/owa/?ae=Item&t=IPM.Note&id=RgAAAAASvuHZSl46QY%2fMDL%2b
K5ZUUBwCoqADgsQPHQpT8VkAqEkiIAADIn6... 1/1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
